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ABSTRACT 
AN INSIGHT INTO ASYMMETRIC SYNTHESIS AND BIOORGANIC 
APPLICATIONS OF NOVEL C
α
-METHYL-LYSINE, -PROLINE, 
 -NIPECOTIC ACID ANALOGUES  
by Souvik Banerjee 
December 2013 
 Prochiral malonic diesters consisting of a quaternary carbon center have been 
successfully converted into a different set of 
t
Boc-Fmoc-α2,2-methyllysine-OH analogues 
through chiral malonic half-ester intermediates achieved via enzymatic (Pig Liver 
Esterase, PLE) hydrolysis. The selection of chiral half-ester intermediates, which vary 
from 1 to 6 methylene units in the side chain, are achieved in high optical purity (92% - 
97% ee) and in good yields (65% - 72%). The PLE hydrolysis of malonic diesters with a 
variety of side chain lengths observed to obey the Jones’s PLE model as evidenced from 
the stereochemical configurations of the resulting chiral half-esters. The optimized 
synthetic strategy allows the construction of both enantiomers of α2,2-methyllysine 
analogues, and a (S)-β2,2-methyllysine analogue from a common synthon by 
straightforward exploitation of protecting groups. Two different straightforward synthetic 
strategies are illustrated for the synthesis of α2,2-methyllysine analogues. The described 
strategies should find significant usefulness in preparing novel peptide libraries with 
unnatural lysine analogues. A Vapreotide analogue incorporating (S)-α2,2-methyllysine 
was constructed. However, the Vapreotide analogue with (S)-α-methyl-α-lysine is found 
to lose its specific binding to somatostatin receptor subtype 2 (SSTR2). In an additional 
project, a stereoselective and enantiodivergent cyclization strategy for the preparation of 
  
iii 
 
γ/δ-lactams is exhibited. The cyclization strategy exploits chiral malonic esters prepared 
from enantiomerically enriched (92% ee - 97% ee) mono esters of disubstituted malonic 
acid. The cyclization takes place with the selective departure of a substituted benzyl 
alcohol as the leaving group. A Hammett study demonstrates that the cyclization is under 
electronic control. The resulting γ/δ-lactam was readily converted into a novel 
proline/nipecotic acid analogue. 
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CHAPTER I 
 INTRODUCTION 
 Over the last few decades unnatural amino acids have drawn remarkable attention 
from researchers in diverse fields of science due to a number of reasons. Researchers 
have made continuous efforts to come up with different structural motifs of unnatural 
amino acids and have used them extensively to constitute biologically active 
peptidomimetic therapeutic leads due to the ability of unusual amino acids to stabilize 
secondary structures of peptides. However, unnatural amino acids have not only been 
implicated in peptidomimetics but also in construction of enzyme inhibitors, receptor 
antagonists, antibacterial agents and so on. Mother nature has also created several 
nonnatural amino acids and presented them as therapeutic leads by themselves or as an 
essential constituent of complex therapeutic agent structure. One of the most important 
factors that has propelled the nonnatural amino acids in huge demand at diverse fields of 
science is their conformation rigidity. In this introduction I am going to be discussing the 
recent utilities of nonnatural amino acids in different scientific fields and unique 
approaches to synthesize them. 
Unnatural Amino Acids (UAAs) in Peptidomimetics 
  UAAs have been extensively employed in peptidomimetics in order to develop a 
variety of inhibitors of enzymes that are responsible for disease progression.
2-6
  It is 
evident that the presence of artificial backbones in the unnatural peptides confers a higher 
degree of resistance to enzymatic degradation as opposed to their natural counterparts.
4
  
A few years ago, Oh et al. reported that the introduction of unnatural amino acids in anti-
2 
 
 
 
microbial peptides improves their protease resistance as much as three times without 
affecting their activity.
7
 
Unnatural Amino Acids in Foldamers 
  Currently, scientists are highly interested in the ability of the UAAs to introduce 
the tendency of acquiring specific compact conformation (tertiary structure) into 
synthetic peptides.
8-11
 Professor Gellman introduced the term "foldamers" to describe any 
synthetic peptide that strongly adopts the highly stable tertiary structures in organic and 
aqueous solutions.
8
 A few years ago Seebach et al. reported that the β-peptides not only 
have a strong tendency to form foldamers but are highly resistant to the action of 
proteases as well.
12
 Recently, Saludes et al. reported that the /δ-peptides form stable 
foldamer structures in solution and exhibit two to three orders of magnitude higher half-
life than -peptides in human blood plasma.13 
Unnatural Amino Acids in Antibiotics 
 Mother nature has created few classes of non-proteinogenic amino acids with 
anti-herbicidal and antibiotic properties.
14, 15
 One of the most important antibiotic unusual 
amino acids produced by Mother Nature is Furanomycine.
15
 Furanomycine was extracted 
from metabolites of Streptomycesthreomyceticus in 1967, and this class of unusual -
amino acids (Figure 1) suppresses the growth of number of bacterial species.
15
 
 
 
 
 
Figure 1. L-furanomycine, a nature made nonproteinogenic amino acid. 
O
O
OH
NH2
H
L-Furanomycine  
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UAAs as Building Blocks of Complex Molecular Structures 
 Unnatural amino acids have often served their role as the starting materials or 
building blocks of advanced molecules with unique biological activity.
16-18
 Recently 
Wohlrab et al. reported total synthesis of Plusbacin A3, a depsipeptide antibiotic, 
containing a number of non-proteinogenic amino acids.
17
  Chandrashekhar et al. reported 
a concise total synthesis of Azumamide E, a marine cyclic terapeptide containing novel 
β2,3-amino acids, that shows inhibitory activity to histone deacetylase.19 Recently, Konno 
established total synthesis of three marine natural products (miraziridine A, tokaramide A, 
and callipeltins) containing unusual amino acids, showing strong cysteine protease 
inhibitor activity.
20
 
UAAs as Chiral Auxiliaries and Organocatalysts 
  UAAs serve as chiral auxiliary/organocatalyst by themselves or as building blocks 
of the complex chiral auxiliary/organocatalyst structure. 
21-25
 A few years ago, Vicario et 
al. pointed out nonnatural α-amino acids, β-amino alcohols, and related compounds that 
have been utilized recently as chiral auxiliaries, or catalysts in the asymmetric aldol 
reaction.
22
 Barbas et al. established unnatural proline analogues as one of the most 
promising catalysts for the anti-Mannich type reactions.
23
 Barbas et al. also reported that 
the non-natural pipecolic acid analogues function as strong catalysts for the syn-Mannich 
type reactions.
26
 Recently Wang et al. have discovered that the β-aminoaldehyde, which 
is formed as the product in syn-Mannich type reactions, could be employed as  an 
autocatalyst to drive the asymmetric syn-Mannich type reactions.
24
 Lately Momami et al. 
have exhibited a number of hydroxyl-L-proline analogues as very promising catalysts for 
the asymmetric aldol, Mannich, and Michael reactions.
25
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C
,
-Disubstituted Non-Proteinogenic Amino Acids 
 In recent years, there has been growing interest in optically pure ,-
disubstituted-/β-nonproteinogenic amino acids in a number of fields of science.27-29 This 
class of sterically constrained amino acids have mostly drawn the attention of researchers 
in biochemical research and drug discovery.
29
 The reason they greatly attract biochemical 
researchers to the ,-disubstituted-quaternary amino acids is that they do not undergo in 
vivo racimization due to absence of the C

-hydrogen.
30
 This class of sterically restricted 
amino acids have been witnessed to strongly stabilize secondary structures of the peptides 
as opposed to their C

-substituted partners.
30
 This class of conformationally constrained 
amino acids are often found in nature either in free form or as a building block of  
complex natural product.
31
 In addition, synthesis of alkaloids or other natural products 
consisting of amine moiety attached to a quaternary carbon center has been known to be 
difficult, since effective installation of such centers is greatly challenged by the steric 
congestion.
32
 
Secondary Structures of the Peptides Consisting of C
α,α
-Disubstituted Amino Acids  
 The secondary structures of peptides can be construed in term of torsion angles ψ, 
φ, ω, and the side chain conformations of the amino acids are illustrated by the torsion 
angles χ1, χ2, χ3 (Figure 2). The torsion angle values in protein and peptides are 
determined through number of experimental structural data and computational simulation. 
In reality, it is possible to predict the effect of conformationally restricted amino acids on 
the outcome of the secondary structure of a peptide by evaluating the torsion angles of 
the conformationally rigid amino acids.
33
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Figure 2. The backbone and side chain dihedral angles of the C
α,α
-disubstituted amino 
acids. 
 
 One of the most frequently known C
α,α
-disubstituted amino acids is α-
aminoisobutyric acid (Aib, dimethylglycine, α-methyl-alanine) (Figure 3). In Aib residue, 
substitution of the α-hydrogen atom in alanine by a methyl group considerably restricts 
the available conformational space (Figure 4).
33
 It is evident from a number of 
experimental results that Aib induces right handed (P) and left handed (M) 310-helical 
structures (φ, ψ = 600,  300) in a 1:1 ratio, both in solution and the crystal state.33, 34  
The reason behind the generation of two enantiomeric P and M- helices by Aib is that 
Aib is an achiral amino acid. To strongly emphasize, Aib residues neither induce semi-
extended conformations nor extended conformations, unlike alanine which is found in 
both folded and extended conformations.
33
 
 
 
 
 
 
H3C N
C
O
H O
N
H
CH3
H3C
H3C
   
2
1
Ac-D-Iva-NHMe  
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Figure 3. Structure of α,α-disubstituted amino acids and peptaibol antibiotics. 
 
 Each 310-helix gives rise to an intramolecular hydrogen bonded ring containing 10 
atoms, and one 310-helix turn accommodates 3 amino acid residues (Figure 5).
34
 On the 
contrary, one α-helix (3.613-helix) gives birth to an intermolecular hydrogen bonded ring 
consisting of 13 atoms and each α-helix turn accommodates 3.6 amino acid residues 
(Figure 5).
34
 Thus, it is conceivable that the 310-helix is more compact than α-helix.
34
 In 
addition to Aib (achiral C
α,α
-disubstituted amino acid), intensive efforts have been made 
by a number of research groups to explore the conformations of homo- or hetero-peptides 
consisting of chiral C
α,α
-disubstituted amino acids (including Cα-methyl quaternary 
amino acids).
34
 The consequences of all the precedent studies are in consensus revealing 
that the chiral C
α,α
-disubstituted amino acids induce the 310-helix in peptides as well. 
However, helical screw sense (right handedness) relies on the R or S absolute 
configuration at the α-carbon of chiral Cα,α-disubstituted amino acids.34 
 
HO2C NH2
R1H
H R2 HO2C NH2
R1R2
L-amino acid -disubstituted amino acid
HO2C NH2
HO2C NH2
HO2C NH2
Aib Deg (S)-Iva
Antiamoebin 1 (4):
 Ac-Phe-Aib-Aib-Aib-D-Iva-Gly-Leu-Aib-Aib-Hyp-Gly-D-Iva-Hyp-Aib-Pro-Phl
Alamethicin F- 30 (5):
 Ac-Aib-Pro-Aib-Ala-Aib-Aia-Gln-Aib-Val-Aib-Gly-Leu-Aib-Pro-Val-Aib-Aib-Glu-Gln-Phl
1 2 3
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Figure 4. Newman projection exhibiting limited conformational space availability for the 
C
α,α
-disubstituted amino acids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Hydrogen bonding pattern of 310-helix and α-helix. 
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C
,
-Nonproteinogenic Amino Acids in Peptidomimetics 
  Oligopeptides consisting of naturally occurring L--amino acids often lead to 
unordered or unstable secondary structures due to the conformational flexibility of 
natural amino acids.
34
  This is why C
,
-disubstituted non-proteinogeninc amino acids 
have made their strong demand in the widely extended field of preparation of peptides 
with the interest to humanity. Natural peptaibol antibiotics, such as anti-amoebin, 
alamethicin, and zervamicin, have been found to be composed of Aib residues (Figure 
3).
34
 This is why α,α-disubstituted amino acids should be named as nonproteinogenic 
amino acids or non-coded amino acids as opposed to unnatural amino acids. Aib is one of 
the most widely used amino acids not only to introduce helical secondary structures into 
peptides but to design and synthesis of organocatalyst and drug candidates as well.
34
 
Substitution of the α-hydrogen atom in an L-α-amino acid, which results in Cα,α-
disubstituted amino acid, with an alkyl moiety results in (1) improved chemical stability 
of the amino acids, (2) improved hydrophobicity of the amino acids, (3) constrained 
conformational freedom of the amino acid side chain, and (4) restricted conformation 
flexibility of the peptides containing them, and as a consequence enhanced metabolic 
stability of their peptides (Figure 1).
34
 
 In recent years, a variety of C
α,α
-disubstituted nonproteinogenic amino acids have 
been used in the synthesis of medicinally important peptides due to their propensity to 
stabilize secondary structures of the peptides by introducing tremendous helix inducing 
potential.
29, 34-39
 This helix inducing propensity is considered to be capable of stabilizing 
the secondary structures of the peptides by rigidifying the peptide backbone.
29, 34, 39-41
  
Hence, the peptides with higher conformational stability present improved resistance 
9 
 
 
 
against enzymatic and chemical degradations.
35, 36, 41, 42
  Thus, α,α-disubstituted amino 
acids have very often been introduced in the peptide synthesis to confer enhanced 
metabolic stability to synthetic peptides (Figure 6).
3, 35-37
 In addition, the remarkable helix 
inducing potential employed by C
α,α
-disubstituted nonproteinogenic amino acids is 
believed to be responsible for the bacterial membrane destabilization effort produced by 
peptaibol antibiotics.
29
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Synthetic peptides consisting of C
α,α
-disubstituted amino acids.
35, 37
 
C
α,α
-Disubstituted Amino Acids in Therapeutic Leads 
C
α,α
-disubstituted class of nonproteinogenic amino acids has been frequently employed as 
a pharmaceutical active agent (enzyme inhibitors or receptor antagonist) by itself or as a 
building block of the complex therapeutic agent.
29, 43-45
 The remarkable increment in the 
steric congestion imparted by an additional -substituent of  C,-disubstituted amino 
HO2C N
H
H
N
O
S
S
O
OH
O
N
H
O
H
N CO2H
O
HO
O
NH3
NH3
Oxidized glutathione consisting C-disubstituted cysteine
D-Phe-Cys-Tyr-D-Trp-Orn-XY-Pen-Thr-NH
XY = Aib (1), Deg (2)
Somatostatin octreotide analogue consisting C-disubstituted amino acids
6
7
+
+
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acids either keeps the substrate from accessing the active site of enzyme or hinders the 
enzyme from initiating its catalyzing activity.
29, 36, 37
 Thus, conformational constraint 
plays an important role in order for this class of amino acids being potent inhibitors of 
enzymes (reversible or irreversible).
36, 37, 46
  Recently, Ilies et al. have developed two 
novel C
α,α
-disubstituted amino acid analogues (Figure 7) as potent inhibitors of human 
arginase that is known to hydrolyze L-arginine to L-ornithine.
44
 
 
 
 
Figure 7. C
α,α
-disubstituted amino acids as potent arginase inhibitor.
44
 
 Recently, our group has illustrated how the incorporation of C

-methyl-cysteine 
into glutathione inhibits glutathione reductases from cleaving the disulphide bond of 
oxidized glutathione GSSG (Figure 6, compound 6).
36
 A couple of years ago Hoffmann-
La Roche AG had introduced a few potent macrocyclic inhibitors of Janus Kinases (JAKs) 
consisting of C
,
-disubstituted amino acids (Figure 8).
47
 Inhibitors of JAKs are used in 
the treatment of cancer and inflammatory diseases.
47
 
 The restricted conformational flexibility and improved metabolic stability of C
,
-
disubstituted amino acids make them an important constituent in complex receptor 
antagonist structures.
45
 A few years back, a group of scientists from Meck & Co. 
developed a potent inhibitor of neurokinin 1 (NK1) receptor consisting of cyclic C
,
-
disubstituted-β-amino acid (Figure 9).45  This group illustrates that the C,-disubstituted 
amino acid framework is important for effective inhibition.
45
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Figure 8. JAKs inhibitor consisting -methyl-β-proline.47 
 
 
 
 
 
 
 
 
 
Figure 9. NK1 receptor antagonist consisting C
,
-disubstituted amino acid.
45
 
 Recently, Novartis AG has discovered a novel small molecule potent antagonist 
of S1P receptor (for the treatment of diseases caused by S1P receptor modulators) 
consisting of constrained C
,
-disubstituted amino acid as an important building block 
(Figure 10).
1
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Figure 10. S1P receptor antagonist consisting C

-methyl-β-proline.1 
Current State of the Art Toward Asymmetric Synthesis of C
,
-Disubstituted Amino 
Acids 
    Although a number of synthetic strategies have been reported to date, synthesis of 
quaternary chiral centers is still one of the toughest challenges to synthetic organic 
chemists. Recently Vogt et al.
29
 reviewed the recent widely explored synthetic strategies, 
which are employed to constitute quaternary chiral centers for the preparation of C
,
-
disubstituted amino acids as follows 
1. Asymmetric Strecker Reaction Involving Aldimines or Ketimines or Strecker Related 
Reactions (Scheme 1).
28
 
 
 
 
 
 
 
 
 
Scheme 1. Asymmetric Strecker reaction mediated trough ketimine.
28
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2. Electrophilic Alkylation of the Enolates Resulting from Oxazinones, Oxazolines, 
Oxazolidines, Azalactones, or Imines Derived from Amino Acids as Chiral Auxiliaries 
(Scheme 2).
30
 
 
 
 
 
 
 
 
 
 
Scheme 2. Oxazinones as chiral auxiliaries.
30
 
3. Electrophilic Alkylation of Chiral Imine Attached to an Oxazinone (Scheme 3).
48
 
 
 
 
 
 
 
 
 
 
Scheme 3. Electrophilic alkylation of chiral imine.
48
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4. Organo Catalyzed Electrophilic -Amination of the -Substituted Carbonyl 
Compounds (Scheme 4).
49
 
 
 
 
 
 
Scheme 4. Organocatalyzed electrophilic -amination.49 
 
5. Phase Transfer Catalyst Mediated Electrophilic Alkylation of Schiff Bases Derived  
from Amino Acids (Scheme 5).
29
 
 
 
 
 
 
 
 
Scheme 5. PTC catalyzed electrophylic alkylation of Schiff bases.
29
 
 
6. Nucleophilic Addition to C-N Multiple Bond Leads to the Synthesis of C
,
-
Disubstituted Amino Acids (Scheme 6).
50, 51
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Scheme 6. Nucleophilic addition to C-N multiple bonds.
50, 51
 
 
7. Synthesis of C
,
-Disubstituted-Amino Acids through Stereospecific Ring Opening of 
Epoxides or Aziridines and Rearrangement Reaction (Scheme 7).
52
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7. Stereospecific ring opening of epoxide leading to the formation of C
,
-
disubstituted-amino acids.
52
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 In continuation, Smith et al. presented the synthesis of several α,α-disubstituted-α-
amino acids from a common intermediate employing nucleophilic “O-Alkyl Fission” ring 
opening of the NBn2-α-methylserine lactone, using various organocuprates (Scheme 8).
53
 
Green et al. reported a novel strategy to prepare C
,
-disubstituted amino acids through a 
Mitsunobu approach starting with optically pure ,-disubstituted--hydroxy ester 
(Scheme 9).
54
 Cabrera et al. optimized a unique strategy implicating organocatalyzed 
Michael addition of oxazolone enolates to the Michael acceptors (Scheme 10).
42
 Recently,  
Hartmann et al. reported the synthesis of optically enriched α-methyl phenylglycine 
through L-proline catalyzed amination of racemic 2-arylpropionaldehydes, using DEAD 
and DBAD (Scheme 11).
55
 
 
 
 
 
Scheme 8. O-alkyl fission ring opening of β-lactone.53 
 
 
 
 
 
 
Scheme 9. Mitsunobu approach to prepare C
,
-disubstituted amino acids.
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Scheme 10. Organocatalyzed Michael addition leading to C
,
-disubstituted amino acid.
42
 
 
 
 
 
 
 
Scheme 11. L-proline catalyzed -sulphimidation of ,-disubstituted aldehydes.55 
 
Pig Liver Esterase (PLE) Desymmetrization Approach to Prepare C
,
-Disubstituted 
Amino Acids 
  Although numerous synthetic methodologies are established to construct α,α-
disubstituted-α-amino acids, most often they rely on expensive chiral auxiliaries. Most of 
the time, different chiral auxiliaries are required to produce different stereoisomers of the 
same α,α-disubstituted amino acids. In addition, there are very few synthetic strategies 
allowing the constitution of both –α- and β- amino acid from a common synthon. This is 
why Pig Liver Esterase (PLE) is used. PLE is cheap and has proven its excellence in 
hydrolyzing a wide variety of prochiral quaternary malonic diesters to the corresponding 
optically enriched α,α-disubstitutedmalonic half-esters, which have been extensively 
employed as ideal precursors of α,α-disubstituted amino acids.3, 32, 37, 46, 56, 57 To the best 
of our knowledge, Kedrowski
46
 is the first to report both enantiomers of orthogonally 
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protected α-methyl-α-cysteine from the common optically enriched quaternary malonic 
half-ester, derived from PLE hydrolysis of prochiral dimethyl malonate (Scheme 12). 
Very recently Iosub et al.
58
 has also shown the synthesis of α,α-disubstituted-α-amino 
acid from enantiomerically enriched PLE hydrolyzed methyl malonic half-ester . 
However, dimethyl-2-methyl malonate that is used for enolization is expensive compared 
to diethyl-2-methyl malonate. Masterson et al. have recently reported synthesis of both 
(R)- and (S)-α2,2-, β2,2-, and β3,3-Cysteine and serine analogues from the common PLE 
hydrolyzed optically enriched quaternary ethyl malonic half-esters with respective amino 
acid side chains (Scheme 13).
3
 Recently, Falgner et al.
56
 have also established the 
synthesis of both (R)-and (S)-α-methyl-trimethylsilyl alanine with excellent enantio 
purity starting with PLE desymmetrized ethyl malonic half-ester and the same 
manipulation of protecting group as Kedrowski and Masterson reported earlier.
3, 46
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 12. PLE desymmetrization approach by Kedrowski.
46
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Scheme 13. Strategy of Masterson et al.
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CHAPTER II 
PIG LIVER ESTERRASE DESYMMETRIZATION APPROACH TO PREPARE 
DIVERSE ORTHOGONALLY PROTECTED C
,
-DISUBSTITUTED LYSINE 
ANALOGUES  
Background 
 The growing importance of C
,
-disubstituted class of non-proteinogenic amino 
acids in various fields has drawn the interest of synthetic organic chemists over the last 
two decades.
3, 46, 59
 This class of sterically constrained amino acids, which consist of 
quaternary carbon center, have exhibited enhanced chemical stability, improved 
hydrophobicity, conformational inflexibility of the amino acid side chain, and thus, 
restricted conformational flexibility of the peptides containing them.
34
  This class of 
quaternary amino acids are of the most frequently and widely used structural motifs in 
peptidomimetics, since they introduce enormous helix inducing potential into the 
peptides to acquire stable secondary structures. 
3, 29, 34, 36, 37
 The precedent experimental 
reports suggest that the peptides consisting of ,-disubstituted amino acids achieve 
more stable secondary structure (310-helix) with rigid backbone in comparison to those 
containing natural amino acids.
34
 The propensity of C
,
-disubstituted amino acids to 
impart profound helix inducing potential in the peptides is found to be the causative 
reason for the membrane destroying impact exerted by peptaibol class of peptide broad 
spectrum antibiotics.
29, 34
 This class of sterically congested amino acids has also been 
widely employed as enzyme inhibitors by themselves or a crucial moiety of the complex 
inhibitor structures.
35, 36
 Previous experimental evidences strongly suggests that an 
additional -substitutent in C,-disubstituted amino acids confer enough steric 
21 
 
 
 
congestion to keep the substrates from reaching the enzyme active site.
29, 36, 37
 Thus, the 
above examples reveal the growing interest in preparation of the C
,
-disubstituted amino 
acids in the medicinal chemistry community. 
 Although a number of synthetic strategies have been reported to prepare different 
optically enriched ,-disubstituted amino acids, very few reports exist on the C,-
disubstituted lysine analogues.
30, 59-61
 Lysine is an essential amino acid and is one of the 
mandatory building blocks in number of biologically active peptides for their function.
62-
66
 However, peptides consisting of lysine are often susceptible to degradation by serine 
like proteases.
67
 Hence, organic chemists have been exploring more options to prepare 
C
α,α
-disubstituted-lysine analogues to derive protease resistant peptides.
30
 Recently, 
Berkowitz et al. have discovered that unlike D-lysine, -vinyl-lysine strongly behaves as 
an inhibitor of lysine decarboxylase.
68, 69
 Few years back, Jones et al. reported that C
,
-
disubstituted malonic diesters carrying lysine amino acid side chain functionality does 
not undergo hydrolysis with trypsin.
70
 
 All the above examples point to the growing interest in α,α-disubstituted lysine 
analogues. However, appropriate protection of two nitrogen atoms in lysine to prepare it 
for solid phase polypeptide synthesis has come out as a challenging task to synthetic 
chemists. Few years ago Seebach et al.
59
 reported the synthesis of α-methyl-α-lysine 
analogues in free diamino form employing self-regeneration of stereo center (SRS) 
principle (Scheme 14). However, the Seebach strategy allows us to synthesize only α-
methyl-α-lysine in low yield. Recently, Cativiela et al. reported the synthesis of (S)-α-
methyl-α-lysine via chiral cyanopropanoate using a chiral auxiliary in ten steps, but this 
strategy also let us synthesize only (S)-α-methyl-α-lysine in unprotected form (Scheme 
22 
 
 
 
15). To the best of our knowledge Chauhan is the first to report 
t
Boc-Fmoc protected (S)-
α-methyl-α-lysine using William’s Oxazinone as a chiral auxiliary in eight steps with 
overall 26% yield and 95% optical purity (Scheme 16).
30
 However, this methodology 
needs to be using expensive chiral auxiliary, and the same auxiliary cannot be utilized to 
result in both (R)- and (S)-α-methyl-α-lysine derivative. In addition, this methodology 
requires the use of explosive azide to attain lysine side chain functionality, hence, could 
be dangerous in scale up batch. Moreover, this methodology has been able to obtain the 
final product in only 90% purity, what in addition would be problematic for the 
incorporation of the amino acid in to a peptide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 14. Seebach's strategy to prepare optically enriched ,-disubstituted-lysine.59 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 15. Strategy of Cativiela et al to prepare (S)--methyl--lysine.60 
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Scheme16. Chauhan's strategy to prepare protected C-methyllysine analogue.
30
 
  Hence, all the previously reported synthetic strategies to prepare C
α,α
-disubstituted 
lysine analogues indicate that there is a lack of a synthetic strategy that is capable of 
deriving diverse orthogonally protected C
α,α
-lysine analogues from common 
intermediate types. To the best of our knowledge, Masterson et al. is the first group to 
report diverse cysteine and serine analogues from a common intermediate type without 
using expensive chiral auxiliaries (Scheme 13).
3
 Hence, based on the previous success of 
our group we have drawn our first hypothesis, which is as follows: 
Hypothesis 1.  
Our unique enantiodivergent synthetic strategy allows us to derive a variety of 
orthogonally protected C
,
-disubstituted--/β-lysine analogues and prepare both 
enantiomers of C

-methyl--lysine from Pig Liver Esterase desymmetrized optically 
enriched common intermediate types (Scheme 17). 
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 I have developed a PLE catalyzed enzymatic desymmetrized approach to prepare 
both orthogonally protected (R)- and (S)-α-methyl-α-lysine, orthogonally protected (S)-
2,3-diaminopropanoic acid, and orthogonally protected (S)--methyl-β2,2-lysine analogue 
from the optically enriched (52%~97% ee) half-esters (common intermediate types). The 
optimized synthetic strategy is convenient and flexible, allowing for the alteration of the 
side chain of lysine analogues from one to six methylene units, construct both 
enantiomers of an α2,2-methyllysine analogue from the same common intermediate. In 
continuation, the same synthetic strategy allows to homologate the (S)-α2,2-methyllysine 
to the relevant (S)-β2,2-methyllysine. I have optimized two different synthetic strategies to 
obtain orthogonally protected α2,2-lysine analogues from chiral malonic half-esters in 
good yield. One of the synthetic strategies consists of  seven steps (long path) and the 
other consists of total three steps (Short Path) from PLE derived chiral malonic half-ester 
with lysine side chain functionality. The short path, which I have recently achieved, is the 
most concise strategy to date. Scheme 17 illustrates the convergent strategy to synthesize 
diverse C
α
-methyl lysine analogues from a common synthon. I altered the side chain 
length of lysine in order to explore the effect of chain length in PLE hydrolysis 
71, 72
. 
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Scheme 17. General synthetic strategy to prepare diverse orthogonally protected lysine 
analogues from common intermediate types. 
 
Results and Discussion 
 Synthesis of optically enriched half-ester intermediates: The prochiral malonic 
diesters (9a-f) were prepared by electrophylic alkylation of diethyl-2-methylmalonate 
with the appropriate N-(bromoalkyl)-phthalimide as shown in Scheme 18. The 
consequential diesters, with the exception of 9b, were purified and isolated in good yield 
(65% - 71%). The poor yield of 9b was due to the dehydrohalogenation of 8b as 
evidenced by isolation of significant quantities of alkene (51%).  Compounds 9a-9f were 
subjected to enzymatic hydrolysis using crude PLE at pH 7.4. The hydrolysis resulted in 
enantiomerically enriched half-esters 10a-10f in good isolated yields as shown in Scheme 
18. Interestingly, PLE was observed to provide 10a-f predominantly of the (R)-
enantiomer with significant optical activity in all cases. 
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Scheme 18. Synthesis of optically enriched half-esters (10a - 10f).
73
 
 
 Half-esters 10a-10f were successfully resolved employing chiral HPLC 
techniques and the enantioselectivity was determined by integration of the relevant 
chromatographic peaks (Figure 11). The chiral HPLC chromatograms of the half-esters 
were matched to those of racemic standards of 10a-10f prepared by standard non-
enzymatic strategy. 
 The stereochemical configuration of the major enantiomer of 10a was determined 
to have the (R) absolute stereochemistry as shown in Scheme 19.
74
 The absolute rotation 
of the half-ester 17, which was obtained from the half-ester 12 by synthesis, was 
compared with the one obtained from 10a. The stereochemical configuration of the major 
enantiomer of 10b was determined by synthesis
75
 as shown in Scheme 20. The optical 
activity of compound 22 was compared to literature values in order to establish the 
absolute configuration of 10b. The configurations of 10c and 10d were determined by 
conversion into 24a and 24b as shown in Scheme 21. The optical rotations of 24a and 
24b were compared with literature values in order to determine the stereochemical 
configurations of 10c and 10d.
59
 The stereochemical configurations of 10e and 10f were 
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also determined by synthetic means as shown in Scheme 22. 
76-78
 The half-esters 10e and 
10f were converted into ,-disubstituted amino acids 28a and 28b to compare their 
absolute rotation to the literature values.
77, 78
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Chiral HPLC chromatograms of few half-esters (10b and 10d). 
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Scheme 19. Absolute configuration of 10a.
74
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 20. Absolute configuration of 10b.
73
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Scheme 21. Absolute stereochemical configuration of 10c and 10d.
73
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 22. Absolute stereochemical configuration of 10e and 10f.
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Insight into PLE Biocatalytic Hydrolysis of the Prochiral Diesters (9a-9f) 
 It is evident from the Figure 12 and Figure 13 that the PLE hydrolysis of diesters 
9a-9f obey the Jones Active Site Model (JASM) (Figure 13).
72
 JASM is a 3D model, 
which is not shown here.
72
 PLE hydrolysis of diester 9c results in the highest level of 
optical purity. I hypothesize that the size of the side chain of 9c closely matches with the 
size of the large hydrophobic pocket (HL) in the JASM. The other prochiral diesters 
having relative disparity of size with the large hydrophobic pocket of the JASM results in 
diminished enantioselectivity with respect to 9c. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. PLE hydrolysis assay of 10a-10f. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Jones active site model for Pig Liver Esterase. 
 
Ser
HL
HS
PF
PB
O
O
O
O
N
O
O
 
31 
 
 
 
Conversion of half-esters (10a-10f) into Moz protected carbamates: The acid-esters (10a-
10f) were subjected to the Curtius rearrangement resulting in Moz-protected (S)-α2,2-
carbamates (23a-23f) in good isolated yields as shown in Scheme 23. Compounds 23a-
23f can be taken into consideration as fully protected non-proteinogenic amino acids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 23. Conversion of the half-esters (10a-10f) into fully protected amino acids.
73
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Synthesis of Orthogonally Protected (S)-Fmoc-α2,2-Lysine-Boc-OH (Long Path) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 24. Synthesis of orthogonally protected (S)-α2,2-lysine analogue.  
 Scheme24 illustrate the synthesis of (S)-α2,2-Fmoc-lysine-Boc-OH (34) in seven 
steps starting with the optically enriched 10d with good isolated yield. In the first step the 
chiral half-ester (10d) was subject to a Curtius rearrangemt producing the Moz protected 
α-amino ester (23d) in good isolated yield. The carbamate (23d) was then treated with 
TFA in methylene chloride in order to chemoselectively deprotect the Moz group leading 
to free α-amine (29).46 Compound 29 was then subject to dibenzylation  using excess 
BnBr and K2CO3 under reflux for 48 hours preparing dibenzylated-α-amine(30).
53
 The 
simple base hydrolysis of 30 using 8N  NaOH/EtOH over 72 hours resulted in 
saponification of the ethyl ester and deprotection of the phthalimido group in a single step 
leading to free amino acid (31) in good yield. The free amine (31) was then selectively 
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protected with the Boc group using Boc anhydride and NaHCO3 in a H2O/Dioxane 
system producing 32 in good isolated yield. The chemoselective hydrogenolysis of 32 led 
to the α-free amino acid 33 in nearly quantitative yield. The free α-amino acid (33) was 
reprotected with Fmoc group leading to tBoc, fmoc protected (S)-α2,2-Lysine analogue 
(34) with good reproducible isolated yields in overall seven steps from the chiral half-
ester. 
Synthesis of (S)-Fmoc-α2,2-Lysine-Boc-OH (Short Path) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 25. Short path synthesis of (S)-Fmoc-α2,2-lysine-Boc-OH analogue.73 
 The short path synthetic strategy (Scheme 25) leads to the 
t
Boc-Fmoc-(S)-α2,2-
lysine (34) in three steps starting with optically enriched 10d. The bulky quaternary chiral 
half-ester (10d) was directly converted to the Fmoc protected carbamate (35) by Ti (IV) 
isopropoxide catalyzed Curtius rearrangement with good isolated yield.
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hydrolysis, that was employed in 5N HCl/dioxane system under reflux, of the carbamate 
(35) hydrolyzed both pthalimido group and ethyl ester leading to the free amino acid (36), 
as evident by ESI-MS.
80
 The crude free amino acid (36) was undertaken for reprotection 
of the side chain amine by the Boc group without further purification. Eventually, the 
t
Boc-Fmoc-(S)-α2,2-lysine-OH (34) is obtained in three steps. Hence, the short path 
synthetic strategy is the most concise way to synthesize 
t
Boc-Fmoc-(S)-α2,2-Lysine-OH.30 
Preparation of (R)-Fmoc-α2,2-Lysine-Boc-OH Analogue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 26. Synthesis of (R)-Fmoc-α2,2-Lysine-Boc-OH.73 
 In order to achieve the synthesis of 42, the chiral half-ester 10d was turned into 
the mixed diester 37.
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excellent yield. Amino acid 39 was transformed into 40 using standard reaction 
conditions. The sterically restricted carboxylic acid 40 was then converted into Fmoc 
protected α-amino ester 41 in good yield employing Curtius rearrangement using DPPA 
and 9-fluorenylmethanol in presence of catalytic Ti (IV) isopropoxide.
79
 However, the 
chemoselective deprotection of the tert-butyl ester in the presence of Boc did not work 
out in our hands using known literature procedures.
81-83
 This failure is attributed to the 
inaccessibility of the sterically hindered ester by those reagents. Hence, we had to treat 
the amino ester 41 with TFA to deprotect both the tert-butyl and Boc groups followed by 
treatment with (Boc)2O. However, this deprotection and reprotection was a one pot 
strategy that gave birth to the (R)-α2,2-methyllysine analogue 42 in eight steps in 
reasonable overall yield (30%). 
Synthesis of Orthogonally Protected (S)-α2,2-2,3-Diaminopropanoic Acid 
 Scheme 27 describes the synthesis of orthogonaly protected (S)-α2,2-2,3-
diaminopropanoic acid (49) in eight steps starting with optically enriched half-ester 10a 
in good isolated yield. At first the chiral half-ester (10a) was subjected to a Curtius 
rearrangement resulting in the Moz protected α-amino ester (23a). The carbamate (23a) 
was then allowed to react with TFA to chemoselectively deprotect the Moz group 
resulting in 43.
46
 Compound 43 was then allowed to undergo a dibenzylation using 
excess BnBr and K2CO3 at solvent reflux for 48 hours leading to 44.
53
 However, standard 
base hydrolysis failed to drive the deprotection of the phthalimide group along with ester 
saponification in a single step starting with the α-dibenzylated aminoester (44). This 
failure was considered to be due to the closeness of phthalimido group to the bulky 
quaternary center. However, the chemoselective cleavage of the phthalimide of the 
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dibenzylated amino ester (44) employing hydrazine resolved the problem providing 
access to 45. Saponification of 45 results in the desired 46. The free amino acid (46) was 
then taken up for a selective installation of Boc group using Boc anhydride and NaHCO3 
in H2O/Dioxane system producing 47 in good isolated yield. The selective 
hydrogenolysis of 47 resulted in the α-free amino acid 48 in near quantitative yield. The 
free α-amino acid (48) was reprotected with the Fmoc group leading to tBoc, Fmoc 
protected amino acid analogue (49) in total ten steps in 14% overall yield. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 27. Synthesis of orthogonally protected (S)-α2,2-2,3-diaminopropanoic acid.73 
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 Based on precedent literature, Nadir et al
61
 is the first group to report the 2,3-
diaminopropanoic acid in the free form (unprotected form of 49), which is not convenient 
in terms of solid phase peptide synthesis (SPPS). This success allowed us to synthesize 
(S)-2,3-diaminopropanoic acid appropriate for SPPS in eight steps starting with optically 
enriched chiral half ester 10a. Additionally, we have recently presented that the optical 
purity of the acid-ester (10a) could be further enhanced to 95% ee by substituting the 
crude PLE with PLE Isoenzyme 1, and 2% EtOH as a co-solvent in the biocatalytic 
hydrolysis of 9a.
74
 Hence, this established synthetic strategy is capable of providing 
access to (S)-2,3-diaminopropanoic acid in high optical purity, and in properly protected 
form for SPPS. 
Synthesis of (S)-Fmoc-β2,2-Methyllysine-Boc-OH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 28. Synthesis of orthogonally protected (S)-β2,2-methyllysine analogue.73 
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 Scheme 28 describes the synthesis of orthogonally protected (S)-β2,2-methyllysine 
(53) in eight steps starting with optically pure half-ester 3d. The chiral half-ester (40), 
that was achieved from 3d following Scheme 8, was transformed into diazoketone (50) 
using standard procedures. The diazoketone (50) was then taken for  photolysis resulting 
in the γ-keto acid (51). The γ-keto acid (51) was then allowed to undergo a Curtius 
rearrangement leading to the the Fmoc protected β-amino ester (52). β-amino ester 52 
was eventually converted into the 
t
Boc-Fmoc-(S)-β2,2-methylysine (53) using well 
established procedures. 
Conclusions 
 I have optimized two convenient straightforward synthetic strategies to derive a 
variety of orthogonally protected α2,2-, and β2,2-methyllysine analogues  mediated through 
inexpensive PLE hydrolysis derived acid-ester intermediates. This developed technique 
does not necessarily require expensive chiral auxiliaries and reagents to introduce the 
needed chiral quaternary carbon center. In addition, this enantiodivergent methodology 
permits to prepare both D and L- isomers of the orthogonally protected α2,2-lysine-OH 
starting with the enantiomerically enriched common synthon by simple manipulation of 
the protecting groups. To the best of my knowledge, this is the first time synthesis of such 
diverse lysine analogues were made possible in properly protected form through a 
common and simple synthetic strategy.  Additionally, Scheme 22 has made available the 
previously difficult to synthesize α,α-disubstituted amino acids containing hydrophobic 
side chain in moderate to high % ee via a straightforward reductive deaminiation 
procedure. 
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Experimental 
 General Methods: THF, CH2Cl2, and DMF were dried by passage through a 
column of activated alumina. All reagents were used as received from commercial 
sources unless otherwise stated. Melting points were determined in open capillary tubes 
and are uncorrected. P-60 silica gel was used to conduct flash chromatography. Silica 
pre-coated TLC plates were used to perform TLC analysis. Normal phase pre-coated 
silica rotors were chosen to perform radial chromatography. NMR was obtained using 
400 MHz Bruker or 300 MHz Varian instruments. MS was obtained using ESI/FTICR-
MS, and low resolution MS was obtained by ESI/ion trap. IR was conducted on Thermo 
Nicolet nexus 470 FT-IR instrument. Pig Liver Esterase (PLE) is the commercially 
available crude preparation. 
General Experimental Procedure for the Synthesis of Malonate Esters (9a-9f) 
 A 250 mL roundbottom 3-neck flask fitted with a nitrogen inlet, an addition 
funnel, and a reflux condenser was charged with 1.2 eq. of NaH (60% dispersion in 
mineral oil), a stirbar, and 100 mL of dry THF. The resulting suspension was cooled to 0 
o
C in an icebath. A 50 mL solution of diethyl-2-methylmalonate (1eq) in THF was added 
over 30 min with stirring. The reaction mixture was then allowed to stir for 60 min at 
room temperature. A 100 mL solution of N-(bromoalkyl)-phthalimide (1eq) in THF was 
added over 30 min with stirring. The reacton mixture was then heated to reflux solvent 
for 12 h. The solution was cooled to RT, diluted with ether (300 mL), washed twice with 
1 N HCl, washed with brine and dried over MgSO4. The resulting suspension was then 
filtered and the solvent was evaporated "in vacuo". The resulting yellowish liquid was 
purified by flash chromatography. 
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Diethyl 2-(N-Methylphthalimido)-2-Methyl Malonate (9a) 
 9a was prepared following the general procedure for the formation of diester (9a-
9f) with 10g (57.4 mmol) diethyl-2-methylmalonate. The resulting yellowish liquid was 
purified by flash chromatography (30:70 EtOAc/Hexanes), giving the pure product as a 
white solid (12.5g, 65%).
74
 Rf 0.54 (30:70 EtOAc/hexanes), MP= 89 
o
C. 
1
H-NMR (300 
MHz, CDCl3): 7.84 (m, 2H), 7.73 (m 2H), 4.27 (s, 2H), 4.26 (q, 4H, J= 7 Hz), 1.41 (s, 
3H), 1.30 (t, 6H, J=7 Hz), 
13
C-NMR (75 MHz, CDCl3): 14.0, 18.3, 42.0, 54.0, 62.0, 123.0, 
132.0, 134.7, 168.5, 170.5. HRMS (C17H19NO6Na
+
): calculated = 356.1104, found = 
356.1100. 
Diethyl 2-(N-Ethylphthalimido)-2-Methyl Malonate (9b) 
  9b was prepared following the general procedure for the formation of diester (9a-
9f) with 10g (57.4 mmol) diethyl-2-methylmalonate, 14.6g (57.4 mmol) N-(bromoethyl)-
phthalimide, and 2.74g (68.9 mmol) NaH. The resulting yellowish liquid was purified by 
flash chromatography (18:82 EtOAc/Hexanes), giving the pure product as a white solid 
(9g, 45%).
84
 
Diethyl 2-(N-Propylphthalimido)-2-Methyl Malonate (9c) 
  9c was prepared following the general procedure for the formation of diester (9a-
9f) with 10g (57.4 mmol) diethyl-2-methylmalonate, 15.4g (57.4 mmol) N-
(bromopropyl)-phthalimide and 2.74g (68.9 mmol) NaH. The resulting yellowish liquid 
was purified by flash chromatography (30:70 EtOAc/Hexanes), giving the pure product 
as a colorless liquid (12.8g, 62%). Rf = 0.36 (30% EtOAc/Hexanes). IR (cm
-1
) = 2981, 
1772, 1705, 1614. 
1
H-NMR (CDCl3, 400 MHz): δ 7.84 (m, 2H), 7.72 (m, 2H), 4.16 (q, 
4H, J = 7Hz), 3.69 (t, 2H, J = 7Hz), 1.91 (m, 2H), 1.67 (m, 2H), 1.39 (s, 3H), 1.23 (t, 6H, 
41 
 
 
 
J = 7Hz). 
13
C- NMR (CDCl3, 100 MHz): δ 172.0, 168.0, 134.0, 132.0, 123.0, 61.0, 53.0, 
38.0, 32.5, 23.3, 20.0, 14.0. HRMS (C19H23NO6Na
+
) calculated = 384.1423, found = 
384.1406. 
Diethyl 2-(N-Butylphthalimido)-2-Methyl Malonate (9d) 
  9d was prepared following the general procedure for the formation of diester (9a-
9f) with 10g (57.4 mmol) diethyl-2-methylmalonate, 16.2g (57.4 mmol) N-(bromobutyl)-
phthalimide and 2.74g (68.9 mmol) NaH. The resulting yellowish liquid was purified by 
flash chromatography (30:70 EtOAc/Hexanes), giving the pure product as a white solid 
(15.2g, 70%). Rf = 0.40 (30% EtOAc/Hexanes). IR (cm-1) = 2950, 1702. MP = 48 
0
C. 
1
H- NMR (CDCl3, 300 MHz): δ 7.85 (m, 2H), 7.71 (m, 2H), 4.17 (q, 4H, J = 7Hz), 3.67 
(t, 2H, J = 7Hz), 1.90 (m, 2H), 1.69 (m, 2H), 1.39 (s, 3H), 1.27 (m, 8H). 
13
C-NMR 
(CDCl3, 75 MHz): δ 172.0, 168.0, 134.0, 132.0, 123.0, 61.0, 53.0, 38.0, 35.0, 29.0, 22.0, 
20.0, 14.0. HRMS (C20H25NO6Na
+
) calculated = 398.1574, found = 398.1573. 
Diethyl 2-(N-Pentylphthalimido)-2-Methyl Malonate (9e) 
  9e was prepared following the general procedure for the formation of diester (9a-
9f) with 10g (57.4 mmol) diethyl-2-methylmalonate, 17g (57.4 mmol) N-(bromopentyl)-
phthalimide and 2.74g (68.9 mmol) NaH. The resulting yellowish liquid was purified by 
flash chromatography (30:70 EtOAc/Hexanes), giving the pure product as a colorless 
liquid (14.8g, 66%). Rf = 0.42 (30% EtOAc/Hexanes). IR (cm
-1
) = 2938, 1772, 1706. 
1
H-
NMR (CDCl3, 300 MHz): δ 7.83 (m, 2H), 7.71 (m, 2H), 4.17 (q, 4H, J = 7Hz), 3.68 (t, 
2H, J = 7Hz), 1.82 (m, 2H), 1.67 (m, 2H), 1.30 (m, 13H). 
13
C-NMR (CDCl3, 75 MHz): δ 
172.0, 168.0, 134.0, 132.0, 123.0, 61.0, 54.0, 38.2, 35.2, 28.5, 27.0, 24.0, 20.0, 14.0. 
HRMS (C21H27NO6Na
+
) calculated = 412.1730, found = 412.1728. 
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Diethyl 2-(N-Hexylphthalimido)-2-Methyl Malonate (9f) 
  9f was prepared following the general procedure for the formation of diester (9a-
9f) with 10g (57.4 mmol) diethyl-2-methylmalonate, 17.8g (57.4 mmol) N-
(bromopentyl)-phthalimide and 2.74g (68.9 mmol) NaH. The resulting yellowish liquid 
was purified by flash chromatography (40:60 Et2O/Hexanes), giving the pure product as a 
colorless liquid (16.5g, 71%). Rf = 0.44 (30% EtOAc/Hexanes). IR (cm
-1
) = 2940, 1702. 
1
H-NMR (CDCl3, 400 MHz): δ 7.83 (m, 2H), 7.71 (m, 2H), 4.16 (m, 4H), 3.67 (m, 2H), 
1.84 (m, 2H), 1.66 (m, 2H), 1.36 (m, 7H), 1.24 (m, 8H). 
13
C-NMR (CDCl3, 100 MHz): δ 
172.0, 168.0, 134.0, 132.0, 123.0, 61.0, 54.0, 38.0, 35.0, 29.0, 28.0, 27.0, 24.0, 20.0, 14.0. 
HRMS (C21H27NO6Na
+
) calculated = 426.1893, found = 426.1894. 
General Experimental Procedure for the Formation of Chiral Half-Esters (10a-10f) 
  10g (1 eq) of the appropriate malonate (9a-9f) was dispersed in 1000 mL of 
rapidly stirring phosphate buffer (0.1N, pH 7.4) containing 2% (vol/vol)EtOH as a 
cosolvent. The pH was maintained using an autotitrator set to maintain a pH of 7.4 and 
titrate to a volume of 1 eq NaOH (1.06M). PLE (27 units/mg, 90 units per mmol of the 
substrate) was added and the titration was started. The hydrolysis proceeded for 1-6 days 
depending on substrate. The reaction was stopped when 1 eq. of NaOH was added. The 
reaction mixture was extracted three times with 500 mL of Et2O. The aqueous layer was 
then acidified to pH = 1 using 12 M HCl, extracted eight times with Et2O. The organic 
layer was dried over MgSO4, filtered, and concentrated in vacuo. 
(R)-2-(N-Methylphthalimido)-3-Ethoxy-2-Methyl-3-Oxopropanoic Acid (10a) 
  10a was prepared following the general procedure for the formation of half-esters 
(10a-10f) with 10g (30 mmol) of 9a. An amount of 6g (65%) of 10a was obtained as a 
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white solid in 52% ee.
74
 MP = 148 
o
C. Rf = 0.31 (40:60 EtOAc/hexanes). 
1
H-NMR (300 
MHz, CDCl3): 9.63 (s, 1H), 7.86 (m, 2H), 7.74 (m, 2H), 4.29 (m, 4H), 1.48 (s, 3H), 1.34 
(t, 3H, J= 7 Hz), 
13
C- NMR (75 MHz, CD3OD) 14.0, 19.0, 42.0, 53.0, 62.0, 124.0, 133.0, 
135.0, 170.0, 174.0, 175.0. HRMS (C15H15NO6Na
+
) calculated = 328.0791, found = 
328.0787. The % ee was determined by chiral HPLC (Chiracel OJ-H, 305 nm, 5% Ipr-
OH/hexane) Rt(S) = 33 min, Rt(R) = 47.8 min (52% ee).  = +5.2 (c = 1, MeOH). 
(R)-2-(N-ethylphthalimido)-3-ethoxy-2-methyl-3-oxopropanoic acid (10b): 10b was 
prepared following the general procedure for the formation of half-esters (10a-10f) with 
10g (29 mmol) of 9b.  An amount of 7.2g (71%) of 10b was obtained as a white solid in 
92% ee.
84
 
(R)-2-(N-Propylphthalimido)-3-Ethoxy-2-Methyl-3-Oxopropanoic Acid (10c) 
  10c was prepared following the general procedure for the formation of half-esters 
(10a-10f) with 10g (28 mmol) of 9c. The resulting half-ester was purified by flash 
chromatography (40:60 EtOAc/Hexanes) giving the product as a colorless liquid (6.4g, 
68%). The % ee was determined to be 97% by chiral HPLC (Diacel Chiralpak OJ-H, 4% 
iPrOH/Hexanes, flow rate = 1 mL/min, λ = 305 nm) Rt(S) = 54.9 min (Area = 130.13), 
Rt(R) = 58.8min (Area = 7770.41). Rf = 0.22 (40% EtOAc/Hexanes). IR (cm
-1
) = 2983, 
2937, 1773, 1747, 1697. = + 5.8 (c = 2, MeOH). 
1
H-NMR (CDCl3, 400 MHz): δ 
7.85 (m, 2H), 7.73 (m, 2H), 4.21 (q, 2H, J = 7Hz), 3.71 (t, 2H, J = 7Hz), 1.93 (m, 2H), 
1.71 (m, 2H), 1.45 (s, 3H), 1.26 (t, 3H, J = 7Hz). 
13
C-NMR (CDCl3, 100 MHz): δ 176.0, 
172.0, 168.0, 134.0, 132.0, 123.0, 62.0, 53.0, 38.0, 33.0, 24.0, 20.0, 14.0. HRMS 
(C16H17NO6Na
+
) calculated = 356.3256, found = 356.3253. 
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(R)-2-(N-Butylphthalimido)-3-Ethoxy-2-Methyl-3-Oxopropanoic Acid (10d) 
   10d was prepared following the general procedure for the formation of half-esters 
(10a-10f) with 10g (27 mmol) of 9d, The resulting half-ester was purified by flash 
chromatography (40:60 EtOAc/Hexanes) giving the pure product as a white solid (6.6g, 
70%). The % ee was determined to be 95% by chiral HPLC (Diacel Chiralpak OJ-H, 4% 
iPrOH/Hexanes, flow rate = 1mL/min, λ = 305 nm) Rt(S) = 63.0 min (Area = 325.24), Rt(R) 
= 49.6 min (Area = 11659.65). Rf = 0.24 (40% EtOAc/Hexane). IR (cm
-1
) = 3250, 2943, 
1718, 1696. MP = 63 
0
C. = + 3.3 (c = 1, CH2Cl2), 
1
H-NMR (CDCl3, 300 MHz): δ 
9.82 (bs, 1H), 7.82 (m, 2H), 7.73 (m, 2H), 4.21 (q, 2H, J = 7Hz), 3.71 (t, 2H, J = 7Hz), 
1.93 (m, 2H), 1.69 (m, 2H), 1.45 (s, 3H), 1.35 (m, 2H), 1.26 (t, 3H, J = 7Hz),
13
C-NMR 
(CD3Cl3, 100 MHz): δ 176.0, 174.0, 169.2, 135.3, 133.2, 124.0, 62.0, 54.3, 39.0, 36.0, 
30.0, 23.0, 20.0, 14.0. HRMS (C16H17NO6Na
+
) calculated = 370.1261, found = 370.1256. 
(R)-2-(N-Pentylphthalimido)-3-Ethoxy-2-Methyl-3-Oxopropanoic Acid (10e) 
  10e was prepared following the general procedure for the formation of half-esters 
(10a-10f) with 10g (26 mmol) of 9e. The resulting half-ester was purified by flash 
chromatography (40:60 EtOAc/Hexanes) giving the pure product as a colorless liquid 
(5.8g, 61%). The % ee was determined to be 81% by chiral HPLC (Diacel Chiralpak AD-
H, 3% iPrOH/Hexanes, flow rate = 1 mL/min, λ = 305 nm) Rt(S) = 114.60 min (Area = 
1591.84), Rt(R) = 78.75min (Area = 15497.54). Rf = 0.28 (40% EtOAc/Hexanes). IR (cm
-1
) 
= 3250, 2938, 1770, 1700.  = + 3.2 (c = 2, CHCl3), 
1
H-NMR (CDCl3, 300 MHz): δ 
7.83 (m, 2H), 7.72 (m, 2H), 4.21 (q, 2H, J = 7.19), 3.68 (t, 2H, J = 7 Hz), 1.86 (m, 2H), 
1.69 (m, 2H), 1.44 (s, 3H), 1.34 (m, 4H), 1.27 (t, 3H, J = 7 Hz), 
13
C-NMR (CDCl3, 75 
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MHz): δ 178.0, 172.0, 168.4, 134.0, 132.0, 123.0, 61.4, 54.0, 38.0, 35.5, 28.3, 27.2, 24.0, 
20.0, 14.0. HRMS (C19H23NO6Na
+
) calculated = 384.1417, found = 384.1413. 
(R)-2-(N-Hexylphthalimido)-3-Ethoxy-2-Methyl-3-Oxopropanoic Acid (10f) 
  10f was prepared following the general procedure for the formation of half-esters 
(10a-10f) with 10g (25 mmol) of 9f. The resulting half-ester was purified by flash 
chromatography (40:60 EtOAc/Hexanes) giving the pure product as a colorless liquid 
(6.12g, 61%). The % ee was determined to be 64% by chiral HPLC (Diacel Chiralpk OJ-
H, 3% iPrOH/Hexanes, flow rate = 1 mL/min, λ = 305 nm) Rt(R) = 57.7 min (Area = 
13605958), Rt(S) = 71.7min (Area = 2954776).  = + 2.05 (c = 2, CHCl3), 
1
H-NMR 
(CDCl3, 400 MHz): δ 7.83 (m, 2H), 7.72 (m, 2H), 4.21 (q, 2H, J = 7.19), 3.68 (t, 2H, J = 
7.12), 1.86 (m, 2H), 1.69 (m, 2H), 1.44 (s, 3H), 1.34 (m, 4H), 1.27 (t, 3H, J = 7.15), 
13
C-
NMR (CDCl3, 100 MHz): δ 177.0, 173.0, 168.4, 134.0, 132.0, 123.0, 61.3, 53.0, 38.0, 
35.5, 29.2, 28.2, 26.3, 24.0, 20.0, 14.0. HRMS (C20H25NO6Na
+
) calculated = 398.1574, 
found = 398.1572. 
(R)-2-(Ethoxycarbonyl)-3-Hydroxy-2-Methylpropanoic Acid (13) 
  A 100 mL roundbottom flask was charged with a stirbar, 400 mg of 10% Pd/C, 
4.0g (15 mmol) of (R)-12, and 50 mL of THF.
85
 The resulting suspension was stirred 
rapidly under a hydrogen atmosphere (atmospheric pressure) for 5 h. The reaction 
mixture was then filtered through a Celite® bed and the filtrate was evaporated to give 
2.5 g (14.2 mmol, 95%) of 13 as a yellow viscous liquid. The characterization data 
matched with the literature values.
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(S)-1-Benzyl-3-Ethyl-2-(Hydroxymethyl)-2-Methylmalonate (14) 
A 100 mL roundbottom flask was charged with a stirbar, 2.3g of 13 (13 mmol), and 20 
mL of DMF. The flask was placed under a nitrogen atmosphere and cooled to 0 
o
C with 
stirring and 2.15 g of K2CO3 (15.6 mmol) was added. Benzyl bromide (1.96g, 11.5 mmol) 
was added drop wise to the stirring suspension. The suspension was allowed to stir 
overnight at room temperature. The suspension was then diluted with 100 mL of diethyl 
ether and the organic layer was washed three times with water. The organic layer was 
then dried over MgSO4, filtered, and evaporated under reduced pressure. The crude liquid 
was then purified by flash chromatography (40% EtOAc/Hexane) giving 2.7 g (10.1 
mmol, 88%) of 14 as a viscous liquid. Rf = 0.5 (40% EtOAc/Hexane). 
1
H-NMR (300 
MHz, CDCl3): 7.33 (5H, m), 5.2 (2H, s), 4.16 (2H, q, J = 7Hz), 3.87 (2H, s), 2.92 (1H, 
bs), 1.47 (3H, s), 1.18 (3H, t, J = 7Hz). 
13
C-NMR (75 MHz, CDCl3): 172.0, 135.0, 128.8, 
128.6, 128.3, 67.3, 66.9, 62.0, 56.0, 17.8, 14.0. IR (cm
-1
): 3528, 2983, 1721. HRMS 
(C14H18O5Na
+
) calculated= 289.1098, found = 555.2197 (C14H18O5)2Na
+
). 
(S)-Benzylethyl-2-Methylsulfonylmethyl-2-Methyl Malonate (15) 
  A 100 mL sealed tube was charged with a stir bar, 2.6g of 14 (9.7 mmol), and 20 
mL of DMF. Et3N (1.2g, 11.7 mmol) was then added drop wise and the solution was 
allowed to stir for 5 min. followed by the rapid addition of 1.34g (11.7 mmol) of 
methanesulfonyl chloride. The tube was tightly sealed and allowed to stir at room 
temperature for 6 h. The tube was opened and the reaction mixture was diluted with 100 
mL of diethyl ether. The organic layer was washed three times with water, dried over 
MgSO4, filtered, and evaporated under reduced pressure to give 2.7 g (7.8 mmol, 80%) of 
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15 as colorless liquid. Due to the potential reactivity of 15, it was used in the next step 
without further purification. 
(S)- 1-Benzyl-3-Ethyl-2-(Azidomethyl)-2-Methylmalonate (16) 
 A 100 mL sealed tube was charged with a stirbar, 20 mL of DMF, and 2.7g of 15 
(7.8 mmol). The solution was sparged for 5 min. with dry nitrogen gas and then 1g (15.7 
mmol) of NaN3 was added. The tube was sealed and allowed to stir at 90 
o
C for 12 h. The 
reaction mixture was cooled and diluted with 100 mL of diethyl ether. The resulting 
organic layer was washed three times with water, dried over MgSO4, and evaporated 
under reduced pressure. The crude product was purified by column chromatography 
(30% EtOAc/Hexane) giving 0.8 g (2.7 mmol, 35%) of 10 as a pale yellow liquid. Rf = 
0.74 (30% EtOAc/Hexane), (c = 2.86, CHCl3),   
1
H-NMR (300 MHz, 
CDCl3): 7.35 (m, 5H), 5.20 (s, 2H), 4.16 (q, 2H, J = 6 Hz), 3.75 (s, 2H), 1.52 (s, 3H), 
1.17 (t, 3H, J = 7 Hz), 
13
C-NMR (75 MHz, CDCl3): 14.0, 18.0, 54.0, 56.0, 62.0, 68.0, 
129.0, 136.0, 170.0. IR (cm
-1
):1727, 2104. HRMS (C14H17O4N3Na
+
) calculated = 
314.2923, found = 605.2329 (C14H17N3O4)2Na
+
). 
(R)-2-(Ethoxycarbonyl)-3-Amino-2-Methylpropanoic Acid (17) 
  A 50 mL roundbottom flask was charged with 100 mg of 10% Pd/C, 10 mL of 
THF, 0.5g (1.7 mmol) of 16, and a stir bar. The roundbottom flask was fitted with a 
septum and a balloon filled with hydrogen was attached to the flask via a needle. The 
mixture was stirred vigorously under a hydrogen atmosphere for 12 h. The reaction vessel 
was then opened and the contents were filtered through a pad of Celite
®
 and the filter 
cake was washed with additional THF. The filtrate was evaporated under reduced 
pressure at room temperature giving 0.27 g (1.5 mmol, 88%) of 17 as a white solid. Rf = 
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0.2 (10% MeOH/CH2Cl2), MP = 114 
o
C,   = - 4.16 (c = 1.25, MeOH). 
1
H-NMR (300 
MHz, CDCl3): 4.19 (m, 2H), 3.25 (d, 1H, J= 14 Hz), 3.03 (d, 1H, J= 14Hz), 1.47 (s, 3H), 
1.27 (t, 3H, J= 7 Hz). 
13
C-NMR (75 MHz, CDCl3): 13.0, 19.0, 44.0, 52.0, 61.0, 173.0, 
175.0. IR (cm
-1
): 1582, 3245. HRMS (C7H13NO4Na
+
) calculated = 198.1824, found = 
373.1579 (C7H13NO4)2Na
+
). 
(R)-2-(Ethoxycarbonyl)-3-Amino-2-Methylpropanoic Acid (17) from 10a 
  A 50 mL round bottom flask was charged with 0.5g (1.6 mmol) of 10a, 20 mL of 
MeOH, 0.058g (1.8 mmol) of hydrazine hydrate (35% in water), and a stir bar. The flask 
was fitted with a reflux condenser and the reaction mixture was heated to 60 
o
C. The 
reaction was allowed to proceed for 6 h. The reaction mixture was allowed to cool and 
then filtered. The filtrate was evaporated under reduced pressure and the resulting residue 
was purified by column chromatography (8% MeOH/CHCl3) to give 0.15g (0.86 mmol, 
54%) of 17 as a white solid. = - 2.4 (c = 1.25, MeOH). The characterization data 
matched with 17 that was prepared from 16 as indicated above. 
Synthesis of (S)–1-Benzyl-3-Ethyl-2-Methyl-2-(2-(1,3-Dioxoisoindolin-2-Yl)Malonate (18)  
 A 250 mL round bottom flask was charged with 10g of 10b (31 mmol), 4.3 g of 
K2CO3 (31 mmol), 100 mL of anhydrous DMF, and a stirbar. A solution of 4.8g benzyl 
bromide (28 mmol) in 20 mL anhydrous DMF was slowly added over 15 minutes. The 
reaction was allowed to stir approximately 12 hr. under a nitrogen atmosphere. The 
reaction mixture was then diluted with 100 mL of water and the resulting mixture was 
washed with Et2O (3 x 100 mL). The combined ether layer was washed with water (5 x 
100 mL), washed with brine (2 x 100 mL), dried over MgSO4, and the solvent was 
removed under reduced pressure. The product was purified by flash chromatography 
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(40% Et2O/Hexanes) providing 11g of 18 (27 mmol, 96%) as a colorless liquid. Rf = 0.2 
(40% Et2O/Hexanes).  = -3.08 (c = 1, CHCl3). IR (cm
-1
): 2980, 1773, 1708. 
1
H-
NMR (CDCl3, 400 MHz): δ 7.83 (m, 2H), 7.70 (m, 2H), 7.33 (m, 5H), 5.15 (m, 2H), 4.10 
(m, 2H), 3.74 (m, 2H), 2.28 (m, 2H), 1.56 (s, 3H), 1.16 (t, 3H, J = 7 Hz). 
13
C-NMR 
(CDCl3, 100 MHz): δ 171.4, 171.3, 168.0, 135.5, 134.0, 132.0, 128.5, 128.3, 128.1, 123.0, 
67.0, 61.0, 52.0, 33.8, 33.8, 20.0, 14.0. HRMS (C23H23NO6Na
+
): calculated = 432.1417, 
found = 432.1406. 
Synthesis of (R)-Ethyl-3-Methyl-2-Oxopyrrolidine-3-Carboxylate (19a) 
 A volume of 930 µL (10.2 mmol) 35% hydrazine in water was added to a solution 
of 3.8g (9.3 mmol) of 18 in 50 mL MeOH. The mixture was heated to reflux solvent 
overnight. A white precipitate was observed within an hour of reflux. The reaction 
mixture was allowed to cool to RT, and the resulting mixture was filtered. The filtrate 
was evaporated under reduced pressure. The resulting residue was taken up in CH2Cl2 
and washed with water. The organic layer was dried over MgSO4, evaporated under 
reduced pressure, and purified by column chromatography using 30% Hexanes/EtOAc 
giving 1.2 g of a 10:1 mixture of 19a:19b as a white solid. The mixture was recrystallized 
in cold Et2O giving 1g (6 mmol, 64.5%) of pure 19a as white crystals. Rf (5) = 0.31 (30% 
Hexanes/EtOAc). MP = 63 
0
C. = +19.0 (c = 2, MeOH). IR (cm
-1
): 3245, 2985, 1726, 
1698, 1660. 
1
H-NMR (CDCl3, 400 MHz): δ 7.06 (bs, 1H), 4.20 (m, 2H), 3.47 (m, 1H), 
3.36 (m, 1H), 2.64 (m, 1H), 2.02 (m, 1H), 1.45 (s, 3H), 1.28 (t, 3H, J = 7 Hz), 
13
C-NMR 
(CDCl3, 100 MHz): δ 177.0, 172.0, 61.0, 51.0, 40.0, 34.0, 20.0, 14.0. HRMS 
(C8H13NO3Na
+
): calculated = 194.0788, found = 194.0795. 
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(R)–3-Methyl-2-Oxopyrrolidine-3-Carboxylic Acid (20) 
  An amount of 1.6g (9.4 mmol) of 19a was dissolved in 15 mL ethanol. A volume 
of 7 mL 1N NaOH was added to the reaction mixture. The solution was brought to reflux 
solvent for an hour. The solution was cooled and acidified with HCl to pH 4. The water 
layer was concentrated at 35 
0
C under high vacuum. A volume of 10 mL MeOH was 
added to the residue and stirred for 5 min. The MeOH layer was decanted from the 
remaining solid and concentrated in vacuo giving 1g of 20 (6.9 mmol, 73%) as a white 
solid. MP = 155 
0
C. IR (cm
-1
) = 3363, 3368, 2975, 2906, 1749, 1722, 1704, 1636, 1485. 
Rf = 0.17 (5% MeOH/ CH2Cl2). 
1
H-NMR (CD3OD, 400 MHz): δ 3.35 (m, 1H), 3.25 (m, 
1H), 2.49 (m, 1H), 1.95 (m, 1H), 1.27 (s, 3H). 
13
C-NMR (CD3OD, 100 MHz): δ 179.6, 
175.7, 52.1, 40.7, 35.0, 20.3. ESI-MS (C6H10NO3)
+
 
 
= 143.1, observed = 143.2. 
Benzyl (R)-3-Methyl-2-Oxopyrrolidin-3-Ylcarbamate (21) 
   An amount of 1.77g (12.4 mmol) of 20 was dissolved in 50 mL of dry 
dichloroethane. A volume of 3.6 mL (26 mmol) Et3N was added followed by 3.1 mL 
(13.6 mmol) diphenylphosphorylazide (DPPA). The solution was allowed to stir for 2 hrs 
at RT and then heated to reflux solvent for 2 hr. A volume of 1.8 mL (17.4 mmol) benzyl 
alcohol was then added and the solution was allowed to reflux solvent over night. The 
dichloroethane layer was concentrated in vacuo and the residue was purified by flash 
chromatography (40% EtOAc/Hexanes) giving 1.97g of 21 as a white wax (7.9 mmol, 
64%). Rf = 0.10 (40% EtOAc/Hexanes). IR (cm
-1
) = 3225, 1725, 1693, 1657, 1536. 
1
H-
NMR (CDCl3, 400 MHz): δ 7.33 (m, 5H), 6.75 (bs, 1H), 5.55 (bs, 1H), 5.06 (m, 2H), 
3.34 (m, 2H), 2.52 (m, 1H), 2.31 (m, 1H), 1.40 (s, 3H). 
13
C-NMR (CDCl3, 100 MHz): δ 
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178.2, 155.2, 136.2, 128.7, 128.3, 128.2, 66.7, 57.2, 39.0, 34.8, 22.3. HRMS 
(C13H16N2O3Na
+
) = 271.1053, observed = 271.1047. 
(R)- Tert-Butyl- 3- Methyl- 2-Ooxopyrrolidin-3- Ylcarbamate (22) 
 An amount of 1.6 g (6.4 mmol) of 21 was dissolved in 25 mL MeOH in a pressure 
bottle. An amount of 0.16g Pd-C (10%) was added to the reaction mixture. The reaction 
mixture was allowed to shake under 20 psi H2 pressure for 12 hr. The MeOH layer was 
filtered off through a Celite bed. The filtrate was concentrated "in vacuo" giving 0.66g of 
the free amine (5.8 mmol), which was then dissolved in 20 mL THF. A volume of 1.7mL 
(11.6 mmol) Et3N was added to the reaction mixture. A solution of 1.5g (BOC)2O (6.9 
mmol) in 10 mL THF was added to the reaction mixture drop wise. The reaction mixture 
was allowed to stir over night at RT. The THF was concentrated and the resulting residue 
was extracted with Et2O and water. The ether layer was concentrated and the residue was 
rinsed with hexane giving 0.83g of the 22 (3.9 mmol, 61% over two steps) as a white 
solid. The characterization of 22 complied with the literature.
75
  = -16 (c = 0.35, 
CHCl3). 
General Experimental Procedure for the Formation of Carbamates (23a-23f) 
 An amount of 10g (1eq) of the appropriate chiral half-ester (10a-10f) was 
dissolved in 50 mL dichloroethane in a 500 mL round bottom flask with a stirbar under a 
N2 atmosphere. A measured volume of Et3N (2.1 eq) and diphenylphosphorylazide 
(DPPA) (1.1eq) was added to the solution and the solution was allowed to stir at RT for 
90 min. At this point the reaction was heated to reflux solvent for 2 hrs. A measured 
volume of para-methoxybenzyl alcohol (PMB-OH) (1.4 eq) was added to the reaction 
mixture and the reaction was continued to reflux solvent for 12 hrs. The reaction was 
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cooled and diluted with CH2Cl2, filtered through a silica bed (1” bed in a Buchner funnel) 
and evaporated. The resulting residue was purified by flash chromatography (40% 
EtOAC/Hexanes) giving the pure product as a white wax or colorless viscous oil. 
4-Methoxybenzyl-(S)-2-(Ethoxycarbonyl)-1-(1,3-Dioxoisoindolin-2-Yl)Propan-2-
Ylcarbamate(23a) 
 23a was prepared following the general synthetic procedure for the formation of 
carbamates (23a-23f). An amount of 11.7g (26.5 mmol, 79%) of product was obtained as 
a white wax. Rf = 0.25 (40% EtOAc/Hexanes). IR (cm
-1
) = 3368, 2958, 1774, 1708, 1612. 
 = - 1.2 (c = 1.2, CHCl3). 
1
H-NMR (CDCl3, 400 MHz): δ 7.84 (m, 2H), 7.73 (bs, 
2H), 7.31 (d, 2H, J = 9 Hz), 6.87 (d, 2H, 9 Hz), 6 (bs, 1H), 5 (q, 2H, J = 12 Hz), 4.18 (m, 
2H), 4.12 (s, 2H), 3.8 (s, 3H), 1.65 (S, 3H), 1.25 (m, 3H). 
13
C-NMR (CDCl3, 100MHz): δ 
171.0, 168.5, 159.0, 155.0, 134.0, 132.0, 130.0, 128.4, 123.0, 113.3, 66.0, 62.0, 60.2, 55.0, 
43.4, 20.0, 14.0. HRMS (C23H24N2O7Na
+
) calculated = 463.1476, found = 463.1469. 
4-Methoxybenzyl-(S)-2-(Ethoxycarbonyl)-4-(1,3-Dioxoisoindolin-2-Yl)Butan-2-
Ylcarbamate(23b) 
 23b was prepared following the general synthetic procedure for the formation of 
carbamates (23a-23f). An amount of 12g (26.4 mmol, 84%) of product was obtained as a 
colorless viscous oil. Rf = 0.29 (35% EtOAc/Hexanes). IR (cm
-1
) = 3353, 2952, 1771, 
1704, 1612.  = + 11.3 (c =1, CH2Cl2). 
1
H-NMR (CDCl3, 400 MHz): δ 7.81 (m, 2H), 
7.69 (m, 2H), 7.28 (m, 2H), 6.87 (m, 2H), 5.78 (bs, 1H), 4.94 (m, 2H), 4.07 (m, 2H), 3.80 
(s, 3H), 3.67 (m, 2H), 2.57 (bm, 1H), 2.36 (m, 1H), 1.60 (s, 3H), 1.12 (t, 3H, J = 7Hz), 
13
C-NMR (CDCl3, 100MHz): δ 173.0, 168.0, 159.0, 154.0, 134.0, 132.0, 130.0, 128.6, 
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123.0, 114.0, 66.0, 62.0, 58.0, 55.0, 34.0, 33.6, 24.0, 14.0. HRMS (C24H26N2O7Na
+
) 
calculated = 477.1638, found = 477.1635. 
4-Methoxybenzyl-(S)-2-(Ethoxycarbonyl)-5-(1,3-Dioxoisoindolin-2-Yl)Pentan-2-
Ylcarbamate(23c) 
  23c was prepared following the general synthetic procedure for the formation of 
carbamates (23a-23f). An amount of 11.8g (25.2 mmole, 84%) of product was obtained 
as a colorless viscous oil. Rf = 0.27 (35% EtOAc/Hexane). IR (cm
-1
) = 3359, 2939, 1770, 
1702, 1612.  = - 6.0 (c = 0.8, CH2Cl2). 
1
H-NMR (CDCl3, 400 MHz): δ 7.82 (m, 2H), 
7.70 (m, 2H), 7.28 (m, 2H), 6.88 (m, 2H), 5.63 (bs, 1H), 4.95 (s, 2H), 4.16 (m, 2H), 3.79 
(s, 3H), 3.65 (m, 2H), 2.26 (m, 1H), 1.84 (m, 1H), 1.69 (m, 1H), 1.54 (s, 3H), 1.48 (m, 
1H), 1.21 (t, 3H, J = 7Hz). 
13
C-NMR (CDCl3, 100MHz): δ 174, 168, 160, 154, 134, 132, 
130, 128, 123, 114, 66, 62, 60, 55, 38, 34, 23.5, 23.4, 14. HRMS (C25H28N2O7Na
+
) 
calculated = 491.1789, found = 491.1782. 
4-Methoxybenzyl-(S)-2-(Ethoxycarbonyl)-6-(1,3-Dioxoisoindolin-2-Yl)Hexan-2-
Ylcarbamate(23d) 
 23d was prepared following the general synthetic procedure for the formation of 
carbamates (23a-23f). An amount of 11.5g (24 mmol, 83%) of product was obtained as a 
colorless viscous oil. Rf = 0.31 (35% EtOAc/Hexanes). IR (cm
-1
) = 3360, 2958, 1768, 
1701, 1612.  = - 1.5 (c = 1.5, CHCl3). 
1
H-NMR (CDCl3, 400 MHz): δ 7.82 (m, 2H), 
7.69 (m, 2H), 7.30 (m, 2H), 6.88 (m, 2H), 5.62 (bs, 1H), 4.99 (s, 2H), 4.17 (m, 2H), 3.8 (s, 
3H), 3.63 (t, 2H, J = 7Hz), 2.17 (m, 1H), 1.83 (m, 1H), 1.65 (m, 2H), 1.56 (s, 3H), 1.33 
(m, 1H), 1.23 (t, 3H, J = 7Hz), 1.12 (m, 1H). 
13
C-NMR (CDCl3, 100MHz): δ 174.0, 
168.0, 159.5, 154.6, 134.0, 132.1, 130.0, 128.7, 123.2, 114.0, 66.2, 62.0, 60.0, 55.3, 38.0, 
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36.0, 28.4, 23.4, 21.4, 14.1. HRMS (C26H30N2O7Na
+
) calculated = 505.1945, found = 
505.1930. 
4-Methoxybenzyl-(S)-2-(Ethoxycarbonyl)-7-(1,3-Dioxoisoindolin-2-Yl)Heptan-2-
Ylcarbamate(23e) 
 23e was prepared following the general synthetic procedure for the formation of 
carbamates (23a-23f). An amount of 11.5g (23 mmol, 82%) of product was obtained as a 
colorless viscous oil. Rf = 0.33 (35% EtOAc/Hexanes), IR (cm
-1
) = 3367, 2938, 1770, 
1703, 1612.  = + 1.4 (c = 1, CH2Cl2). 
1
H-NMR (CDCl3, 400 MHz): δ 7.83 (m, 2H), 
7.70 (m, 2H), 7.28 (d, 2H, J = 9Hz), 6.87 (m, 2H, J = 9Hz), 5.63 (bs, 1H), 4.99 (s, 2H), 
4.18 (m, 2H), 3.79 (s, 3H), 3.64 (t, 2H, J = 7Hz), 2.12 (bm, 1H), 1.76 (m, 1H), 1.64 (m, 
2H), 1.55 (s, 3H), 1.27 (m, 7H). 
13
C-NMR (CDCl3, 100MHz): δ 174.0, 168.0, 159.0, 
155.0, 134.0, 132.0, 130.0, 129.0, 123.0, 114.0, 66.0, 61.0, 60.0, 55.0, 38.0, 36.0, 28.0, 
27.0, 24.0, 23.5, 14.0. HRMS (C27H32N2O7Na
+
) calculated = 519.2102, found = 
519.2095. 
4-Methoxybenzyl-(S)-2-(Ethoxycarbonyl)-8-(1,3-Dioxoisoindolin-2-Yl)Octan-2-
Ylcarbamate(23f) 
23f was prepared following the general synthetic procedure for the formation of 
carbamates (23a-23f). An amount of 11.3g (22 mmol, 83%) of product was obtained as 
colorless viscous oil. Rf = 0.34 (35% EtOAc/Hexanes). IR (cm
-1
) = 3366, 2936, 2859, 
1770, 1703, 1612.  = - 1.7 (c = 1.4, CH2Cl2).  
1
H-NMR (CDCl3, 400 MHz): δ 7.74 
(m, 2H), 7.62 (m, 2H), 7.22 (d, 2H, J = 7Hz), 6.80 (d, 2H, J = 8Hz), 5.51 (bs, 1H), 4.91 (s, 
2H), 4.11 (m, 2H), 3.73 (s, 3H), 3.58 (t, 2H, J = 7Hz), 2.04 (m, 1H), 1.67 (m, 1H), 1.56 
(m, 2H), 1.47 (s, 3H), 1.20 (m, 8H), 0.98 (bm, 1H). 
13
C-NMR (CDCl3, 100MHz): δ 173.0, 
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167.0, 157.0, 154.0, 133.0, 131.0, 129.0, 128.0, 122.0, 113.0, 65.0, 60.0, 59.0, 54.0, 37.0, 
36.0, 28.0, 27.0, 26.0, 23.0, 22.0, 13.0. HRMS (C28H34N2O7Na
+
) calculated = 533.2258, 
found = 533.2251. 
Synthesis of (S)- 2- Methyl-Ornithinedihydrochloride (24a) 
A volume of 30 mL 6N HCl solution was added to 1g of 23c (2.1 mmol) in a 
round bottom flask. The reaction mixture was heated to reflux solvent for 24 hr. The 
aqueous layer was evaporated to dryness under reduced pressure. The resulting gummy 
solid was triturated with EtOAc multiple times leading to 0.4g (1.8 mmol, 86%) of 24a as 
a white solid. All the characterization data of the product complied with the literature.
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 = + 6.86 (c = 0.7, 4N HCl). 
Synthesis of (S)- 2- Methyl-Lysinedihydrochloride (24b) 
A volume of 30 mL 6N HCl solution was added in 1g of 23d (2.1 mmol) in a 
round bottom flask. The reaction mixture was heated to reflux solvent for 24 hr. The 
aqueous layer was evaporated to dryness under reduced pressure. The resulting gummy 
solid was triturated with EtOAc multiple times leading to 0.36g (1.5 mmol, 71%) of 24b 
as a white solid. All the characterization data of the product complied with the 
literature.
59
  = + 7.25 (c = 1, 4N HCl). 
General Synthetic Procedure for the Formation 25a, and 25b 
 An amount of 10e/10f (1 equivalent) was dissolved in DMF under N2. A 
calculated amount of K2CO3 (1.2 equivalent) was added to the solution. A measured 
volume of benzyl bromide (0.95 equivalents) was added to the reaction mixture. The 
reaction was allowed to stir over night under N2. Water was added to the reaction mixture, 
and the  aqueous layer was extracted with Et2O (3 x 50 mL). The combined ether layer 
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was given a water wash (10 x 50 mL). The Et2O layer was dried over MgSO4, 
concentrated, and the residue was purified by flash chromatography (40% Et2O/ Hexanes) 
giving the product as a colorless oil. 
(S)-1-Benzyl-3-Ethyl-2-Methyl-2-(5-(1,3-Dioxoisoindolin-2-Yl)Pentyl)Malonate (25a) 
 25a was synthesized following the general synthetic procedure for the formation 
of 25a/25b using 5g (14 mmol) of 10e. An amount of 5.2g of 25a (11.5 mmol, 82%) was 
obtained as a colorless viscous oil after purification (40% Et2O/Hexanes). Rf = 0.16 (40% 
Et2O/Hexanes). IR (cm
-1
) = 2938, 1770, 1700. 
1
H-NMR (CDCl3, 400 MHz): δ 7.83 (m, 
2H), 7.70 (m, 2H), 7.32 (m, 5H), 5.15 (m, 2H), 4.11 (q, 2H, J = 7Hz), 3.64 (t, 2H, J = 
7Hz), 1.85 (m, 2H), 1.64 (m, 2H), 1.41 (s, 3H), 1.28 (m, 4H), 1.15 (t, 3H, J = 7Hz). 
13
C-
NMR (CDCl3, 100 MHz): δ 172.2, 172.0, 168.4, 136.0, 134.0, 132.2, 128.4, 128.2, 128.0, 
123.2, 66.6, 61.1, 54.0, 38.0, 35.4, 28.2, 27.0, 24.0, 20.0, 14. HRMS (C26H29NO6Na
+
)
 
calculated = 474.1887, observed = 474.1905. 
(S)-1-Benzyl-3-Ethyl-2-Methyl-2-(6-(1,3-Dioxoisoindolin-2-Yl)Hexyl)Malonate (25b) 
 25b was synthesized following the general synthetic procedure for the formation 
of 25a/25b using 5g (13.3 mmol) of 10f. An amount of 5.3g of 25b (11.4 mmol, 86%) 
was obtained as a colorless viscous oil after purification (40% Et2O/Hexanes). Rf = 0.30 
(40% Et2O/Hexanes). IR (cm
-1
) = 2936, 1771, 1706. 
1
H-NMR (CDCl3, 400 MHz): δ 7.83 
(m, 2H), 7.70 (m, 2H), 7.32 (m, 5H), 5.15 (m, 2H), 4.11 (q, 2H, J  = 7Hz), 3.64 (t, 2H, J  
= 7Hz), 1.85 (m, 2H), 1.64 (m, 2H), 1.41 (s, 3H), 1.30 (m, 4H), 1.17 (m, 5H). 
13
C-NMR 
(CDCl3, 100 MHz): δ 172.3, 172.1, 168.4, 136.0, 134.0, 132.2, 128.5, 128.2, 128.0, 123.2, 
66.7, 61.1, 54.0, 38.0, 35.5, 29.4, 28.5, 26.5, 24.2, 20.0, 14. HRMS (C27H31NO6Na
+
) 
calculated = 488.2043, observed = 488.2030. 
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General Synthetic Procedure for the Formation of 26a and 26b 
 A measured amount of 25a/25b (1 equivalent) was dissolved in methanol. A 
calculated amount of 35% N2H4.H2O in water (1.2 equivalents) was added to the reaction 
mixture. The reaction mixture was heated to reflux solvent for 6 hr. The reaction mixture 
was cooled to RT and the white precipitate was filtered off. The MeOH layer was 
concentrated "in vacuo" and the gummy solid was taken up in CH2Cl2 leading to more 
white precipitate. The white precipitate is again removed by filtration and the CH2Cl2 
layer was again concentrated "in vacuo" giving pure product as colorless oil. 
(S)-1-Benzyl-3-Ethyl-2-(5-Aminopentyl)-2-Methylmalonate (26a) 
26a was prepared from 25a following the general synthetic procedure for the 
formation of 26a/26b using 5g of 25a (11 mmol). An amount of 3.3g (10.3 mmol, 94%) 
of 26a was obtained as a colorless viscous oil. Rf = 0.12 (3% MeOH/CH2Cl2). IR (cm
-1
) = 
3100, 3000, 2938, 1724. 
1
H-NMR (CDCl3, 400 MHz): δ 7.32 (m, 5H), 5.15 (m, 2H), 4.11 
(q, 2H, J = 7Hz), 2.65 (t, 2H, J = 7Hz), 1.87 (t, 2H, J = 8Hz), 1.61 (bs, 2H), 1.41 (m, 5H), 
1.24 (m, 7H). 
13
C-NMR (CDCl3, 100 MHz): δ 172.3, 172.2, 136.0, 128.5, 128.2, 128.0, 
67, 61.2, 54.0, 42.0, 35.4, 33.5, 27.0, 24.0, 20.0, 14.0. HRMS (C18H27NO4Na
+
) calculated 
= 344.1832, observed = 344.1823. 
(S)-1-Benzyl-3-Ethyl-2-(6-Aminohexyl)-2-Methylmalonate (26b) 
26b was prepared from 25b following the general synthetic procedure for the 
formation of 26a/26b using 5g of 25b (10.7 mmol). An amount of 3g (8.9 mmol, 83%) of 
26b was obtained as colorless viscous oil. Rf = 0.14 (3% MeOH/CH2Cl2). IR (cm
-1
) = 
3300, 2932, 1726. 
1
H-NMR (CDCl3, 400 MHz): δ 7.25 (m, 5H), 5.07 (m, 2H), 4.04 (q, 
2H, J = 7Hz), 2.68 (bs, 2H), 2.61 (t, 2H, J = 7Hz), 1.77 (t, 2H, J = 7Hz), 1.33 (m, 5H), 
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1.14 (m, 9H). 
13
C-NMR (CDCl3, 100 MHz): δ 171.3, 171.2, 135.0, 127.5, 127.2, 127.0, 
66.0, 60.1, 53.0, 41.0, 34.5, 32.0, 28.5, 25.5, 23.1, 19.0, 13.0. HRMS (C19H29NO4Na
+
) 
calculated = 358.1988, observed = 358.1983. 
General Synthetic Procedure for the Formation of 27a and 27b 
  27a/27b were synthesized from 26a/26b following a literature procedure.
87
 A 
measured amount of 26a/26b (1 equivalent) was dissolved in 24 mL 2:1 2.5M 
NaOH/EtOH mixture. The solution was cooled to 0 
0
C and a measured amount of 
NH2OSO3H (2 equivalent) was added to the solution. The solution was stirred at 0 
0
C for 
35 minutes. At that point an additional amount of NH2OSO3H (1 equivalent) and 5 mL 
2.5 M NaOH were added to the reaction mixture. The reaction was allowed to stir at 0 
0
C 
for another 90 minutes and then allowed to warm to RT overnight. The reaction mixture 
was acidified to pH 1.  The aqueous layer was extracted with Et2O (3 x 50 mL). The 
combined organic layer was washed with brine, dried over MgSO4, concentrated "in 
vacuo", and purified in 1:1 Et2O/Hexanes giving the product as a colorless oil. 
(R)- 2-(Ethoxycarbonyl)-2-Methylheptanoic Acid (27a) 
 27a was prepared from 26a following the general synthetic procedure of making 
27a/27b using 3g of 26a (9.3 mmol). An amount of 1.2g of 27a was obtained (5.5 mmol, 
59%) after purification. Rf = 0.49 (50% Et2O/Hexanes). IR (cm
-1
) = 2956, 2930, 2871, 
1705.  = + 3.15 (c = 2, CH2Cl2). 
1
H-NMR (CDCl3, 400 MHz): δ 10.38 (s, 1H), 4.21 
(q, 2H, J = 7Hz), 1.87 (m, 2H), 1.44 (s, 3H), 1.27 (m, 9H), 0.88 (t, 3H, J = 7Hz). 
13
C-
NMR (CDCl3, 100 MHz): δ 178.0, 172.5, 61.5, 53.6, 35.7, 32.0, 24.0, 22.3, 20.0, 14.0, 
13.9. HRMS (C11H20O4Na
+
) calculated = 239.1255, observed = 239.1253. 
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(R)- 2-(Ethoxycarbonyl)-2-Methyloctanoic Acid (27b) 
 27b was prepared from 26b following the general synthetic procedure of making 
27a/27b using 3g of 26b (8.9 mmol). An amount of 1.3g pure 27b was obtained (5.6 
mmol, 63%) after purification. Rf = 0.51 (50% Et2O/Hexanes). IR (cm
-1
) = 2955, 2927, 
2858, 1705.  = + 2.2 (c = 1, CH2Cl2). 
1
H-NMR (CDCl3, 400MHz): δ 4.21 (q, 2H, J 
= 7Hz), 1.87 (m, 2H), 1.44 (s, 3H), 1.28 (m, 11H), 0.88 (t, 3H, J = 7Hz). 
13
C-NMR 
(CDCl3, 100MHz): δ 178.0, 172.6, 61.6, 53.6, 35.8, 31.4, 29.4, 24.2, 22.6, 20.0, 14.1. 
14.0. HRMS (C12H22O4Na
+
) calculated = 253.1410, observed = 253.1409. 
General Synthetic Procedure for the Formation of 28a and 28b 
 A measured amount of 27a/27b (1 equivalent) was dissolved in 3 mL of H2O, 
and 1 mL of acetone was added to the solution. A solution of Et3N (1.2 equivalent) in 1 
mL acetone was added to the reaction mixture drop wise followed by a solution of 
methylchloroformate (1.55 equivalent) in 1 mL acetone. The reaction was allowed to stir 
for 30 minutes at RT. A solution of NaN3 (1.6 equivalent) in 3 mL H2O was added to the 
reaction mixture and the mixtures was stirred for 2hrs. The reaction mixture was then 
poured into 25 mL of ice cold water. The water layer was extracted with ether (3 x 50 
mL). The combined ether layer was dried over MgSO4, concentrated "in vacuo" giving 
the acylazide as colorless oil. The acylazide was dissolved in toluene and heated to reflux 
solvent for 2 hrs. The toluene was concentrated "in vacuo" giving the isocyanate as 
yellowish oil. A volume of 10 mL 4M HCl was added to the isocyanate and the mixture 
was heated to reflux solvent for 4 hrs. The water layer was concentrated under reduced 
pressure giving the (S)-α-alkyl-alaninehydrochloride as a pale yellowish solid. The 
28a/28b HCl salt was then dissolved in MeOH and NaHCO3 was added portion wise to 
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neutralize it to (S)-α-alkyl-alanine (28a/28b). The MeOH layer was filtered and 
concentrated giving 28a/28b as a white solid. 
Synthesis of (S)-α-Pentylalanine (28a) 
28a was prepared following the general synthetic procedure for the formation of 
28a/28b using 1g of 27a (5 mmol). An amount of 0.5g (3 mmol, 60%) of (S)-α-
pentylalanine (28a) was obtained as a white solid after neutralization. All the 
characterization data of 28a complied with the literature.
78, 88
 = + 4.1 (c = 1, 
MeOH).  
Synthesis of (S)-α-Hexylalanine (28b) 
 28b was prepared following the general synthetic procedure for the formation of 
28a/28b using 1g of 27b (4.6 mmol). An amount of 0.55g (3.4 mmol, 74%) of (S)-α-
pentylalanine (28b) was obtained as a white solid after neutralization. All the 
characterization data of 28b complied with the literature.
78, 88
 = + 6.7 (c = 0.15, 
MeOH). 
Synthesis of (S)-Ethyl 2-Amino-2-Methyl-6-(1,3-Dioxoisoindolin-2-Yl)Hexanoate (29) 
 An amount of 10gm (21 mmol) 23d was dissolved in 60 mL of methylene 
chloride. A volume of 10 mL TFA was added. The solution was stirred over 1 h. The 
solution turned dark purple. A volume of 100 mL H2O was added to the solution. The 
methylene chloride layer was extracted, washed with NaHCO3 solution, washed with 
H2O, dried over MgSO4. The crude was purified by flash chromatography (5% 
MeOH/CH2Cl2) giving 6.2gm (19.4mmoles, 92%) of the pure product as a white wax. 
TLC Rf = 0.35 (5% MeOH/CH2Cl2), 
1
H NMR (CDCl3, 400MHz) 7.81(m, 2H), 7.71(m, 
2H), 4.15(q, 2H, J= 7Hz), 3.67(t, 2H, J= 7Hz), 1.67(m, 6H), 1.39(m, 1H), 1.31(s, 3H), 
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1.25(m, 4H)., 
13
C NMR (CDCl3, 400MHz) 177, 168, 134, 132, 123, 61, 57, 40, 37, 28, 26, 
21, 14.. HRMS (C17H22N2O4Na
+
) calculated = 341.1477, observed = 341.1464. 
Synthesis of (S)-Ethyl 2-(dibenzylamino)-2-methyl-6-((1,3-dioxoisoindolin-2-
yl)hexanoate(30) 
 An amount of 5g (16 mmol) 29 was dissolved in 60 mL of distilled acetonitrile in 
a 250 mL three necked flask under N2 atmosphere. An amount of 13.3gm (96 mmol) of 
K2CO3 was added with stirring. A volume of 9.5 mL (80 mmol) of BnBr was added drop 
wise. The reaction was brought to reflux for 12 hrs. The reaction mixture was diluted 
with 50 mL of H2O. The solution was extracted with ether three times. The ether layer 
was washed with H2O, washed with brine, dried over MgSO4 and evaporated. The crude 
was then purified by flash chromatography (30% EtOAc/Hexane), giving 3.84 g (7.7 
mmoles, 48%) of the pure product as white solid. TLC Rf = 0.61 (30% EtOAc/Hexane), 
MP = 91
o
C. 
1
H NMR (CDCl3, 300MHz) 7.82(m, 2H), 7.69(m, 2H), 7.15(m, 10H), 
4.13(m, 2H), 3.80(m, 4H), 3.61(t, 2H, J=7Hz), 1.79(m, 2H), 1.52(m, 3H), 1.29(m, 7H). 
13
C NMR (CDCl3, 75MHz) 175, 169, 142, 134, 132, 128.6, 128, 127, 123, 67, 61, 55, 38, 
37, 29, 21.7, 21.6, 15. HRMS (C31H34N2O4Na
+
) calculated = 521.2416, observed = 
521.2398. 
Synthesis of (S)-6-Amino-2-(Dibenzylamino)-2-Methylhexanoic Acid (31) 
 An amount of 3.5g (10.3 mmoles) 30 was dissolved in 15mL EtOH in a 250mL 
single neck round bottom falsk with a stir bar. A volume of 100mL 8N NaOH solution 
was added to it and the resulting reaction mixture was brought to reflux over 48 hrs. The 
water layer was acidified to pH 2, evaporated out under reduced pressure, and triturated 
with MeOH. The MeOH layer was neutralized by solid NaHCO3, evaporated out under 
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reduced pressure giving 2.8g (8.5mmoles, 82%) pure 31 as white wax, which was taken 
for next step without further purification. 
1
H NMR (CD3OD, 300MHz): 7.26(bs, 10H), 
4.34(m, 4H), 2.81(bs, 2H), 1.90(m, 2H), 1.54(m, 6H), 1.24(b, 1H). 
Synthesis of (S)-2-(Dibenzylamino)-6-(Tert-Butyloxycarbonylamino)-2-Methylhexanoic 
Acid (32) 
A solution of 1gm 31 (1eq) in 10mL water was placed in 50mL round bottom 
flask. A measured amount of NaHCO3 (2eq) was added with stirring. The solution was 
cooled down to 0
O
C under ice. A solution of (Boc)2O (1.4eq) in 10mL 1,4 dioxane was 
added dropwise. The reaction was continued to stir at 0
O
C over an hr. The reaction was 
then allowed to come back to RT and continued to stir over the night. The reaction was 
diluted with 15mL H2O, acidified to pH4 by NaHSO4, extracted with Et2O twice. The 
combined ether layer was washed with water (5 X 30mL), washed with brine, dried over 
MgSO4, and evaporated out. The crude was cromatographed (40% EtOAc/hexanes), 
giving 1.14g (2.6 mmol, 87%) pure 32 as white solid. TLC Rf = 0.31 (40% 
EtOAc/Hexane). MP = 57
o
C. 
1
H NMR (CDCl3, 400MHz) 7.27(m, 10H), 4.51(bs, 1H), 
3.89(m, 4H), 3 (bs, 2H), 1.68(m, 2H), 1.39(m, 16H). 
13
C NMR (CDCl3, 100MHz) 175, 
156, 137, 128.8, 128.6, 128, 79, 71,  55, 40, 37, 30, 29, 22, 18. HRMS (C26H36N2O4Na
+
) 
calculated = 463.2573, observed = 463.2562. 
(S)-2-Amino-6-(Tert-Butyloxycarbonylamino)-2-Methylhexanoic Acid (33) 
A solution of 1g 32 (1eq) in 25mL MeOH was placed in a pershaker bottle. An 
amount of 0.2gm (20% by weight) Pd-C was added to the bottle. The reaction was 
continued to shake at 25psi over 12 hrs at room temperature. The reaction mixture was 
filtered through selite bed. The filtrate was evaported giving the pure product. An amount 
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of 0.55gm (2.1 mmoles, 91%) product was obtained. The product was confirmed by 
1
H 
NMR and HRMS. However, 
13
C NMR showed up an extra peak. The product was taken 
for next step without further purification. Rf = 0.21 (5% MeOH/CH2Cl2) , IR (cm
-1
), 
1
H 
NMR (CD3OD, 400MHz): 3.03(t, 2H, J=7Hz), 1.45(m, 18H). HRMS (C12H24N2O4Na
+
) 
calculated = 283.1634, observed = 283.1628. 
Synthesis of (S)-tBoc-Fmoc-α-Methyl-α-Lysine-OH (34) 
An amount of NaHCO3 (2eq) was added to a solution of 0.5gm 33 (1eq) in 15mL water 
with stirring. The solution was cooled down to 0 
O
C under ice. A solution of Fmoc-Osu 
(1.5 eq) in 15mL 1,4-dioxane was added to the reaction mixture over 20min. The reaction 
was continued to stir at 0 
O
C over an hr and at ambient temperature over 12 hrs. At that 
point the reaction was diluted with 30mL of water, acidified to pH 4 with 4M HCl, 
extracted (3X50mL) with Et2O. The combined ether layer was given brine wash, dried 
over MgSO4, and evaporated out at reduced pressure giving crude as light yellowish oil. 
The crude product was purified by radial chromatography using 5% MeOH/CH2Cl2, 
giving 0.78g pure 34 (1.62 mmol, 85%) as white solid. Rf = 0.33 (5% CH2Cl2/MeOH), IR 
(cm
-1
) = 3350, 2941, 1681, 1504,  = +14.4 (C=1, CHCl3). MP = 95 
0
C 
1
H NMR 
( CD3OD, 400MHz) 7.69(d, 2H, J=8Hz), 7.55(d, 2H, J=8Hz), 7.28(t, 2H, J=8Hz), 7.21(t, 
2H, J=8Hz), 4.22(d, 2H, J=7Hz), 4.11(t, 1H, J=7Hz), 2.92(t, 2H, J=7Hz), 1.77(bs, 2H), 
1.33(m, 16H). 
13
C NMR (CD3OD,MHz)  176,157, 155, 144, 143.9, 141, 127, 126.7, 125, 
119, 78, 66, 59, 40, 36, 29, 27, 21, 20. HRMS (C27H34N2O6Na
+
) calculated = 505.2309, 
observed = 505.2296. 
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Synthesis of (9H-Fluoren-9-Yl)-Methyl-(S)-2-(Ethoxycarbonyl)-6-(1,3-Dioxoisoindolin-2-
Yl)Hexan-2-Ylcarbamate (35) 
A volume of 320 µL Et3N (2.3 mmol) was added to a solution of 0.7g (1.9 mmol) 
10d in 25 mL dichloroethane under a  N2 atmosphere. A volume of 460 µL DPPA (2 
mmol) was added to the reaction mixture. The mixture was allowed to stir at RT for 2 hrs. 
The mixture was then heated to reflux solvent for 3 hrs. The reaction was cooled and 
washed with saturated NH4Cl solution. The organic layer was dried over MgSO4, filtered, 
and evaporated under reduced pressure giving the crude isocyanate. The isocyanate was 
dissolved in dry toluene under a N2 atmosphere. An amount of 0.75g (3.8 mmol) 9-
fluorenylmethanol and a volume of 66 µL Ti (IV) isopropoxide was added to the solution. 
The mixture was heated to 80 
0
C for 12 hrs. The mixture was cooled and the toluene was 
evaporated under reduced pressure giving the crude product. The residue was purified by 
chromatography (10% Hexanes/CH2Cl2), giving 0.95g 35 (1.75 mmol, 92%) as a white 
solid. Rf = 0.29 (10% Hexanes/CH2Cl2). IR (cm
-1
) = 3365, 2940, 1769, 1704, 1613, 1504. 
MP = 81 
0
C,  = -14.3 (c = 1, CHCl3). 
1
H-NMR (CDCl3, 400MHz): δ 7.78 (m, 4H), 
7.64 (m, 4H), 7.40(t, 2H, J = 7Hz), 7.32 (t, 2H, J = 7Hz), 5.72 (bs, 1H), 4.35 (bm, 2H), 
4.20 (bm, 3H), 3.65 (bm, 2H), 2.21 (bm, 1H), 1.85 (bm, 1H), 1.60 (m, 5H), 1.35 (bm, 1H), 
1.24 (bm, 3H), 1.13 (bm, 1H). 
13
C-NMR (CDCl3, 100MHz): δ 174.0, 168.0, 144.0, 141.0, 
134.0, 132.0, 128.0, 127.0, 125.0, 123.0, 120.0, 66.0, 62.0, 60.0, 47.0, 37.5, 36.0, 28.0, 
23.4, 21.0, 14.0. HRMS (C32H32N2O6Na
+
) calculated = 563.2152, observed = 563.2144. 
Fluorenylmethyloxycarbonylamino)-2-Methylhexanoic Acid.HCl (36) 
 36 was synthesized from 35 following a literature published procedure.
89
 An 
amount of 0.9g (1.7 mmol) 35 was dissolved in 12 mL 1, 4-dioxane. A volume of 12 mL 
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5N HCl was added to the solution. The solution was heated to reflux solvent for 24 hrs. 
At which time the reaction was found to be completed by ESI-MS. The solution was 
concentrated under reduced pressure and the residue was taken for the next step without 
further purification. 
Synthesis of (S)-
t
Boc-Fmoc-α-Methyl-α-Lysine-OH (34) 
An amount of 0.25g NaHCO3 (3 mmol) was added to a solution of 0.6g of 36 
(~1.5 mmol) in 15 mL of water with stirring. The solution was cooled to 0 
0
C. A solution 
of 0.65g (Boc)2O (3 mmol) in 15 mL 1, 4-dioxane was added to the reaction mixture over 
20 min. The reaction was allowed to stir at 0 
0
C for an hour and then at ambient 
temperature for 12 hrs. The mixture was given pentane wash to remove excess (Boc)2O. 
The reaction mixture was diluted with 30 mL of water, acidified to pH 4 with 2M HCl, 
and extracted (3 x 50 mL) with Et2O. The combined ether layer was washed with brine, 
dried over MgSO4, evaporated under reduced pressure giving the crude product as light 
yellow oil. The residue was purified by radial chromatography using 5% MeOH/CH2Cl2 
giving 0.78g (1.6 mmol, 94% over two steps) of product as a white solid. Rf = 0.33 (5% 
MeOH/CH2Cl2). IR (cm
-1
) = 3350, 2941, 1681, 1504. MP = 95 
0
C.  = +14.4 (c = 1, 
CHCl3), 
1
H-NMR (CD3OD, 400MHz): δ 7.69 (d, 2H, J = 8Hz), 7.55 (d, 2H, J = 8Hz), 
7.28 (t, 2H, J = 8Hz), 7.21 (t, 2H, J = 8Hz), 4.22 (d, 2H, J = 7Hz), 4.11 (t, 1H, J = 7Hz), 
2.92 (t, 2H, J = 7Hz), 1.77 (bs, 2H), 1.33 (m, 16H). 
13
C-NMR (CD3OD, 100 MHz): 176.0, 
157.0, 155.0, 144.0, 143.9, 141.0, 127.0, 126.7.0, 125.0, 119.0, 78.0, 66.0, 59.0, 40.0, 
36.0, 29.0, 27.0, 21.0, 20.0. HRMS (C27H34N2O6Na
+
) calculated = 505.2309, observed = 
505.2296. 
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Synthesis of (S)-1-Tert-Butyl 3-Ethyl 2-[4-(1,3-Dioxoisoindolin-2-Yl)Butyl]-2-
Methylmalonate (37) 
A volume of 3 mL conc. H2SO4 was added to a solution of 10g 10d (29 mmol) in 
100 mL CH2Cl2 in a 250 mL sealed tube. The solution was cooled to -7 
0
C in an ice salt 
bath. A volume of 50 mL of condensed isobutylene was added to the solution. The tube 
was capped tightly and allowed to stir over night at RT. The tube was uncapped and 
allowed to stir for 2 hrs at ambient pressure to allow the excess isobutylene to evaporate. 
The solution was diluted with CH2Cl2 and gently washed three times with 1N NaOH (50 
mL). The CH2Cl2 layer was dried over MgSO4, evaporated under reduced pressure, and 
purified by chromatography (40% EtOAC/Hexanes), giving 10.8g of product (26.7 mmol, 
92%) as a colorless liquid. Rf = 0.60 (40% EtOAc/Hexanes), IR (cm
-1
) = 2977, 2937, 
1771, 1707. 
1
H-NMR (CDCl3, 400MHz): δ 7.84 (m, 2H), 7.71 (m, 2H), 4.16 (q, 2H, J = 
7Hz), 3.68 (t, 2H, J = 7Hz), 1.85 (m, 2H), 1.69 (m, 2H), 1.42 (s, 9H), 1.28 (m, 8H). 
13
C-
NMR (CDCl3, 100MHz): δ 172.0, 171.0, 168.0, 134.0, 132.0, 123.0, 81.0, 61.0, 54.0, 
38.0, 35.0, 29.0, 28.0, 22.0, 20.0, 14.0. HRMS (C22H29NO6Na
+
) calculated = 426.1887, 
observed = 426.1873. 
Synthesis of (S)-1-Tert-Butyl 3-Ethyl 2-(4-Aminobutyl)-2-Methylmalonate (38) 
A volume of 2.8 mL (31.4 mmol) N2H4.H2O (35% in H2O) was added in a 
solution of 10.5g 37 (26 mmol) in 60 mL MeOH. The solution was heated to reflux 
solvent for 6 hrs. The reaction mixture was found to turn turbid and a white precipitate 
formed within 2 hrs of reflux. The reaction was monitored by TLC. The reaction was 
cooled to RT and the MeOH was removed "in vacuo". The residue was taken up in 
CH2Cl2 and the white precipitate was filtered off. The CH2Cl2 was evaporated under 
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reduced pressure, giving 6.75g (24.7 mmol, 95%) of 38 as a colorless oil. Rf = 0.16 (5% 
MeOH/CH2Cl2), IR (cm
-1
) = 3395, 2977, 2934, 2867, 1723, 1654. 
1
H-NMR (CDCl3, 
400MHz): δ 4.17 (q, 2H, J = 7Hz), 2.70 (t, 2H, J = 7Hz), 1.82 (m, 2H), 1.53 (bs, 2H), 
1.45 (m, 11H), 1.35 (s, 3H), 1.27 (m, 5H). 
13
C-NMR (CDCl3, 100MHz): δ 172.0, 171.0, 
81.0, 61.0, 54.0, 42.0, 35.0, 34.0, 28.0, 21.0, 19.0, 14.0. HRMS (C14H27NO4Na
+
) 
calculated = 296.1832, observed = 296.1828. 
Synthesis of (S)-2-(Tert-Butoxycarbonyl)-6-Amino-2-Methylhexanoic Acid(39) 
An amount of 1.76g LiOH (73.5 mmol) was added in a solution of 6.7g 38 (24.5 
mmol) in 30 mL of 3:7 EtOH/H2O mixture. The solution was allowed to stir for 48 hrs at 
RT. The solvents were evaporated under reduced pressure upon completion as 
determined by TLC (5% MeOH/CH2Cl2). The residue was triturated with MeOH to 
precipitate excess LiOH. The MeOH layer was evaporated under reduced pressure giving 
5.76g of 20 (96%, 23.5 mmol) as a white wax. Rf = 0.10 (5% MeOH/CH2Cl2). IR (cm
-1
) 
= 3297, 2961, 2937, 1541, 1448. 
1
H-NMR (CD3OD, 400MHz): δ 2.64 (t, 2H, J = 7Hz), 
1.79 (m, 2H), 1.46 (m, 11H), 1.29 (m, 5H). 
13
C-NMR (CD3OD, 100MHz): δ 178.0, 175.0, 
80.0, 56.0, 41.0, 36.0, 33.0, 26.0, 21.0, 20.0.  ESI-MS (C12H23NO4Na
+
) calculated 268.3, 
observed 268.2. 
Synthesis of (S)-2-(Tert-Butoxycarbonyl)-6-(Tert-Butyloxycarbonylamino)-2-
Methylhexanoic Acid (40) 
An amount of 3.9g NaHCO3 (46.5 mmol) was added to a solution of 5.7g of 39 
(23.2 mmol) in 20 mL H2O. The solution was cooled to 0
 0
C. A solution of 6g of (Boc)2O 
(28 mmol) in 20 mL 1,4-dioxane was added drop wise to the reaction mixture. The 
reaction was allowed to stir at 0 
0
C for an hr and then brought to RT. The reaction was 
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allowed to stir at RT for 12 hrs. The reaction mixture was extracted with pentane. The 
aqueous layer was acidified to pH 4 using 2N HCl and extracted three times with Et2O 
(50 mL). The combined ether layer was dried over MgSO4, evaporated under reduced 
pressure, and purified by chromatography (40% EtOAc/Hexanes), giving 7.6g (22 mmol, 
95%) of 40 as a colorless viscous oil. Rf = 0.54 (40% EtOAc/ Hexanes), IR (cm
-1
) = 3380, 
2976, 2934, 1706, 1522. 
1
H-NMR (CDCl3, 400MHz): δ 4.61 (bs, 1H), 3.12 (bm, 2H), 
1.84 (m, 2H), 1.46 (m, 23H), 1.29 (m, 2H). 
13
C-NMR (CDCl3, 100MHz): δ 177.0, 172.0, 
156.0, 82.0, 79.0, 54.0, 40.0, 35.0, 30.0, 28.4, 27.8, 22.0, 20.0. HRMS (C17H31NO6Na
+
) 
calculated = 368.2043, observed = 368.2035. 
Synthesis of (R)-Tert-Butyl-2-(9-Fluorenylmethylamino)-6-(Tert-
Butyloxycarbonylamino)-2-Methylhexanoate (41) 
A volume of 2.7 mL of Et3N (19.4 mmol) was added to a solution of 5.6g 40 
(16.2 mmol) in 60 mL dichloroethane under a N2 atmosphere. A volume of 3.9 mL (17.3 
mmol) of DPPA was added to the reaction mixture. The mixture was allowed to stir at 
RT for 2 hrs. The mixture was heated to reflux solvent for 3 hrs. The reaction was cooled, 
and the organic layer was extracted with saturated NH4Cl solution, dried over MgSO4 and 
evaporated under reduced pressure giving the isocyanate. The isocyanate was taken up in 
dry toluene under a N2 atmosphere. An amount of 6.4g (32.4 mmol) 9-fluorenylmethanol 
was added to the solution along with 300 µL of Ti (IV) isopropoxide. The solution was 
heated to 80 
0
C over night. The reaction was cooled, and the organic layer was 
evaporated under reduced pressure. The residue was then purified by chromatography 
(CH2Cl2) giving 7.75g (14.4 mmol, 89%) of 41 as colorless wax. An amount of 50mg of 
41 was further purified by reversed phase HPLC (40% CH3CN/H2O to 100% CH3CN in 
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15 min at 262 nm, Rt = 16.6 min), giving 35mg of pure 41 as a colorless oil. Rf = 0.57 
(CH2Cl2), IR (cm
-1
) = 3359, 2975, 2931, 1707, 1516. 
1
H-NMR (CDCl3, 400MHz): δ 7.76 
(d, 2H, J=8Hz), 7.61 (d, 2H, J = 8Hz), 7.40 (t, 2H, J = 7Hz), 7.32 (t, 2H, J = 7Hz), 5.82 
(bs, 1H), 4.47 (m, 2H), 4.18 (t, 1H, J = 7Hz), 4.02 (bs, 1H), 3.07 (bm, 2H), 2.23 (bm, 1H), 
1.74 (bm, 1H), 1.45 (m, 25H). 
13
C-NMR (CDCl3, 100 MHz): δ 173.2, 156.03, 154.3, 
143.9, 141.4, 127.6, 127.0, 125.1, 120.0, 82.2, 79.2, 66.3, 60.1, 47.2, 40.1, 35.8, 29.7, 
28.3, 27.9, 23.7, 21.2. HRMS (C31H42N2O6Na
+
) calculated = 561.2935, observed = 
561.2924. 
Synthesis of (R)-
t
Boc-Fmoc-α-Methyl-α-Lysine-OH (42) 
An amount of 2g (3.7 mmol) of 41 was dissolved in 20 mL of 1:1 TFA/CH2Cl2. 
The solution was allowed to stir for 12 hrs at RT under a N2 atmosphere. The reaction 
was monitored by TLC (5% MeOH/CH2Cl2) and ESI-mass spectrometry for completion. 
At which point the TFA/CH2Cl2 layer was evaporated under reduced pressure giving free 
amino acid. The residue was taken up in 15 mL of H2O and 0.76g (9 mmol) of NaHCO3 
was added to the solution slowly to control the effervescence. The mixture was cooled to 
0 
O
C. A solution of 0.96g (4.4 mmol) (Boc)2O in 15 mL 1,4-dioxane was added to the 
mixture slowly at 0 
O
C. The reaction was allowed to stir at 0
 0
C for an hour. The reaction 
was then allowed to warm to RT and stir for 12 hrs. The reaction mixture was extracted 
with pentane to remove excess (Boc)2O. The aqueous layer was then acidified to pH 4 
with 2N HCl, and extracted three times with Et2O (50 mL). The combined ether layer 
was dried over MgSO4, evaporated under reduced pressure, and purified by 
chromatography (5% MeOH/CH2Cl2), giving 1.52g (3.15 mmol, 85% over two steps) of 
42 as a white solid similar 34. All characterization data of 42 complied with the data for 
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34. The polarimetry reading confirmed 42 as the enantiomer to 34.  = -11.5 (c = 1, 
CHCl3). 
Synthesis of (S)-Ethyl 2-Amino-2-((1,3-Dioxoisoindolin-2-Yl) Methyl) Propanoate (43) 
 An amount of 10g (23 mmol) 23a was dissolved in 60 mL of methylene chloride 
and 10 mL TFA was added. The solution was stirred for 1 hr. The solution became dark 
purple in color. A volume of 100 mL H2O was added to the solution and the organic layer 
was washed with NaHCO3 solution, washed with H2O, and dried over MgSO4. The 
residue was purified by flash chromatography (5% MeOH/CH2Cl2), giving 5.7g 
(20.6mmol, 90%) of 43 as a white wax. Rf = 0.64 (5% MeOH/CH2Cl2), IR (cm
-1
). = 3391, 
3325, 3000, 2959, 1770, 1731, 1704, 1557. 
1
H-NMR (CDCl3, 400 MHz): δ 7.85 (m, 2H), 
7.73 (m, 2H), 4.20 (m, 2H), 3.91 (m, 2H), 1.77 (bs, 2H), 1.41 (s, 3H), 1.29 (t, 3H, J = 7 
Hz), 
13
C-NMR (CDCl3, 100 MHz): δ 175.0, 169.0, 134.0, 132.0, 123.0, 61.0, 58.0, 46.0, 
24.0, 14.0. HRMS (C14H16N2O4Na
+
) calculated = 299.1002, observed = 299.1002. 
Synthesis of (S)-Ethyl-2-(Dibenzylamino)-2-[(1,3-Dioxoisoindolin-2-
Yl)Methyl]Propanoate (44) 
An amount of 4.2g (15.2 mmol) of 43 was dissolved in 60 mL of distilled 
acetonitrile in a 250 mL three necked flask under a N2 atmosphere. An amount of 12.6g 
(91.2 mmol) of K2CO3 was added with stirring. A volume of 9 mL (76 mmol) of BnBr 
was added drop wise. The reaction mixture was heated to reflux solvent for 12 hrs. The 
reaction mixture was diluted with 50 mL of H2O and the solution was extracted with 
ether three times. The ether layer was washed with H2O, washed with brine, dried over 
MgSO4, and evaporated. The residue was then purified by flash chromatography (30% 
EtOAc/Hexanes) giving 5.6g (12.3 mmol, 81%) of 44 as a white solid. Rf = 0.59 (30% 
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EtOAc/Hexanes), IR (cm
-1
) = 2970, 1770, 1713, 1620. MP = 83 
0
C. 
1
H-NMR (CDCl3, 
400MHz): δ 7.83 (m, 2H), 7.71 (m, 2H), 7.34 (d, 4H, J = 8Hz), 7.12 (m, 6H), 4.23 (q, 2H, 
J = 7 Hz), 3.95 (m, 6H), 1.35 (m, 6H). 
13
C-NMR (CDCl3, 100MHz): δ 174.0, 168.0, 
141.0, 134.0, 132.0, 128.3, 128.0, 126.0, 123.0, 68.0, 61.0, 55.0, 44.0, 19.0, 14.0. HRMS 
(C28H28N2O4Na
+
) = 479.1941, observed = 479.1938. 
(S)-Ethyl-3-Amino-2-(Dibenzylamino)-2-Methylpropanoate (45) 
 An amount of 3.2 g (7 mmol) of 44 was dissolved in 20 mL of (8:2) MeOH and 
CH2Cl2 . A volume of 1.7 mL (21 mmol) of N2H4 (35% in H2O) was added. The solution 
was heated to reflux solvent for 3 hrs. The formation of a white precipitate indicated the 
completion of the reaction. The reaction mixture was filtered and the filtrate was 
evaporated giving 2g (6.5 mmol, 92%) of 45 as a yellowish oil. Rf = 0.65 (5% 
MeOH/CH2Cl2). IR (cm
-1
) = 2979, 1717, 1601. 
1
H-NMR (CDCl3, 400MHz): δ 7.21 (m, 
10H), 4.16 (m, 2H), 3.84 (m, 4H), 2.95 (s, 2H), 1.35 (s, 3H), 1.31 (t, 3H, J = 7 Hz), 1.20 
(bs, 2H), 
13
C-NMR (CDCl3, 100MHz): δ 174.0, 141.0, 128.4, 128.0, 126.0, 69.0, 60.0, 
55.0, 48.0, 20.0, 14.0. HRMS (C20H26N2O2Na
+
) calculated = 349.1886, observed = 
349.1873. 
(S)-Ethyl-3-Amino-2-(Dibenzylamino)-2-Methylpropanoicacid (46) 
 An amount of 1.41 g (4.3 mmol) of 45 was dissolved in 25 mL of EtOH. An 
amount of 0.52 g (12.9 mmol) of well crushed NaOH pellets were added. The solution 
was heated to reflux solvent for 4 hrs. The EtOH layer was acidfied to pH 2, evaporated 
to dryness under high vacuum, and  triturated with MeOH. The MeOH layer was 
neutralized with solid NaHCO3, filtered, and evaporated under reduced pressure giving 
1.16g (3.9 mmol, 90%) of 46 as yellowish wax. 
1
H-NMR (CD3OD, 400MHz): δ 7.18 (m, 
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10H), 3.91 (m, 4H), 2.83 (m, 2H), 1.87 (s, 3H). 
13
C-NMR (CD3OD, 100MHz): δ 182.0, 
144.0, 129.6, 129.0, 127.0, 70.0, 56.0, 22.0. HRMS (C18H22N2O2Na
+
) calculated = 
321.1573, observed = 321.1573. 
Synthesis of (S)-2-(Dibenzylamino)-3-(Tert-Butyloxycarbonylamino)-2-Methylpropanoic 
Acid (47) 
A solution of 1g of 46 (3.4 mmol) in 10 mL water was placed in a 50 mL round 
bottom flask. An amount of 0.56g (6.7 mmol) of NaHCO3 (2eq) was added with stirring. 
The solution was cooled to 0 
0
C. A solution of 0.98g (4.7 mmol) (Boc)2O (1.4eq) in 10 
mL 1,4 dioxane was added drop wise. The reaction was allowed to stir at 0 
0
C for an hour. 
The reaction was then allowed to warm to RT overnight. The reaction mixture was 
diluted with 15 mL H2O, acidified to pH 4 with NaHSO4, and extracted twice with Et2O. 
The combined ether layer was washed with water (5 x 30 mL), washed with brine, dried 
over MgSO4, and evaporated. The residue was purified by chromatography (40% 
EtOAc/Hexanes), giving 1.2g (3 mmol, 91%) of 47 as a white solid. Rf = 0.28 (40% 
EtOAc/Hexane). IR (cm
-1
) = 2977, 1698, 1494. MP = 58 
0
C. 
1
H-NMR (CDCl3, 400 
MHz): δ 7.21 (m, 10H), 5.44 (bs, 1H), 4.09 (m, 4H), 3.64 (m, 2H), 1.42 (m, 12H). 13C-
NMR (CDCl3, 100 MHz): δ 175.0, 156.0, 137.0, 128.8, 128.5, 127.7, 79.0, 71.0, 55.0, 
44.0, 28.0, 20.0. HRMS [C23H30N2O4Na
+
] calculated = 421.2097, observed = 421.2094. 
(S)-2-Amino-3-(Tert-Butyloxycarbonylamino)-2-Methylpropanoic Acid (48) 
A solution of 1g (2.5 mmol) of 47 in 25 mL MeOH was placed in a pressure 
bottle. An amount of 0.2g (20% by weight) of Pd-C was added to the bottle. The solution 
was placed on a Parr shaker hydrogenation apparatus and allowed to shake with 30 psi 
hydrogen gas for 12 hrs. The reaction mixture was filtered through a Celite bed to remove 
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the catalyst. The filtrate was evaporated giving 48. An amount of 0.5g (2.3 mmole, 92%) 
of 48 was obtained as a white wax. Rf = 0.3 (5% MeOH/CH2Cl2). IR (cm
-1
) = 2977, 1701, 
1602, 1508. MP = 204 
0
C. 
1
H-NMR (CD3OD, 400MHz): δ 3.44 (s, 2H), 1.47 (m, 12H). 
13
C-NMR (CD3OD, 100MHz): δ 174.0, 158.0, 79.0, 61.0, 46.0, 27.0, 19.0. HRMS 
(C9H18N2O4Na
+
) calculated = 241.1159, 241.1158. 
Synthesis of (S)-2-(9-Fluorenylmethyloxycarbonylamine)-3-(Tert-
Butyloxycarbonylamino)-2-Methylpropanoic Acid (49) 
 An amount of 0.35g of NaHCO3 (4.1 mmol) was added to a solution of 0.45g 29 
(2.1 mmol) in 15 mL water with stirring. The solution was cooled 0 
0
C. A solution of 
1.1g Fmoc-Osu (3.2 mmol) in 15 mL 1, 4-dioxane was added to the reaction mixture over 
20 min. The reaction was allowed to stir at 0 
0
C for an hour and then at ambient 
temperature for 12 hrs. At that point the reaction was diluted with 30 mL of water, 
acidified to pH 4 with 4M HCl, extracted (3 x 50 mL) with Et2O. The combined ether 
layer was washed with brine, dried over MgSO4, and evaporated under reduced pressure. 
The residue was purified by radial chromatography using 5% MeOH/CH2Cl2 giving 
0.86g (1.96 mmol, 85%) of 49 as a white solid. Rf = 0.41 (5% MeOH/CH2Cl2), IR (cm
-1
) 
= 3317, 2974, 1694, 1513. MP = 82 
0
C.  = -10.5 (c = 1, CHCl3), 
1
H-NMR (CD3OD, 
400 MHz): δ 7.80 (d, 2H, J = 7 Hz), 7.68 (d, 2H, J = 7 Hz), 7.39 (t, 2H, J = 7 Hz), 7.31 (t, 
2H, J = 7 Hz), 4.31 (bs, 2H), 4.22 (t, 1H, J = 7 Hz), 3.55 (m, 2H), 1.44 (s, 12H). 
13
C-
NMR (CD3OD, 100 MHz): δ 159.0, 157.0, 145.4, 145.3, 143.0, 129.0, 128.0, 126.4, 
126.3, 121.0, 80.0, 68.0, 55.0, 46.0, 28.0, 21.0. HRMS (C24H28N2O6Na
+
) calculated = 
463.1839, observed = 463.1835. 
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Synthesis of (S)-Tert-Butyl 2-Tert-Butyloxyaminobutyl-4-Diazo-2-Methyl-3-
Oxobutanoate (50) 
 Acid 40 (3g, 8.7 mmol) was dissolved in 10 mL THF and cooled to -25 
0
C. A 
measured 1 equivalent of Et3N (1.2 mL, 8.7 mmol), and 1.05 equivalents of ClCO2Me 
(710 µL, 9.1 mmol) was added drop wise to the THF solution. The mixture was stirred 
for 2 hrs. giving rise to the mixed anhydride, which was taken immediately for the next 
step. The resulting white suspension of the mixed anhydride was allowed to warm to 0 
0
C 
and a solution of dry diazomethane (2 equivalent, 17.4 mmol) in Et2O was carefully 
added. The reaction mixture was allowed to stir for 12 hrs. in the dark at 0 
0
C. Excess 
diazomethane was removed by passing N2 through the solution for 30 mins. The reaction 
mixture was then diluted with Et2O, washed with saturated NaHCO3, saturated NH4Cl, 
and brine. The organic layer was dried over MgSO4, and concentrated under reduced 
pressure. The resulting residue was purified by chromatography (1:1 Et2O/Hexanes), 
giving 2.62g (7.1 mmol, 82%) of 50 as a clear yellowish oil. Rf = 0.42 (1:1 
Et2O/Hexanes). IR (cm
-1
) = 3381, 2976, 2934, 2110, 1704, 1517. 
1
H-NMR (CDCl3, 400 
MHz): δ 5.41 (s, 1H), 4.58 (bs, 1H), 3.09 (bm, 2H), 1.85 (m, 1H), 1.71 (m, 1H), 1.45 (m, 
21H), 1.28 (m, 4H). HRMS (C18H31N3O5Na
+
) 392.2156, observed = 392.2153. 
(S)-3-Tert-Butyloxyaminobutyl-4-Tert-Butyloxy-3-Methyl-4-Oxobutanoic Acid (51) 
 An amount of 2.5g 50 (6.8 mmol) was dissolved in 15 mL 3:7 H2O/THF in a 50 
mL round bottom flask. The flask was purged with N2 and the resulting solution was 
photolyzed with a Hanovia lamp (500 W) at a distance of approximately 10 cm. The 
photolysis was allowed to proceed for 48 hrs. At that point the reaction was found to be 
completed as evident by TLC. The clear and colorless solution was concentrated under 
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reduced pressure and the water layer was extracted three times with Et2O. The combined 
Et2O layer was washed with brine, dried over MgSO4, and evaporated under reduced 
pressure. The residue was purified by chromatography (30% EtOAc/Hexanes), giving 
1.83g of 51 (5.1 mmol, 75%) as a yellowish oil. The 
1
H-NMR and the HRMS is highly 
indicative of the product. Hence, the product was taken for the next step without further 
purification. Rf = 0.18 (30% EtOAc/Hexanes), IR (cm
-1
) = 3364, 2977, 2936, 1709, 1521. 
1
H-NMR (CDCl3, 400 MHz): δ 4.54 (bs, 1H), 3.10 (bm, 2H), 2.73 (m, 1H), 2.38 (m, 1H), 
1.55 (m, 22H), 1.20 (m, 5H). 
13
C-NMR (CDCl3, 100 MHz): δ 176.2, 175.2, 155.9, 80.6, 
72.4, 44.4, 42.4, 40.1, 38.8, 30.0, 28.4, 27.8, 21.8, 21.4. HRMS (C18H33NO6Na
+
) 
calculated = 382.2200, observed = 382.2196. 
(S)-Tert-Butyl-2-Tert-Butyloxycarbonylaminobutyl-3-(9-
Fluorenylmethyloxycarbonylamino)-2-Methylpropanoate (52) 
A volume of 0.79 mL Et3N was added to a solution of 1.7g of 51 (4.7 mmol) in 25 
mL dichloroethane under N2 atmosphere. A volume of 1.2 mL (5.2 mmol) DPPA was 
added to the reaction mixture. The reaction was allowed to stir at RT for 2 hrs. The 
mixture was heated to reflux solvent for 3 hrs. The mixture was cooled and the organic 
layer was extracted with saturated NH4Cl solution, dried over MgSO4, and evaporated 
under reduced pressure giving the icocyanate. The icocyanate was taken up in dry toluene 
under N2 atmosphere. An amount of 1.84g (9.4 mmol) 9-fluorenylmethanol was added to 
the solution along with 100 μL of Ti (IV) isopropoxide. The reaction was heated to 80 0C 
overnight.  The reaction was cooled and the organic layer was evaporated under reduced 
pressure. The residue was then purified by chromatography (CH2Cl2 to 3% 
MeOH/CH2Cl2), giving 2g 52 ( 4 mmol, 80%) as sticky light yeollowish wax. The 
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product was found too sticky to dry the solvent all the way. It was characterized by 
1
H-
NMR and HRMS. The product was taken for the next step without further attempt to 
purify it. Rf = 0.78 (3% MeOH/CH2Cl2). IR (cm
-1
) = 3340, 2975, 2933, 1756, 1688, 1513. 
1
H-NMR (CDCl3, 400 MHz): δ 7.76 (d, 2H, J = 7Hz), 7.59 (d, 2H, J = 7Hz), 7.39 (t, 2H, 
J = 7Hz), 7.30 (t, 2H, J = 7Hz), 4.60 (bm, 2H, J = 7Hz), 4.37 (m, 2H), 4.22 (t, 1H, J = 
7Hz), 3.38 (m, 1H), 3.24 (m, 1H), 3.09 (m, 2H), 1.46 (bm, 6H), 1.44 (bm, 21H). HRMS 
(C32H44N2O6Na
+
) calculated = 575.3091, observed = 575.3083. 
Synthesis of (S)-Fmoc-α-Methyl-β2,2-Lysine-Boc-OH (53) 
 An amount of 1.5g of 52 (2.7 mmol) was dissolved in 20 mL of 1:1 TFA/CH2Cl2. 
The solution was allowed to stir for 12 hrs at RT under N2 atmosphere. The reaction was 
monitored by TLC (5% MeOH/CH2Cl2) and ESI-mass spectrometry for the completion. 
At which point the TFA/CH2Cl2 layer was evaporated under reduced pressure giving free 
amino acid. The residue was taken up in 15 mL of H2O and 0.54g (6.5 mmol) NaHCO3 
was added to the solution slowly to control the effervescence. The mixture was cooled to 
0 
0
C. A solution of 0.71g (Boc)2O (3.2 mmol) in 15 mL 1,4-dioxane was added to the 
mixture slowly at 0 
0
C. The reaction was allowed to stir at 0 
0
C for an hour. The reaction 
was then allowed to warm to RT and stir for 12 hrs. The reaction mixture was extracted 
with pentane to remove excess (Boc)2O. The aqueous layer was then acidified to pH 4 
with 2N HCl, extracted three times with Et2O (50 mL). The combines ether layer was 
dried over MgSO4, evaporated under reduced pressure, purified by chromatography (5% 
MeOH/CH2Cl2), giving 1.21g of 53 (2.44 mmol, 90% over two steps) as a white solid 
after purification by flash chromatography (CH2Cl2 to 5% MeOH/CH2Cl2). Rf = 0.50 (5% 
MeOH/CH2Cl2). IR (cm
-1
) = 3338, 2940, 1693, 1518.  = - 6.0 (c = 0.7, CHCl3). MP 
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= 73 
0
C. 
1
H-NMR (CD3OD, 400 MHz): δ 7.81 (d, 2H, J = 7Hz), 7.66 (d, 2H, J = 7Hz), 
7.40 (t, 2H, J = 7Hz), 7.32 ( t, 2H, J = 7Hz), 4.36 (m, 2H), 6.23 (m, 1H), 3.03 (t, 2H, J = 
7Hz), 1.61 (m, 1H), 1.44 (m, 12H), 1.30 (m, 2H), 1.13 (s, 3H). 
1
H-NMR (CDCl3, 400 
MHz): δ 7.75 (d, 2H, J = 7Hz), 7.58 (m, 2H), 7.38 (t, 2H, J = 7Hz), 7.30 (t, 2H, J = 7Hz), 
6.37 (bm, 1H), 5.42 (bm, 1H), 4.58 (m, 1H), 4.35 (m, 1H), 4.21 (m, 1H), 3.36 (m, 2H), 
3.09 (bm, 2H), 1.41 (m, 18H). 
13
C-NMR (CDCl3, 100 MHz): δ 179.5, 156.9, 156.2, 143.6, 
141.2, 127.7, 127.1, 125.1, 120.0, 79.3, 66.8, 47.3, 46.8, 40.0, 36.7, 36.0, 30.4, 28.4, 21.3, 
20.4. HRMS (C28H36N2O6Na
+
) calculated = 519.2965, observed = 519.2459. 
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CHAPTER III 
SYNTHESIS AND BIOLOGICAL EVALUATION OF A VAPREOTIDE 
(SOMATOSTATIN ANALOGUE) CONTAINING α-METHYL-α-LYSINE 
Background 
Small Peptides Containing Lysine and Their Importance 
Several small peptides containing lysine have been found to be medically very 
important. Some of them are: Dermaseptin, AGG01, Stichodactyla toxin, Crotamine, 
Neurotensin, Bombesin, Cholecystokinin, and Somatostatin 
Somatostatin 
Somatostatin (somatotropin release inhibiting factor or SST) was discovered as a 
hypothalamic neurohormone, which inhibits growth factor secretion.
90-92
 SST was 
detected both in the central and peripheral nervous system, and in peripheral tissues 
where it plays many different roles.
90-92
 In periphery the endocrine pancreas and gut are 
the main sources of SST .
92-95
 
SST has several functions
92, 95, 96
 which are as follows: 
1. Inhibition of endocrine and exocrine secretion. 
2. Modulation of neurotransmission. 
3. Motor and cognitive functions. 
4. Inhibition of intestinal motility. 
5. Absorption of nutrients and ions. 
6. Vascular contractility and cell proliferation. 
7. Inhibition of proliferation of several tumor and normal cells. 
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Naturally occurring somatostatin is available in two molecular forms: a 
tetradecapeptide (SST-14) and a 28-amino acid peptide (SST-28) containing the amino 
acid sequence of SST-14, N-terminally extended by 14 amino acid residues as shown in 
Figure 14.
92, 95
 The diverse action of SST peptides are mediated through interaction with 
5 different SST receptors (SSTRs) expressed by variety of normal and malignant 
tissues.
95
 The rationale behind evaluation SST as an anticancer drug is the dual character 
of SST analogues to inhibit hormone release and cell growth.
92, 95
 
 
 
 
 
Figure 14. Structures of SST14 and SST28. The enzymatic cleavage sites on SST14 are 
shown with arrows. 
 
Somatostatin Receptors and Their Lligands/Tissue Expression 
The biological effects of somatostatin are executed by binding to five distinct 
high-affinity G Protein coupled receptors (SSTR1-SSTR5) over expressed on the cell 
surface.
95, 97
 These SST receptors exhibit a high degree of resemblance but differ mainly 
at their amino and carboxy terminal segments. This disparity is attributed to their 
specificity in ligand binding and intracellular signaling.
92, 95
 The up regulation of SSTR 
subtypes has been evidenced in human tissues, diverse tumor tissues and cell lines at 
mRNA level and protein level with SSTR subtype specific ligands.
98
   In addition to the 
Ala Gly Cys Lys Asn Phe Phe
Trp
Lys
ThrCys Ser Thr Phe
S
S
LysArgGlu
Arg
Pro Ala Met Ala Pro Asn Ser Asn Ala Ser
SST14  
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normal tissues, SSTRs have also been witnessed to be over expressed by 
gastroenteropancreatic (GEP) tumors, carcinoid tumors, small-cell lung tumors, prostate 
carcinoma, breast carcinoma, renal carcinoma, frequently nervous system tumors, and 
medullary carcinoma of the thyroid.
95, 98
 Most of the time, cancer cells express more than 
one SST subtypes with SSTR2 most frequently followed by SSTR1, SSTR3, SSTR4, and 
SSTR5.
98
 It has also been observed that there is disparity in the SSTR subtype expression 
pattern in different tumor types, within the same type of tumors, and even in each 
patient.
99
 Multiple SSTR subtype protein expression has also been reported in medullary 
carcinoma of thyroid.
100
 A summary of the present knowledge on SSTR subtype mRNA 
and protein expression in tumor cells is given in the table 1 below.
100
 
Table 1 
Expression of SSTR subtypes in several tumor cells.
98
 
 
Subtype 
 
 
Cancer cell over expressing SSTRs 
  
SSTR1 Prostate carcinomas, sarcomas, GEP tumors, 
phaeochromocytomas. 
SSTR2 Neuroblastomas, meningiomas, medulloblastomas, 
breast carcinomas, lymphomas, renal carcinomas, 
small cell lung carcinomas, hepatocarcinomas, 
pituitary adenomas, GEP tumors, phaeo 
chromocytomas, paraganglomas  etc. 
 
SSTR3 Pituitary adenomas 
SSTR4 - 
 
SSTR5                                                   GH-screening pituitary adenomas 
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Function of SSTR Subtypes and Receptor Binding Specificity of SST Analogues  
Receptors are the binding sites for peptides. One of the most common characteristics of 
SSTRs is that they stimulate rapid internalization of receptor-agonist complex into the 
cell upon binding of agonist to the SSTRs overexpressed on the tumor cells.
101
 The 
internalization of SSTR-agonist complex may take place upon binding of either 
endogenous agonist or exogenous agonist to the SSTRs.
101
  The mechanism of higher 
degree of internalization of SSTR-somatostatin radioligand complex into the tumors 
overexpressing SSTRs is often employed to effectively and specifically accumulate radio 
activity into the tumor cells.
101
 The accumulated somatostatin radioligands permit 
successful tumor imaging in patients as well as targeted chemotherapy.
101
 The 5 receptor 
subtypes (SSTR1-5) bind with the naturally occurring peptides (SST-14 & SST28) with 
low nanomolar affinity.
95, 98
 Out of five SSTR subtypes, only SSTR5 shows a 10 fold 
higher affinity for SST28.
98
 Short synthetic peptides have been observed to bind strongly 
to 3 of 5 SSTR Subtypes (SSTR 2, SSTR3, and SSTR5) as opposed to SST14.
98
 For 
instance, octapeptide analogues of SST, which are currently in use in clinical studies as 
antineoplastic agents (figure 15), are more selective than SST14.
98
 
 
 
 
 
Figure15. SST octapeptide analogues. 
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 Octapeptides (Figure 14) show very low affinity for SSTR1 and SSTR4 (> 1000 
nM), moderate affinity for SSTR3 (225 nM) and high affinity for SSTR2 and SSTR5 (2.8 
~ 9.9 nM).
98, 102
 The hexapeptide, Seglitide, exhibits a similar pattern of binding 
selectivity and potency.
100
 However, some of the tumors overexpress predominantly 
SSTR1 or SSTR4 but lack in SSTR2 and SSTR5.
98
 Lately, there have been many efforts 
to prepare diverse SST analogues, that differ in ring sizes, with selective binding affinity 
for SSTR1 and SSTR4.
103, 104
 Additionally, there has been much research on development 
of SST receptor subtype-selective analogues, both as peptides and nonpeptides.
98, 102, 105
 
There are three reasons behind this type of research: 
1. Evaluation of the distribution of various receptor subtype proteins in tissue. 
2. Determination of the specific biological effects mediated by the various  subtypes. 
3. Design of new drugs for specific therapeutic strategies. 
Mechanism of the Antiproliferative Activity of SST Octapeptide Analogue 
SST octapeptide analogues could influence the tumor cell growth either by 
indirect effect or by direct effect. 
Indirect Effect 
Indirect effect consequences from the inhibition of several growth promoting 
horones and growth factors that stimulates the growth of a variety types of cancers.
98
 For 
instance, it is witnessed that IGF-1, which is excreted by hepatocytes either by dependent 
or independent mechanism, is a growth promoter of a number of tumors that express 
IGF-1 receptors.
98
 Octreotide was found to downregulate the serum IGF-1 level either by 
inhibiting GF secretion, or by directly inhibiting IGF-1 gene expression, or by rising 
circulating IGF-1 binding proteins.
98
 This IGF-1 suppression strategy has been found to 
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be very effective  in the treatment of IGF-1 dependent tumors such as GH screening 
pituitary adenomas and to a lesser extent breast, lung and prostate tumors.
98
 Several other 
growth factors or hormones, which are known to play an important role in tumor growth, 
are being regulated either by naturally occurring somatostatin or SST analogues, as for 
example, gastrin, insulin, glucagon epidermal growth factor, and transforming growth 
factor-alpha.
98
 
Direct Effect 
As mentioned earlier, a number of cancer cells overexpress SSTRs.
98
 Some of 
them often express more than one SST subtypes.
95, 98
 For instance, SSTR expressions 
have been recognized in human primary colorectal carcinomas, small cell lung carcinoma, 
breast cancer, renal cell carcinoma, and malignant lymphoma.
98
 A direct inhibitory effect 
of SST and its analogues have been evidenced for these tumor cell lines.
98
 Hence, 
precedent experimental results indicates that somatostatin can directly interact with the 
blood vessels of the tumor cells through specific receptors.
98, 103, 104
 The antiproliferative 
activity of SST may consequence either from the blockage of mitogenic growth factor 
signal or from the induction of apoptosis, depending on the SSTR subtype or the target 
cell.
98
 Octreotide and vapreotide have been found to inhibit both serum and insulin driven 
proliferation of NIHT3/CHO cell transfected with SSTR2 via stimulation of the tyrosine 
phosphate.
98
 
In comparison to naturally occurring SST (SST14 and SST28), short synthetic 
SST analogues have been found to be even more efficient due to high receptor binding 
affinity and selective binding to the receptors.
95, 98
 Out of several short SST analogues, 
octapeptide analogues (Figure 14) are being used frequently as drugs to suppress 
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cancers.
95
 Out of three synthetic octapeptides (Figure 14), the octreotide is used most 
frequently due to its high binding affinity to SSTR2 and SSTR5. 
Application of Somatostatin Octapeptide Analogues in the Clinic 
At present, there is wide spread application of somatostatin octapeptide analogues in 
treatment of various types of cancers.
106
 Some of important of them are noted below. 
Carcinoid Tumor 
Octreotides and lanreotides are permitted in most countries to treat the hormonal 
symptoms in the patients with carcinoids. Endocrine cells give rise to the carcinoids.
98
  
They generally arise in the ileum and metastasize to liver resulting in so called “carcinoid 
syndrome” (flushing, diarrhea, cardiac vascular lesions).98 Some carcinoids may appear 
in the non-gastrointestinal origin such as lung or ovary. Recent studies suggest that 
octreotide treatment results in a substantial improvement of hormonal symptoms in more 
than 90% of the patients with carcinoids.
98
 
Endocrine Pancreatic Tumors 
  Another application of Octreotide in the field of oncology is its use in the 
treatment of hormonal hypersecretion associated with endocrine pancreatic tumors.
98
 
Octreotide has been well explored in the treatment of insulinomous, gastrinomas, VIP-
oms, glucagonomas, and somatostatinomas with variable effects on symptoms in spite of 
its capability of lowering plasma concentrations of marker peptide in most patients.
95, 98, 
107
 In some cases, VIP-omas cannot be cured either by surgery or by chemotherapy, and 
Octreotide is the only choice of treatment approved by Food and Drug Administration.
98
 
Improvement of symptoms and biochemical processes have been observed in more than 
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80% of the patients.
98
 Octreotide has been found to be beneficial for 50% of the patients 
with insulinomas and 90% of the patients with gastrinomas.
98
 
Pituitary Tumors 
  The best way to treat pituitary tumors is surgical removal of the tumors. However, 
it is not always possible to remove them by surgery because of their extension to pituitary 
and super pituitary areas. In this situation, Octreotide is the treatment of choice to reduce 
the hormone hyper-secretion.
95,98
 Recent observations show that the octreotide 
administered to acromegatic patients stimulated rapid and remarkable clinical 
improvement by lowering the GH levels to less than 5g/L in half of the patients.95, 98 
The size of the pituitary adenoma has been observed to reduce by more than 20% in half 
of the patients on octreotide treatment.
98
 
Other Cancers 
 Octreotide has also been proposed for other cancerous cells based on the SSTR 
expressions, for example: pancreatic tumors, hepatocellular carcinoma, small cell lung 
cancer, breast cancer, Prostate cancer, non-neurodocrine solid tumors.
95, 98, 103, 104
 
Radiolabeled Somatostatin Octapeptide Analogues and Their Applications 
It is always very difficult to determine the localization of neuroendocrine tumors 
in patient bodies by standard techniques such as ultra sonography or computed 
tomography, since those tumors are very small in size. One alternative approach is to 
visualize the SSTRs on the neuroendocrine tumors.
98
 This approach is very promising 
and viable, because SST radiopharmaceuticals are ssuitable for scintigraphy and are 
available.
98
 Moreover, the presence of SSTRs on the endocrine tumors with high density 
made this imaging possible.
98
 The first radioactive SST analogue used for tumor imaging 
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was I
123
-TYR
3
-Octreotide.
98
 Later alternative labeling procedures and radioisotopes were 
explored to minimize several problems, as for example, halogenations of I123-TYR
3
, or 
non specific uptake, etc.
98
   More recently, various novel chelators are being attached to 
the N-terminus of the SST analogues for labeling with radio-metals, which were designed 
and studies in the clinic.
108
 A list of the recent chelators is given below in Figure 16. 
 
 
 
 
 
 
Figure 16. Somatostatin analogues attached to chelators. 
Targeted Chemotherapy 
 Another application of SST in oncology is its use in targeted chemotherapy.
98
 Just 
like targeted radiotherapy, SSTR targeted chemotherapy seems to be a promising 
approach in the treatment of SSTR expressing malignant sites.
95, 98
 More over SSTR 
targeted chemotherapy has been found to be more efficient either from the anti-cancer 
drug alone or from the SST analogues alone.
95
 It was already proven when  nude mice 
bearing xe-nographts of MIA-paca-2 human pancreatic cancer cells were treated with  
this combination, a significant reduction in tumor size was reported as compare to 
anticancer drug alone or the SST analogues alone.
95
 More recently, another compound 
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was synthesized by a different group and that was a complex made of Octreotide 
conjugated to Taxol. This complex has been found to induce apoptosis in MCF-7 cells in 
SSTRs selective way by making the conjugate less toxic than free Taxol itself.
98
 Hence, 
to summarize, there are widespread applications of somatostatin analogues in the field of 
oncology. Short half life period (2-3minutes) of Somatostatin analogues (due to 
proteolytic degradation) is the main problem.
98
 Short synthetic octapeptides (Octreotide, 
Lanreotide and Vapreotide) have 45 times higher half life than SST14.
98
 However, 
octapeptide treatment require further improvement in half-lives of the SST analogues.
98
 
This problem has become a major impediment for frequent clinical use of SST analogues. 
Since the last decade, there has been much focus on the improvement of somatostatin 
analogues to make it more potent to proteolytic degradation.
35, 109
  Work has been 
carrying out by several research groups to give birth to a new protease resistant SST 
analogue. 
Instability and Amelioration of Somatostatine Analogues 
  Both naturally occurring somatostatins (SST-14 and SST-28) are extremely 
sensitive to peptidases, and they rapidly degrade due to cleavage of peptide bonds by 
several types of peptidases present in most tissues (Trypsin, Plasmin, Plasma 
Kallikrein).
35, 98, 109
 The naturally occurring SST-14 contains at least four sites susceptible 
to proteolytic degradation.
98
 Out of these four sites, Lys
9
-Thr
10
 bond is more important 
because cleavage of this bond results in loss of agonist action.
98
 In most of the cases, 
trypsin plays its role in cleaving the bond next to lysine.
67
 In accordance with the recent 
data, it would be rational to work on the improvement of the octapeptide somatostatin 
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analogues, because they have much higher affinity and selectivity to the SSTRs compare 
to the SST-14 and SST-28.
101, 103, 104, 110, 111
 
Identification of the Amino Acids Essential for the Biological Activity of SST 
 Several systematic experiments have been carried out by replacing residues of 
SST by Ala, which is called alanine scan. Alanine scan has revealed that residues in the 
position 7-10 are very important for the activity of SST, whereas the N-terminal amino 
acids (Ala-Gly) are less important.
98
 Among all of them, Lys9 is most important since 
cleavage of Lys-Thr bond leads to loss of SST agonist action.
98
 It has also been found 
that the octapeptide analogues with the sequence of Phe
7
-D-Trp
8
-Lys
9
-Thr
10
 are more 
efficient in receptor binding compare to other Octapeptide analogues.
92, 98
  For instance, 
octreotide with the above sequence and C-terminal amino alcohol have been found to be 
long lasting in blood plasma and 45-70 times more potent than naturally occurring SST in 
prohibition of GH secretion.
92, 98
 Octreotide has also been found to suppress the insulin 
and glucagon secretion to a lesser extent than GH secretion.
98
 Hence, the above 
mentioned evidences suggest that Octreotide is very specific for the inhibition of GH 
secretion. Prolonged studies and observations have proven octapeptides with much higher 
affinity, specific receptor binding ability and most importantly more stability to almost all 
sorts of proteases.
98
 Though the stability of these octapeptides is not yet high enough to 
minimize their doses of administration and cut down the astronomical amount of 
expenses to the common and poor patients around the word.
98
 In most of the cases, 
common patients cannot afford the long term treatment with these ocrapeptides as they 
are required to administer in higher amounts frequently for their low stability towards the 
proteases.
98
  Moreover higher doses give rise to many of the side effects like nausea, 
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transient abdominal cramps, flatulence, diarrhea, delay of insulin release in response to 
meal, formation of gallstones, etc.
98
 Extensive research still needs to be done to improve 
the half life period of somatostatin analogues.
98
 
Current State of Work on Developing Protease Resistant Somatostatin 
 There has been extensive research on developing novel protease resistant SST 
analogues and emphasis is on the Lys-Thr bond. This bond is very important with respect 
to the receptor binding and enzymatic activity of SST. 
Site Directed Mutagenesis and Its Limitation 
 Scientists thought of replacing either Lys or Trp with other amino acids, and this 
is where the concept of site-directed mutagenesis comes into play.
98
 Recently, there has 
been much research on the site directed mutagenesis because it is a powerful tool in 
selectively replacing any amino acid in the peptide of interest with any other natural 
amino acid.
100
 The absolute site specificity and replacement with well characterized 
structures are the strength of this technique.
100
 The down side of this technique is that the 
Lys or Trp must be replaced with other naturally occurring amino acids. Furthermore, in 
the loop of SST, both Trp and Lys are very much essential in terms of receptor binding 
by salt bridge interaction.
112
 This is where the concept of unnatural amino acids arose. 
Unnatural amino acids are chemical modification of the naturally occurring amino acids. 
The problem is natural amino acids cannot be replaced with unnatural Trp or Lys with the 
help of site directed mutagenesis. 
Peptidomimetic 
This technique could incorporate sterically congested unusual amino acids in 
protease specific cut sites in peptides of interest.
100
 The concept is to either block the 
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active site of protease enzymes or slow down the catalytic activity (peptide bond 
degradation) of protease enzymes. Synthesis of the more protease resistant SST 
analogues should not be the only thing to consider, but they should have to have higher 
binding affinity and selectivity to the SSTRs as well.
100
 Recently, there has been much 
research on the synthesis of unnatural α, β, γ- unusual lysine and Trp analogues to make 
SST analogues more stable and more resistant towards proteolytic degradation.
30, 113-117
 
The rationale behind incorporating sterically constrained unnatural amino acids into SST 
analogues is to induce remarkable propensity in the SST analogues to form stable helical 
secondary structures.
34
 It has been observed that peptides consisting of β and γ-amino 
acids can adopt a stable secondary structure in solution with a few as four to six 
residues.
118
 Small peptides of four to six γ-amino acid residues form stable helical 
secondary structure in solution and in solid state.
119
  The improved secondary structure is 
witnessed to provide remarkable stability towards proteolytic degradation as compared to 
naturally occurring α-peptide controls. 115, 118, 119 A few years ago, Rajeswaran et al. 
reported that the introduction of N-methyl-lysine in somatostatin analogues is tolerated 
and retains the binding affinity to SSTR2.
120
 To the best of my knowledge, Prasad et al. is 
the first to report SST octapeptides consisting of C
,
-disubstituted-amino acid analogues 
retain binding affinity to SSTR2 and exhibit improved stability in blood plasma.
35
 Based 
on the precedent literatures, I hypothesize: 
Hypothesis 2. 
Substitution of naturally occuring lysine with conformationally constrained (S)-C

-
methyl--lysine would retain specific binding affinity of the SST octapeptides for SSTRs. 
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Results and Discussion 
To test our hypothesis, I chose Vapreotide (one of the SST octepeptides). 
Vapreotide
®
 is a widely studied somatostatin analogue with anti-neoplastic properties. 
Vapreotide has a higher binding affinity to somatostatin receptor subtype 2 (SSTR2) than 
native somatostatin.
98, 121
 However, Vapreotide is prone to degradation at the Lys-Val 
bond by serine proteases (Trypsin, Plasmin, Plasma Kallikrein, etc.).
67
 We have made an 
effort to prepare a Vapreotide analogue 54 (Figure 17) replacing naturally occurring 
lysine with our (S)-α2,2-methyllysine (34) analogue in order to study the specific binding 
of 54 to SSTR2. The vapreotide analogue was synthesized using properly protected (S)-
α2,2-methyllysine analogue (34). The Vapreotide analogue (54) was 99% pure as 
determined by HPLC. 
 
 
 
 
 
Figure 17. Vapreotide analogue consisting of C

-methyl--lysine 
 
Specific binding studies of the vapreotide analogue were conducted against the 
IMR 32 human neuroblastoma cells. However, it was observed that the vapreotide 
analogue showed no specific binding (Table 2) to SSTR2.  
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Conclusions 
 A simple switch from naturally occurring lysine to C
α,α
-disubstituted lysine 
diminishes the specific binding of the Vapreotide analogue (54) to SSTR2. I suspect that 
the loss of specific binding for SSTR2 is attributed to conformational changes of the 54 
ring resulting from the introduction of conformationally constrained C
α,α
-disubstituted 
lysine.
120, 122
 
Experimental 
Synthesis and specific binding of Vapreotide analogue (54) against IMR 32 Cell 
Line: The Vapreotide analogue (54) was synthesized in collaboration with New England 
Peptide (Gardner, MA), using properly protected (S)-α2,2-metyllysine analogue (34) 
prepared in our laboratories as described in chapter II. The Vapreotide analogue was 
determined to be 99% pure by HPLC. 
Binding of the Vapreotide analogue (54) was conducted against IMR 32 human 
neuroblastoma cells. These cells over express SSTR2 receptors. In order to perform the 
binding assays, four groups of triplicate wells were studied (n = 12 total). Each well 
contained 500,000 IMR 32 cells in 2 mL of media. These wells also contained 100,000 
counts of 
111
In-pentetreotide.  Three wells were competed with 10
-6
 M octreotide and 
three wells were competed with 54. All 12 wells were incubated at 37 
0
C for 20 hours. 
Cells were harvested, washed and counted in a gamma counter. However, gamma counter 
result revealed that the Vapreotide analogue 54 has no specific binding for SSTR2 (Table 
2). 
 
 
93 
 
 
 
Specific Binding of Vapreotide Analogue (54) against IMR 32 Cells  
Table 2 illustrates the specific binding experiments of Vapreotide analogue (54) 
against IMR 32 human neuroblastoma cells that are known to over express SSTR2.
107
 In 
the binding assay 
111
In-Pentetreotide, which is known to effectively bind to SSTR2, was 
used as the radio ligand (Hot ligand).
73
 In addition, Octreotide acetate, which is known to 
have high selectivity for SSTR2, was used as a positive control (Cold ligand 1) to 
compete with the 
111
In-Pentetreotide.
107
 The Vapreotide analogue (54, Cold ligand 2) was 
allowed to compete with the 
111
In-Petetreotide as well (Cold ligand 2). Cells were 
harvested, washed, and counted in gamma counter to determine the quantity of the 
111
In-
Pentetreotide (CPM) bound to the cells. The specific binding of each cold ligand was 
determined from the equation below based on the amount of 
111
In-Pentetreotide bound to 
the IMR 32 cells as obtained from the gamma counter. 
Specific binding of Octreotide Acetate in CPM (cold ligand 1) = competitive binding of 
111
In-Pentetreotide and Octreotide Acetate in CPM (Hot + Cold 1) – binding of 111In-
Pentetreotide in CPM (Hot). 
Specific Binding of Vapreotide analogue (35, cold ligand 2) = competitive binding of 
111
In-Pentetreotide and Vapreotide (35) in CPM (Hot + Cold 2) – binding of 111In-
Pentetreotide in CPM (Hot). 
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Table 2 
Specific binding assay of the Vapreotide (54) against IMR 32 cell line. 
Competitor 
 
CPM (Hot) 
 
CPM (Hot 
+ Cold) 
CPM 
Specific binding (Hot 
– Hot + Cold) 
    
Octreotide 
Acetate (Cold 1) 
 2591 
 3096 
 3238 
317 
332 
287 
2663.0 
Mean CPM  2975 312 
 
   
Standard 
Deviation 
 
 340  22.9  
 
Vapreotide (Cold 
2) (35, Figure 2) 
with (S)-α-
methyl-α-lysine 
 
 3272 
 4062 
 3574 
  4284 
  3415 
  3444 
-78.3 
Mean CPM  3636      3714.3  
Standard 
Deviation 
  398.6    493.6  
Background CPM 40   
Radio Ligand 
Used 
111
In-Pentetreotide (Hot) 
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CHAPTER IV 
STEREOSELECTIVE CYCLIZATION STRATEGY TO PREPARE γ-/δ- LACTAMS 
AND THEIR USE IN THE PREPARATION OF PROLINE AND NIPECOTIC 
ACID ANALOGUES 
Background 
Lactams are one of the most significant classes of amides. Lactams are frequently 
obtained as building blocks in a variety of biologically active molecules and are 
employed very often as intermediates in preparation of diverse materials.
123, 124
 Amongst 
the lactam family, chiral γ-, and δ-lactams have significance, since they provide access to 
the optically enriched γ-/δ-amino acids, chiral pyrrolidine, and chiral piperidine 
analogues.
123, 125
 In continuation, this class of compounds has been utilized in 
peptidomimetics.
126
 A number of synthetic strategies are established to prepare a variety 
of γ-, and δ-lactams from the readily accessible precursors.123, 124, 127-129 
Current State of the Art to Prepare γ-/δ-Lactams 
Over the last few years, researchers have explored a number of ways that led to 
asymmetric synthesis of γ-lactams. Lately, Yokosaka et al. reported an aza-Michael 
cascade reaction strategy to prepare a number of γ-lactam derivatives (Scheme 29).130 
 
 
 
 
 
Scheme 29. Strategy of Yokosaka et al. 
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Recently, Darlene et al. reported a cycloaddition strategy to derive a number of γ-
lactam analogues through malic anhydride derivatives. 
131
 
 
 
 
 
 
 
 
Scheme 30. Strategy of Darlene et al. 
A few years ago, Pohmakotr et al. had shown that the Mukaiyama-Aldol reaction 
provides access to asymmetric synthesis of a variety of γ-lactams (Scheme 31).132 
 
 
 
 
 
Scheme 31. Strategy of Pohmakotr et al. 
 
Park et al. exhibited that the β-lactam rings could be expanded to the 
corresponding γ-lactam derivatives.133 
 
 
 
 
 
 
Scheme 32. Strategy of Park et al. 
Brenner at al. reported that reduction of optically enriched 4-nitro-carboxylic acid 
derivatives followed by cyclization provides access to γ-lactam derivatives.134 In addition, 
a number of methods have been optimized to construct optically enriched γ-lactam 
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derivatives employing chiral auxiliaries,
127, 134
 enantiomerically enriched starting 
materials,
135
 and organocatalysts.
130, 135
 
Similar to γ-lactams, δ-lactams have also drawn considerable attention over the 
last decade.
124, 128, 129, 136, 137
 Lately, Vervisch et al. reported nitrilase enzyme catalyzed 
transformation of cyanoaziridines to relevant δ-lactam derivatives (Scheme 33).128 
Recently, Thai et al reported a novel NHC catalyzed ring expansion reaction providing 
access to δ-lactam derivatives (Scheme 34).138 
 
 
 
 
 
Scheme 33. Chemoenzymatic transformation of aziridines into δ-lactams. 
 
 
 
 
 
 
 
Scheme 34. Synthesis of δ-lactams by ring expansion. 
 
Zhou et al. reported a gold catalyzed highly regioselective cyclization strategy 
deriving a variety of γ-, and δ-lactams (Scheme 35).139 
 
 
 
 
 
Scheme 35. Conversion of N-alkenyl-β-ketoamides to corresponding γ-/δ-lactams. 
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Fiorelli et al. reported a novel ring closing metathesis mediated preparation of δ-
lactams (Scheme 36).
140
 
 
 
 
 
 
 
 
Scheme 36. Preparation of δ-lactams through ring closing metathesis. 
 
Patil et al. reported a novel strategy to prepare δ-lactam derivatives through 
intramolecular hydroamidation of amidoalkynes (Scheme 37).
141
 
 
 
 
 
Scheme 37. Intramolecular hydroamidation of amidoalkynes. 
 
In addition to these, a number of synthetic strategies have been developed to 
provide access to chiral δ-lactams, utilizing aza-Diels Alder reactions142 and metal 
catalyzed C-H bond amination.
143
 
To summarize, a number of methods have been developed to achieve diverse γ-, 
and δ-lactams derivatives. However, there is limited scope to provide access to optically 
pure  γ-, and δ-lactam derivatives.123, 140 To the best of our knowledge, none of the 
synthetic strategies provide access to both enantiomers of a chiral γ-/δ-lactam. In addition, 
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very few synthetic strategies are available to obtain C
,
-disubstituted-γ-, and δ-
lactams.
123, 124
  
 
 
 
 
 
Figure 18. C
α,α
-disubstituted-γ-/δ-lactams. 
 
The family of C
,
-disubstituted-γ-/δ-lactams (Figure 18) have significant 
importance, as they are frequently found as building blocks of the biologically important 
complex natural product structures, and they provide access to chiral C
,
-disubstituted 
pyrrolidine and piperidine analogues.
123, 124
  Among  the class of C
,
-disubstituted-
pyrrolidine/piperidine derivatives, C

-methyl-β-proline, and C-methyl-nipecotic acid 
analogues (Figure 19) have been frequently utilized in peptidomimetics, in natural 
product synthesis, in the synthesis of a variety of enzyme inhibitors, as GABA reuptake 
inhibitors, in the synthesis of a number of receptor antagonists, and as organocatalysts.
1, 
45, 47, 124, 144, 145
 Hence, the above examples point that there is growing demand for the 
prepapration of chiral C
,
-disubstituted-γ-/δ-lactams due to their potential use in the 
preparation of optically pure α-methyl-β-proline, and and α-methyl-nipecotic acid 
analogues. 
 
 
 
 
 
 
Figure 19. Proline and nipecotic acid analogues. 
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Current State of Art to Prepare C
α
-Methyl-β-Proline, and Cα-Methyl-Nipecotic Acid 
Analogue 
Over the last few years, several research groups in academia and in industry have 
explored a number of methods to prepare C
α
-methyl-β-proline, and Cα-methyl-nipecotic 
acid analogues.
1, 45, 47
  However, the number of ways known to prepare these analogues is  
still limited. Recently, Nagata et al. reported a phase transfer catalyst mediated strategy to 
prepare γ-lactam and its transformation into a Cα-methyl-β-proline analogue (Scheme 
38).
144
 However, their method was not able to produce the β-proline analogue in high 
optical purity. Hence, they had to use chiral amine to resolve other enantiomer. This 
group has also exhibited the potent catalytic activity of C
α
-methyl-β-proline analogues in 
anti-Mannich type reactions.
144
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 38. Strategy of Nagata et al. to prepare C
α
-methyl-β-proline. 
A few years back, Shintani et al. reported a Pd catalyzed decarboxylative 
cyclization strategy to prepare chiral C
α,α
-disubstituted nipecotic acid analogues (Scheme 
39). 
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Scheme 39. Synthesis of C
α,α
-disubstituted nipecotic acid analogues through 
decarboxylative cyclization. 
 
Years ago, Huffman et al. discovered a potent NK1 receptor antagonist that 
consists of chiral C
α
-methyl-nipecotic acid as an essential building block (Figure 9, Page 
13).
45
 However, this group was not able to come up with the asymmetric synthetic 
strategy to prepare C
α
-methyl-nipecotic acid analogue.
45
 Hence, they had to resolve two 
enantiomers to use the one to their interest.
45
 Therefore, there are a limited number of 
options to prepare C
α
-methyl-β-proline and Cα-methyl-nipecotic acid analogues. In 
addition, none of the synthetic strategies could derive both enantiomers of C
α
-methyl-β-
proline and C
α
-methyl-nipecotic acid from a common intermediate. Recently, I have 
observed that the optically enriched unsymmetrical malonic esters could be readily 
converted into C
α,α
-disubstituted-γ-lactam (Scheme 39). Based on the precedent 
literatures and my recent success we hypothesize: 
Hypothesis 3. 
  Optically enriched unsymmetrical malonic-diesters could be stereoselectively 
cyclized to the relevant C
α,α
-disubstituted-γ-/δ-lactams (Scheme 39). A Hammett study 
should be able to provide insight into electronic activation of one of the ester groups 
towards nucleophilic attack. The consequential γ-/δ-lactams could be further 
chemoselectively reduced to the corresponding C
α
-methyl-β-proline/Cα-methyl-nipecotic 
acid analogues (Scheme 40). 
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Scheme 40. Stereoselective cyclization strategy. 
 
Results and Discussion 
We had to prepare compound 18 from 10b in our attempt to determine the 
absolute stereochemistry of 10b by synthetic means (Scheme 41). Upon treatment of 18 
with hydrazine a cyclization took place resulting in compounds 19a and 19b as illustrated 
in Scheme 40. Interestingly, the 19a/19b ratio was 10:1 as determined by 
1
H-NMR 
resulting in a selective cyclization that favored ring closure by attack at the benzyl ester 
over the ethyl ester. The cyclization selectivity results in an enantioselective cyclization 
strategy as 19a has the R-absolute stereochemistry and 19b has the S-absolute 
stereochemistry. 
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Scheme 41. Stereoselective cyclization to prepare γ-lactam. 
The option to control the cyclization reaction employing such a straightforward 
set of synthetic manipulations could prove useful in the enantioselective preparation of γ-
lactams from simple half-ester starting materials such as 10b. The 10:1 selectivity was 
exciting keeping in mind that both esters are relatively open toward nucleophilic attack 
by the amine nucleophile. In an attempt to better understand the factors controlling the 
selectivity of the cyclization I performed a series of cyclization experiments where 
substituents were introduced on the para position of the aromatic ring of the benzyl ester 
(Scheme 42). 
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Scheme 42. Cyclization using various benzyl esters. 
The introduction of substituents on the para position allows us to construct a 
Hammett plot providing insight into the electronic factors regulating the selectivity of the 
cyclization. I hypothesized that the σp constants
146
 would provide insight into the 
electronic activation of the benzyl ester toward nucleophilic attack. Figure 20 illustrates 
the results of the Hammett analysis with a strong correlation of product ratio to σp. The 
positive slope clearly indicates that electron withdrawing substituents favor cyclization to 
γ-lactam 19a over γ-lactam 19b. This illustrates that benzyl esters with para electron 
withdrawing substituents activate the carbonyl toward nucleophilic attack by the 1
o
-
amine resulting in selective formation of 19a. 
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Figure 20. Hammett Plot. 
 
I wanted to further extend the stereoselective cyclization concept to provide 19b 
as the major product. The possibility of being able to obtain 19b as the major product 
would allow for a potentially useful enantiodivergent cyclization strategy. The results of 
the Hammett study point that it would be difficult to achieve high selectivity in the 
formation of 19b just by exploring electronic factors on the benzyl ester. I prepared 
diester 55 from 10b that would introduce steric hindrance (Scheme 43). The ethyl ester 
should behave as the better electrophile from a steric congestion standpoint leading to the 
stereoselective cyclization to 56. Product 56 is an analogue of 19b and has the same 
absolute stereochemistry as 19b. 
 
 
 
 
 
 
Scheme 43. Selective cyclization leading to (S)-γ-lactam 56. 
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Upon achievement of (R)-, and (S)-γ-lactams, I wanted to further utilize the 
optimized method to obtain chiral δ-lactams. Upon close inspection of half-ester 10c, it is 
conceivable that unsymmetrical diesters of 10c could be stereoselectively cyclized to the 
δ-lactams. Upon treatment of 57 with hydrazine, the similar cyclization took place 
resulting in compounds 58 and 59 as illustrated in Scheme 44. Interestingly, the 58/59 
ratio was 60:1 as determined by 
1
H-NMR resulting in a selective cyclization that favored 
ring closure by attack at the p-nitro-benzyl ester over the ethyl ester. The cyclization 
selectivity results in the same enantioselective cyclization strategy as Scheme 40, since 
58 has the R-absolute stereochemistry and 59 has the S-absolute stereochemistry. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 44. Stereoselective cyclization leading to δ-lactam. 
 
At this point, 59 was wanted to be achieved as the major isomer in order to be 
able to develop an enantiodivergent strategy to provide access to chiral δ-lactams. Hence, 
the half-ester 60 was synthesized as shown in Scheme 44 following the synthetic strategy 
to prepare (S)-γ-lactam 56 as predominant isomer (Scheme 42). Interestingly, upon 
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treatment of 60 with hydrazine hydrate a stereospecific cyclization took place providing 
the δ-lactam 61 as only isomer (Scheme 45). 
 
 
 
 
 
 
 
 
 
Scheme 45. Stereospecific synthesis of (S)-δ-lactam. 
We wanted to display the potential utility of the γ-/δ--lactams prepared above as 
precursors to unnatural amino acids. Upon inspection of 19a, it is conceivable that a β-
proline analogue
147-153
 could be readily prepared by reduction of the lactam to a 2
o
-amine. 
Similarly, 58 could be readily converted reduced into a nipecotic acid analogue.
45
 I made 
attempt of a direct reduction of the lactam with various reducing agents and conditions 
that are  known to reduce lactams to amines.
154, 155
 However, all attempts at direct 
reduction of the lactam resulted in reduction of both the ester and lactam functional 
groups providing a complex mixture of products.  The synthetic approach shown in 
Scheme 46 was used to overcome the over-reduction problem and ultimately provide the 
unprotected β-proline /nipecotic acid analogue in a reasonable overall yield. 
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Scheme 46. Synthesis of proline and nipecotic acid analogue. 
 
Compounds 19a nad 58 were treated with NaH and benzyl bromide to provide 
the resulting 62a nad 62b in good yield (68% - 75%). The lactams of 62a/62b were 
converted in good yield (80% - 85%) to thiolactam 63a/63b using Lawesson reagent.
156
 
The thiolactams were then easily reduced to the 2
0
-amines 64a/64b by hydrogenation 
over Raney nickel catalyst in good yield. The amines 64a/64b were then subjected to 
saponification giving 65a/65b in 78% - 85% yield. Amino acids 65a/65b were then 
converted to the -methyl-β-proline analogue (66a) and -methyl-nipecotic acid 
analogue (66b) in excellent yield (91% to 95%) by hydrogenation over Pd/C catalyst. The 
overall yield of 66a from 19a is 28% over the five straightforward steps shown in 
Scheme 45. In continuation, the overall yield of 66b from 58 is 45% over the five 
straightforward steps as shown in Scheme 45.  
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C

-Methyl-β-Proline as an Organocatalyst in Anti-Mannich Type Reactions 
Proline and its derivatives have been frequently used as organocatalysts in Aldol, 
Mannich, and Michael type reactions over the last decade.
25, 123, 144, 157
 This class of 
catalysts have proven their excellence in asymmetric synthesis of new C-C bond.
144, 157
 
One of the biggest advantages to use this set of catalysts is the ease of handling as 
opposed to metal-catalysts.
157
 In most cases, this class of catalysts is easily isolated from 
the crude mixture by simple water extraction at the end of the reaction.
144
  In recent years, 
Barbas et al. exhibited a number of β-proline and nipecotic acid analogues as potent 
catalysts in anti-Mannich type reactions (Scheme 47).
23, 158
 This set of catalysts are 
observed to predominantly  produce the anti-Mannich isomers in excellent diastereomeric 
ratio and enantiopurity.
23
  
 
 
 
 
Scheme 47. β-proline analogue in anti-Mannich type reactions. 
However, there was no report until recently utilizing C
,
-disubstituted-β-proline 
in anti-Mannich type reactions.
144
 Hence, we have made an effort to explore the -
methyl-β-proline analogue (66a) made in our hand in Mannich type reactions (Scheme 
47).  We have observed that the β-proline analogue (66a) is a strong anti-selective 
catalyst producing the anti-Mannich product 67a as the predominant stereoisomer in 8: 1 
diastereomeric ratio and 97% ee (Scheme 48, Figure 21). The combined yield was 75%. 
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Scheme 48. C

-methyl-β-proline catalyze anti-Mannich type reactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Chiral-HPLC chromatogram of racemic and optically pure anti-Mannich 
reaction. 
 
Based on the results obtained, we have proposed the plausible transition state of 
the anti-Mannich type reactions employing α-methyl-β-proline (Scheme 49).  
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Scheme 49. Transition state of anti-Mannich type reaction. 
 
Conclusions 
I have shown that enantioselective γ-/δ-lactam formation is possible from 10b/10c 
with careful choice of benzyl ester. The highest level of selectivity was noticed using 18d 
containing a para nitro substituent on the benzyl ester. The cyclization selectivity has a 
strong correlation to σp as established in the Hammett study. The positive slope of the 
Hammett plot indicates that electron withdrawing substituents in the para position of the 
benzyl ester activate the benzyl ester carbonyl toward electrophilic attack. I have 
confirmed that γ-/δ-lactam 19a/58 can be readily converted into 66a/66b providing 
straightforward access to a new class of proline and nipecotic acid analogue. I have also 
demonstrated 66a as a strong catalyst for anti-Mannich selective catalyst. 
Experimental 
 
General Procedure for the Synthesis of 18a-18e 
A 250 mL roundbottom flask was charged with 9.9 g of 10b (31 mmol), 4.3 g of 
K2CO3 (31 mmol), 100 mL of anhydrous DMF, and a stirbar. A solution of the 
appropriately substituted benzyl bromide (28 mmol) in 20 mL of anhydrous DMF was 
slowly added over 15 minutes. The reaction was allowed to stir approximately 12 hr 
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under a nitrogen atmosphere. The reaction mixture was then diluted with 100 mL of 
water and the resulting mixture was washed with Et2O (3 x 100 mL). The combined ether 
layer was washed with water (5 x 100 mL), washed with brine (2 x 100 mL), dried over 
MgSO4, and the solvent was removed under reduced pressure. The product was isolated 
by flash chromatography (40% Et2O/hexanes). 
Synthesis of (S)-1-Benzyl-3-Ethyl-2-Methyl-[2-(1,3-Dioxoisoindolin-2-Yl)Ethyl]Malonate 
(18a) 
18a was synthesized following the general synthetic procedure for the preparation 
of 18a-18e. An amount of 11 g of product (27 mmol, 87%) was obtained after flash 
chromatography purification as a colorless liquid. Rf = 0.2 (40% Et2O/hexanes).  = -
3.08 (c = 1, CHCl3). IR (cm
-1
): 2980, 1773, 1708. 
1
H-NMR (CDCl3, 400 MHz): 7.83 (m, 
2H), 7.70 (m, 2H), 7.33 (m, 5H), 5.15 (m, 2H), 4.10 (m, 2H), 3.74 (m, 2H), 2.28 (m, 2H), 
1.56 (s, 3H), 1.16 (t, 3H, J = 7 Hz). 
13
C-NMR (CDCl3, 100 MHz): 171.4, 171.3, 168.0, 
135.5, 134.0, 132.0, 128.5, 128.3, 128.1, 123.0, 67.0, 61.0, 52.0, 33.8, 33.8, 20.0, 14.0. 
HRMS [C23H23NO6Na
+
]: calcd = 432.1417, found = 432.1406. 
Synthesis of (S)-1-(4-Fluorobenzyl)-3-Ethyl-2-Methyl-[2-(1,3-Dioxoisoindolin-
2Yl)Ethyl]Malonate (18b) 
18b was synthesized following the general synthetic procedure for the preparation 
of  18a-18e. An amount of 9.95 g of product (23.3 mmol, 75%) was obtained after 
purification as colorless liquid. Rf = 0.25 (40% Et2O/hexanes). = -3.7 (c = 1, CHCl3). 
IR (cm
-1
): 2984, 1773, 1708. 
1
H-NMR (CDCl3, 400 MHz): 7.83 (m, 2H), 7.71 (m, 2H), 
7.33 (m, 2H), 7.03 (m, 2H), 5.11 (m, 2H), 4.10 (m, 2H), 3.72 (m, 2H), 2.26 (m, 2H), 1.55 
(s, 3H), 1.16 (t, 3H, J = 7 Hz). 
13
C-NMR (CDCl3, 100 MHz): 171.4, 171.3, 163.0 (d, 
1
J = 
113 
 
 
 
250 Hz), 134.0, 132.0, 131.0 (d, 
4
J =3.6 Hz), 130.0 (d, 
3
J = 8.5 Hz), 123.0, 115.0 (d, 
2
J 
=22 Hz), 123.0, 66.0, 62.0, 52.0, 33.8, 33.7, 20.0, 14.0. HRMS [C23H22FNO6Na
+
]: calcd 
= 450.1323, found = 450.1312. 
Synthesis of (S)-1-(4-Methylbenzyl)-3-Ethyl-2-Methyl-[2-(1,3-Dioxoisoindolin-2Yl)Ethyl] 
Malonate (18c) 
 18c was synthesized following the general synthetic procedure for the 
preparation of  18a-18e. An amount of 9.4 g of product (22.3 mmol, 72%) was obtained 
after purification as colorless liquid. Rf = 0.24 (40% Et2O/hexanes). = -5.3 (c = 1, 
CHCl3). IR (cm
-1
): 2983, 1773, 1708. 
1
H-NMR (CDCl3, 400 MHz): 7.83 (m, 2H), 7.70 
(m, 2H), 7.22 (d, 2H, J = 8 Hz), 7.14 (d, 2H, J = 8 Hz), 5.11 (m, 2H), 4.10 (m, 2H), 3.73 
(m, 2H), 2.34 (s, 3H), 2.26 (m, 2H), 1.55 (s, 3H), 1.16 (t, 3H, J = 7 Hz). 
13
C-NMR 
(CDCl3, 100 MHz): 171.4, 171.3, 168.0, 138.0, 134.0, 132.5, 132.0, 129.0, 128.0, 123.0, 
67.0, 62.0, 52.0, 34.0, 21.0, 20.0, 14.0. HRMS [C24H25NO6Na
+
]: calcd = 446.1574, found 
= 446.1565. 
Synthesis of (S)-1-(4-Nitrobenzyl)-3-Ethyl-2-Methyl-[2-(1,3-Dioxoisoindolin-
2Yl)Ethyl]Malonate (18d) 
18d was synthesized following the general synthetic procedure for the preparation 
of 18a-18e. An amount of 10.27 g of product (22.6 mmol, 73%) was obtained after 
purification as a white solid. mp = 65 
O
C. Rf = 0.1 (40% Et2O/hexanes). = + 1.4 (c = 
1, CHCl3). IR (cm
-1
): 2983, 1773, 1729, 1707, 1517. 
1
H-NMR (CDCl3, 400 MHz): 8.23 
(d, 2H, J = 8 Hz), 7.83 (m, 2H), 7.72 (m, 2H), 7.52 (d, 2H, J = 8 Hz), 5.25 (m, 2H), 4.16 
(m, 2H), 3.74 (m, 2H), 2.29 (m, 2H), 1.59 (s, 3H), 1.21 (t, 3H, J = 7 Hz). 
13
C-NMR 
(CDCl3, 100 MHz): 171.2, 171.1, 168.0, 148.0, 143.0, 134.0, 132.0, 128.0, 124.0, 123.0, 
114 
 
 
 
66.0, 62.0, 52.0, 34.0, 33.8, 20, 14. HRMS [C23H22N2O8Na
+
]: calcd = 477.1268, found = 
477.1266. 
Synthesis of (S)-1-(4-Trifluoromethylbenzyl)-3-Ethyl-2-Methyl-[2-(1,3-Dioxoisoindolin-
2Yl)Ethyl]Malonate (18e) 
 4e was synthesized following the general synthetic procedure for the preparation 
of 18a-18e. An amount of 10.8 g of product (22.6 mmol, 87%) was obtained after 
purification as a colorless liquid. Rf = 0.26 (40% Et2O/hexanes). = -8.33 (c = 3, 
CHCl3). IR (cm
-1
): 2983, 1773, 1709. 
1
H-NMR (CDCl3, 400 MHz): 7.83 (m, 2H), 7.71 
(m, 2H), 7.62 (d, 2H, J = 8 Hz), 7.46 (d, 2H, J = 8 Hz), 5.20 (s, 2H), 4.12 (m, 2H), 3.73 
(m, 2H), 2.29 (m, 2H), 1.57 (s, 3H), 1.17 (t, 3H, J = 7 Hz). 
13
C-NMR (CDCl3, 100 MHz): 
171.3, 171.2, 168.0, 139.0, 134.0, 132.0, 130.0 (q, J = 33 Hz), 128.0, 125.0 (q, J = 4 Hz), 
123.0, 122.0, 66.0, 62.0, 52.0, 34.0, 33.8, 20.0, 14.0. HRMS [C24H22F3NO6Na
+
]: calcd = 
500.1291, found = 500.1278. 
Synthesis of (R)-Ethyl-3-Methyl-2-Oxopyrrolidine-3-Carboxylate (19a) 
A volume of 930 µL (10.2 mmol) 35% hydrazine in water was added to a solution 
of 3.8 g (9.3 mmol) 18a in 50 mL MeOH. The mixture was heated to reflux solvent 
overnight. A white precipitate was observed within an hour of reflux. The reaction 
mixture was allowed to cool to RT, and the resulting mixture was filtered. The filtrate 
was evaporated under reduced pressure. The resulting residue was taken up in CH2Cl2 
and washed with water. The organic layer was dried over MgSO4, evaporated under 
reduced pressure, and purified by column chromatography, using 30% hexanes/EtOAc 
giving 1.2 g of a 10:1 mixture of 19a:19b as a white solid. The mixture was further 
recrystallized in cold Et2O giving 1 g (6 mmol, 64.5%) of pure 19a as white crystals. Rf 
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(19a) = 0.31 (30% hexanes/EtOAc). mp = 63 
O
C. = +19.0 (c = 2, MeOH). IR (cm
-1
): 
3245, 2985, 1726, 1698, 1660. 
1
H-NMR (CDCl3, 400 MHz): 7.06 (bs, 1H), 4.20 (m, 2H), 
3.47 (m, 1H), 3.36 (m, 1H), 2.64 (m, 1H), 2.02 (m, 1H), 1.45 (s, 3H), 1.28 (t, 3H, J = 7 
Hz), 
13
C-NMR (CDCl3, 100 MHz): 177.0, 172.0, 61.0, 51.0, 40.0, 34.0, 20.0, 14.0. 
HRMS [C8H13NO3Na
+
]: calcd = 194.0788, found = 194.0795. 
Synthesis of (S)-1-Tert-Butyl-3-Ethyl-2-Methyl-[2-(1,3-Dioxoisoindolin-2Yl)Ethyl] 
Malonate (55) 
A volume of 600 µL conc. H2SO4 was added to a solution of 2 g of 10b (6 mmol) 
in 30 mL CH2Cl2 in a 100 mL sealed tube. The solution was cooled to -7 
o
C. A volume of 
6 mL condensed isobutylene was added to the solution. The tube was sealed tightly and 
allowed to stir overnight at RT. The tube was uncapped and allowed to stir for 2hrs. at 
ambient pressure to allow excess isobutylene to evaporate. The solution was diluted with 
30 mL of CH2Cl2 and gently washed three times with 1N NaOH (50 mL). The CH2Cl2 
layer was dried over MgSO4, evaporated under reduced pressure, and chromatographed 
(40% EtOAc/hexanes), giving 1.8 g (5 mmol, 83%) of 55 as colorless viscous liquid. The 
viscosity of the material made removal of residual solvent impractical and 55 was utilized 
in the subsequent reaction without further purification. Rf = 0.51 (40% EtOAc/hexanes). 
IR (cm
-1
): 2979, 1774, 1709. 
1
H-NMR (CDCl3, 400 MHz): 7.84 (m, 2H), 7.71 (m, 2H), 
4.17 (m, 2H), 3.72 (m, 2H), 2.19 (m, 2H), 1.50 (s, 3H), 1.48 (s, 9H), 1.28 (t, 3H, J = 7 
Hz). 
13
C NMR (CDCl3, 100MHz) 172.0, 170.5, 168.0, 134.0, 132.2, 123.3, 82.0, 61.0, 
53.0, 34.0, 33.8, 28.0, 20.0, 14.0. HRMS [C20H25NO6Na
+
]: Calcd = 398.1574, found = 
398.1568. 
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Synthesis of (S)-Tert-Butyl-3-Methyl-2-Oxopyrrolidine-3-Carboxylate (56) 
A volume of 398 µL (4.4 mmol) 35% hydrazine in water was added to a solution 
of 1.5 g (4 mmol) 55 in 25 mL MeOH. The mixture was heated to reflux solvent 
overnight. A white precipitate was observed within an hour of reflux. The reaction 
mixture was allowed to cool to RT and the solution was filtered. The filtrate was 
evaporated under reduced pressure and taken up in CH2Cl2. The resulting mixture was 
washed with water and the organic layer was dried over MgSO4, evaporated under 
reduced pressure, and chromatographed using 30% hexanes/EtOAc giving 0.62 g of a 9:1 
mixture of 56:19a as a white solid. The mixture was further recrystallized in cold Et2O 
giving 0.52 g (2.6 mmol, 65%) pure 56 as a white solid. Rf (56) = 0.27 (30% 
hexanes/EtOAc). mp = 130 
O
C. IR (cm
-1
): 3255, 2970, 1727, 1688, 1660. = -14.3 (c 
= 1, CH2Cl2). 
1
H- NMR (CDCl3, 400 MHz): 6.44 (bs, 1H), 3.45 (m, 1H), 3.33 (m, 1H), 
2.55 (m, 1H), 2.0 (m, 1H), 1.46 (s, 9H), 1.39 (s, 3H). 
13
C-NMR (CDCl3, 100 MHz): 177.0, 
171.0, 81.0, 51.0, 40.0, 34.0, 28.0, 20.0. HRMS [C10H17NO3Na
+
]: calcd = 222.1101, 
found = 222.1097. 
Synthesis of (S)-1-(4-Nitrobenzyl)-3-Ethyl-2-Methyl-2-(3-(1,3-Dioxoisoindolin-2-
Yl)Propyl)Malonate (57) 
 A 250 mL round-bottom flask was charged with 6.41 g of 10c (19 mmol), 2.62 g 
of K2CO3 (19 mmol), 75 mL of anhydrous DMF, and a stirbar. A solution of the 4-
nitrobenzyl bromide (17.1 mmol) in 20 mL of anhydrous DMF was slowly added over 15 
min. The reaction was allowed to stir approximately 12 hrs. under a nitrogen atmosphere. 
The reaction mixture was then diluted with 100 mL of water, and the resulting mixture 
was washed with Et2O (3 × 150 mL). The combined ether layer was washed with water 
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(8 × 150 mL) and brine (2 × 100 mL) and dried over MgSO4, and the solvent was 
removed under reduced pressure. The product was isolated by flash chromatography 
(30% EtOAc/hexanes), giving 801g (17.4 mmol, 87%) pure 57 as white solid.  Rf = 0.1 
(30% EtOAc/hexanes).  MP = 66 
0
C. 
1
H NMR (CDCl3, 400 MHz): δ  8.19 (m, 2H), 7.81 
(m, 2H), 7.72 (m, 2H), 7.46 (m, 2H), 5.22 (m, 2H), 4.15 (q, 2H, J = 7 Hz), 3.68 (t, 2H, J = 
7 Hz), 1.95 (m, 2H), 1.65 (m, 2H), 1.44 (s, 3H), 1.18 (t, 3H, J = 7 Hz). 
13
C NMR (CDCl3, 
100 MHz): δ 171.5, 168.2, 148.7, 134.0, 132.0, 128.2, 124.0, 123.3, 65.2, 61.4, 58.5, 53.0, 
37.8, 33.0, 24.0, 20.0, 18.2, 13.6. ESI-MS [C24H24N2O8Na
+
] = 468.4, observed = 468.3.  
Synthesis of (R)-Ethyl 3-Methyl-2-Oxopiperidine-3-Carboxylate (58) 
  A volume of 1.8 mL (20 mmol) 35% hydrazine in water was added to a solution 
of 5.1 g (11 mmol) of 57 in 50 mL of MeOH. The mixture was heated to reflux overnight. 
A white precipitate was observed within 1 hr of reflux. The reaction mixture was allowed 
to cool to rt, and the resulting mixture was filtered through an HPLC filter. The filtrate 
was evaporated under reduced pressure. The resulting residue was taken up in CH2Cl2 
and washed with water. The organic layer was dried over MgSO4, evaporated under 
reduced pressure, and purified by column chromatography using 60% hexanes/EtOAc 
giving 1.5g (8.3 mmol, 75%) of 58 as a white solid. Rf = 0.35 (30% EtOAc/hexanes).  
MP = 65 
0
C. 
1
H NMR (CDCl3, 400 MHz): δ 6.25 (bs, 1H), 4.2 (m, 2H), 3.36 (m, 2H), 
2.26 (m, 1H), 1.84 (m, 2H), 1.73 (m, 1H), 1.50 (s, 3H), 1.27 (t, 3H, J = 7 Hz).  
13
C NMR 
(CDCl3, 100 MHz):  δ 173.6, 172.0, 61.2, 50.3, 42.3, 33.0, 22.4, 90.4, 14.0. ESI-MS 
[C9H15NO3Na
+
] = 208.1, observed = 208.1. 
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Synthesis of (S)-1-Tert-Butyl-3-Ethyl-2-Methyl-2-[3-(1,3-Dioxoisoindolin-
2Yl)Propyl]Malonate (60) 
A volume of 600 µL conc. H2SO4 was added to a solution of 2 g of 10c (6 mmol) 
in 30 mL CH2Cl2 in a 100 mL sealed tube. The solution was cooled to -7 
o
C. A volume of 
6 mL condensed isobutylene was added to the solution. The tube was sealed tightly and 
allowed to stir overnight at RT. The tube was uncapped and allowed to stir for 2hrs at 
ambient pressure to allow excess isobutylene to evaporate. The solution was diluted with 
30 mL of CH2Cl2 and gently washed three times with 1N NaOH (50 mL). The CH2Cl2 
layer was dried over MgSO4, evaporated under reduced pressure, and chromatographed 
(40% EtOAc/hexanes), giving 2 g (5.1 mmol, 87%) of 60 as white solid. Rf = 0.53 (40% 
EtOAc/hexanes).  = - 5.2. IR (cm
-1
): 2979, 1774, 1709. 
1
H-NMR (CDCl3, 400 MHz): 
7.84 (m, 2H), 7.71 (m, 2H), 4.18 (m, 2H), 3.74 (m, 2H), 1.91 (m, 2H), 1.61 (m, 2H), 1.48 
(s, 9H), 1.39 (s, 3H), 1.28 (t, 3H, J = 7 Hz). 
13
C NMR (CDCl3, 100MHz) 172.3, 171.03, 
168.3, 134.0, 132.1, 123.2, 81.5, 61.1, 54.0, 38.1, 34.7, 28.0, 25.3, 20.0, 14.0. ESI-MS 
[C21H27NO6Na
+
]: Calcd = 412.4, found = 412.3. 
Synthesis of (S)-Tert-Butyl-3-Methyl-2-Oxopiperidine-3-Carboxylate (61) 
A volume of 398 µL (4.4 mmol) 35% hydrazine in water was added to a solution 
of 1.5 g (4 mmol) 60 in 25 mL MeOH. The mixture was heated to reflux solvent 
overnight. A white precipitate was observed within an hr of reflux. The reaction mixture 
was allowed to cool to RT and the solution was filtered. The filtrate was evaporated 
under reduced pressure and taken up in CH2Cl2. The resulting mixture was washed with 
water and the organic layer was dried over MgSO4, evaporated under reduced pressure, 
and chromatographed using 30% hexanes/EtOAc giving 0.62 g of 61 as a white solid. Rf 
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(61) = 0.27 (30% hexanes/EtOAc). Mp = 130 
0
C. IR (cm
-1
): 3255, 2970, 1727, 1688, 
1660. = -16.2 (c = 1, CH2Cl2). 
1
H- NMR (CDCl3, 400 MHz): 6.28 (bs, 1H), 3.61 (m, 
2H), 2.2 (m, 1H), 1.8 (m, 2H), 1.61 (m, 1H), 1.42 (s, 12H). 
13
C-NMR (CDCl3, 100 MHz): 
174.2, 173.9, 83.0, 51.0, 43.0, 34.0, 28.0, 20.0, 14.0. ESI-MS [C11H19NO3Na
+
]: calcd = 
236.3, found = 236.2. 
Synthesis of (R)-Ethyl 1-Benzyl-3-Methyl-2-Oxopyrrolidine-3-Carboxylate (62a) 
  A solution of 3.6 g (22 mmol) of 19a in 20 mL anhydrous THF was added 
slowly to a suspension of 0.62 g NaH (26 mmol) in 10 mL THF at 0 
O
C under a N2 
atmosphere. The reaction mixture was allowed to stir 5 minutes. A volume of 3.3 mL 
(4.75 g, 24 mmol) BnBr was added drop wise to the reaction mixture at 0 
O
C. The 
reaction mixture was allowed to stir for 10 minutes at 0 
O
C and then allowed to warm to 
RT. The reaction was continued for 1 hr at RT. A volume of 15 mL dry DMF was added 
to the reaction mixture and continued to stir for 2 hrs. The reaction mixture was poured 
into 25 mL of H2O. The water layer was extracted with Et2O (3 X 50 mL). The combined 
ether layer was washed with water (5 X 30 mL), dried over MgSO4, evaporated under 
reduced pressure, and chromatographed (gradient, 15%-20% EtOAc/hexanes) giving 3.8 
g (15 mmol, 68%) of 62a as a colorless oil. 1H NMR evidenced that the product contains 
some trans-esterified compound as well. The mixture was utilized in the next step without 
further purification. Rf = 0.27 (20% EtOAc/hexanes). IR (cm
-1
): 2979, 1735, 1685. 
1
H-
NMR (CDCl3, 400 MHz): 7.29 (m, 7.5H), 5.16 (m, 0.5H), 4.6 (m, 1.25H), 4.36 (m, 
1.27H), 4.17 (m, 2H), 3.33 (m, 1.26H), 3.17 (m, 1.25H), 2.46 (m, 1.25H), 1.89 (m, 
1.27H), 1.50 (s, 0.76H), 1.47 (s, 3H), 1.23 (t, 3H, J =7 Hz). ESI-MS [C15H20NO3, 62a]
+
 
calcd = 261.3, found = 262.2.  
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Synthesis of (S)-Ethyl-1-Benzyl-3-Methyl-2-Oxopiperidine-3-Carboxylate (62b) 
  A solution of 0.3 g (1.6 mmol) of 58 in 10 mL of anhydrous THF was added 
slowly to a suspension of 0.046 g NaH (1.92 mmol) in 10 mL of THF at 0 °C under a N2 
atmosphere. The reaction mixture was allowed to stir for 5 min. A volume of 210 µL 
(1.76 mmol) of BnBr was added dropwise to the reaction mixture at 0 °C. The reaction 
mixture was allowed to stir for 10 min at 0 °C and then allowed to warm to rt. The 
reaction was continued for 1hr at rt. A volume of 6 mL of dry DMF was added to the 
reaction mixture, which continued to stir for 2 hrs. The reaction mixture was poured into 
15 mL of H2O. The water layer was extracted with Et2O (3 × 25 mL). The combined 
ether layer was washed with water (3 × 10 mL), dried over MgSO4, evaporated under 
reduced pressure, and chromatographed (gradient, 15−20% EtOAc/hexanes) giving 0.36g 
(1.3 mmol, 81%) as a colorless oil. Rf = 0.3 (20% EtOAc/hexanes). 
1
H NMR (CDCl3, 
400 MHz): δ  7.29 (m, 5H), 5.0 (m, 1H), 4.2 (m, 3H), 3.24 (m, 2H), 2.23 (m, 1H), 1.79 
(m, 3H), 1.54 (s, 3H), 1.29 (t, 3H, J = 7 Hz).  
13
C NMR (CDCl3, 100 MHz): δ 173.6, 
169.3, 137.2, 128.5, 127.8, 127.3, 61.4, 50.7, 50.4, 47.3, 33.4, 22.7, 19.4, 14.2. ESI-MS 
[C16H21NO3Na
+
] = 298.3, observed = 298.2. 
Synthesis of (S)-Ethyl 1-Benzyl-3-Methyl-2-Thioxopyrolidine-3-Carboxylate (63a) 
An amount of 5.3 g (13 mmol) Lawesson’s reagent was added to a solution of 3.8 
g (15 mmol) of 62a mixture in 20 mL anhydrous toluene under a N2 atmosphere. The 
reaction mixture was heated to 95 
O
C and stirred over night. The toluene layer was 
evaporated under reduced pressure and the residue was chromatographed (20% 
EtOAc/hexanes) giving 3.3 g (12 mmol, 80%) of 63a as a colorless oil. The conversion of 
lactam (62a) to the corresponding thiolactam (63a) was confirmed by comparing the 
13
C-
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NMR chemical shift of the lactam (62a) carbonyl carbon (172 ppm) to the thiolactam 
(63a) carbonyl carbon (202 ppm). Rf = 0.35 (20% EtOAc/hexanes). IR (cm
-1
): 2980, 
1733, 1505, 1449. 
1
H-NMR (CDCl3, 400 MHz): 7.29 (m, 7.3H), 5.18 (m, 2H), 4.82 (m, 
1.23H), 4.16 (q, 2H, J = 7 Hz), 3.70 (m, 1.24H), 3.51 (m, 1.25H), 2.51(m, 1.23H), 1.92 
(m, 1.32H), 1.61 (s, 0.68H), 1.58 (s, 3H), 1.21 (t, 3H, J = 7 Hz). ESI-MS [C15H20NO2S, 
10a]
+
 calcd = 277.4, found = 278.1.  
Synthesis of (S)-Ethyl 1-Benzyl-3-Methyl-2-Thioxopiperidine-3-Carboxylate (63b) 
   A 1.7 g (4.2 mmol) portion of Lawesson’s reagent was added to a solution of 
1.3 g (4.7 mmol) of 62b in 20 mL of anhydrous toluene under a N2 atmosphere. The 
reaction mixture was heated to 95 °C and stirred over 12 h.  The reaction completion was 
verified by TLC (20% EtOAc/hexanes).  The toluene layer was evaporated under reduced 
pressure, and the residue was chromatographed (20% EtOAc/hexanes) giving 0.97 g (3.3 
mmol, 80%) as colorless oil. The conversion of lactam 62b to the corresponding 
thiolactam 63b was confirmed by comparing the 13C NMR chemical shift of the lactam 
62b carbonyl carbon (173.6 ppm) to the thiolactam (63b) carbonyl carbon (202.5 ppm). 
Rf = 0.3 (20% EtOAc/hexanes).  = +75.2 (c = 1, CH2Cl2).
 1
H NMR (CDCl3, 400 
MHz): δ 7.31 (m, 5H), 5.69 (m, 1H), 5.04 (m, 1H), 4.23 (m, 2H), 3.43 (m, 2H), 2.28 (m, 
1H), 2.01 (m, 1H), 1.83 (m, 2H), 1.75 (s, 3H), 1.30 (t, 3H, J = 7 Hz).  
13
C NMR (CDCl3, 
100 MHz): δ 202.5, 173.6, 135.0, 129.0, 127.7, 127.5, 61.5, 57.7, 55.5, 50.4, 32.1, 27.8, 
19.4, 14.0. ESI-MS [C16H21NO2SNa
+
] calculated = 314.4, observed = 314.3.  
 
Synthesis of (R)-Ethyl 1-Benzyl-3-Methylpyrrolidine-3-Carboxylate (64a) 
An amount of 0.5 g of 63a was dissolved in 15 mL of 4:1 THF/EtOH. An amount 
of 0.05 g Raney-Ni slurry in water (10% by weight) was added to the solution. The 
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solution was stirred vigorously under a H2 atmosphere for 4 hrs, at which point the 
reaction was found to be complete by TLC. The mixture was filtered through a Celite bed, 
and the filtrate was evaporated under reduced pressure. The product was purified by 
radial chromatography using 20% hexanes/CH2Cl2 to give 0.25 g (1.01 mmol, 72%) of 
64a as a colorless liquid. Rf = 0.32 (20% hexanes/CH2Cl2). IR (cm
-1
): 2974, 2790, 1725, 
1452.  = -8 (c = 1, CHCl3). 
1
H-NMR (CDCl3, 400 MHz)(11a): 7.3 (m, 5H), 4.13 (q, 
2H, J = 7 Hz), 3.61 (m, 2H), 2.94 (d, 1H, J = 9 Hz), 2.64 (m, 2H), 2.41 (m, 2H), 1.65 (m, 
1H), 1.33 (s, 3H), 1.25 (t, 3H, J = 7 Hz). 
13
C-NMR (CDCl3, 100 MHz)(11a): 177.0, 139.0, 
128.5, 128.2, 127.0, 64.0, 61.0, 60.0, 54.0, 48.0, 36.0, 25.0, 14.0. HRMS 
[C15H21NO2Na
+
]: calcd = 270.1464, found = 270.1463. 
Synthesis of (R)-Ethyl 1-Benzyl-3-Methylpiperidine-3-Carboxylate (64b) 
 A 0.8 g portion of 63b (2.7 mmol) was dissolved in 20 mL of 4:1 THF/EtOH. A 
0.16 g portion of Raney-Ni slurry in water (20% by weight) was added to the solution. 
The solution was stirred vigorously under a H2 atmosphere for 6 hrs, at which point the 
reaction was found to be half-complete by TLC (10% hexanes/CH2Cl2) . The mixture was 
continued to stir under H2 atmosphere another 6 hrs.  The mixture was found to be 
completed via TLC to give 0.54 g (2 mmol, 78%) of 63b as a colorless liquid. Rf = 0.35 
(20% heanes/CH2Cl2).  = + 11.8 (c = 1, CH2Cl2). 
1
H NMR (CDCl3, 400 MHz): 7.29 
(m, 5H), 4.43 (m, 2H), 3.52 (m, 1H), 3.40 (m, 1H), 2.97 (bm, 1H), 2.58 (bm, 1H), 2.02 
(m, 3H), 1.73 (m, 1H), 1.59 (m, 1H), 1.20 (m, 4H), 1.13 (s, 3H).  
13
C NMR (CDCl3, 100 
MHz): 176.5, 138.2, 128.8, 127.0, 63.1, 62.0, 60.2, 54.0, 43.1, 33.2, 24.0, 23.0, 14.0. ESI-
MS [C16H23NO2Na
+
] calculated = 284.3, observed = 284.3. 
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Synthesis of (R)-1-Benzyl-3-Methylpyrrolidine-3-Carboxylic Acid (65a) 
 An amount of 0.13 g LiOH (6 mmol) was added to a solution of 0.46 g (2 mmol) 
64a in 12 mL 3:2 H2O/EtOH. The reaction was stirred at RT for 24hrs and determined to 
be complete by TLC. The mixture was acidified to pH 3 (4N HCl), and the water layer 
was evaporated under reduced pressure giving a colorless gummy residue. The gummy 
residue was triturated with MeOH multiple times and the MeOH fractions were dried 
over MgSO4. The solvent was removed under reduced pressure giving 0.34 g (1.56 mmol, 
78%) of 12 as a colorless liquid. Rf = 0.13 (5% MeOH/CH2Cl2). IR (cm
-1
): 3371(broad), 
2946, 2615, 1712, 1455.  = -11.3 (c = 1, MeOH). 
1
H-NMR (CD3OD, 400 MHz): 
7.58 (m, 2H), 7.50 (m, 3H), 4.44 (m, 2H), 3.87 (d, 1H, J = 12 Hz), 3.51 (m, 2H), 3.21 (d, 
1H, J = 12 Hz), 2.58 (m, 1H), 2.09 (m, 1H), 1.47 (s, 3H). 
13
C-NMR (CD3OD, 100 MHz): 
176.0, 130.4, 130.2, 129.7, 129.0, 61.0, 58.0, 53.0, 35.0, 22.0. HRMS [C13H17NO2Na
+
]: 
calcd = 242.1151, found = 242.1145. 
Synthesis of (R)-1-Benzyl-3-Methylpiperidine-3-Carboxylic Acid (65b) 
 A 0.125 g portion of crushed LiOH powder (5.2 mmol) was added to a solution 
of 0.46 g (1.7 mmol) of 64b in 20 mL of 3:2 H2O/EtOH. The reaction was stirred at rt 
overnight.  The reaction was determined to be complete by TLC (5% MeOH/CH2Cl2). 
The mixture was acidified to pH 3 (10% HCl), and the water layer was evaporated under 
reduced pressure giving a colorless gummy residue. The gummy residue was triturated 
with 10% MeOH/CH2Cl2 (20 mL x 20), and the MeOH fractions were dried over MgSO4. 
The solvent was removed under reduced pressure giving 0.36 g (1.56 mmol, 88%) of 65b 
as a white solid as verified by TLC and staining with bromocresol green. Rf = 0.15 (5% 
MeOH/CH2Cl2).  = + 19.0 (c = 1, MeOH).  
1
H NMR (CD3OD, 400 MHz): δ 7.52 
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(m, 5H), 4.50 (m, 1H), 4.17 (m, 1H), 3.60 (m, 1H), 3.40 (m, 1H), 3.10 (m, 1H), 2.80 (m, 
1H), 2.20 (m, 1H), 1.98 (m, 1H), 1.80 (m, 1H), 1.54 (m, 1H), 1.2 (s, 3H). 
13
C NMR 
(CDCl3, 100 MHz): δ 178.1, 132.0, 131.2, 130.4, 130.3, 62.1, 57.7, 55.0, 43.4, 33.0, 24.1, 
22.1. ESI-MS [C14H19NO2Na
+
] = 256.3, observed = 256.3. 
Synthesis of (R)-3-Methylpyrrolidine-3-Carboxylic Acid (66a) 
An amount of 0.3 g (2.3 mmol) of 65a was dissolved in 15 mL MeOH and added 
to 0.03g Pd/C (10% by weight). The solution was allowed to stir over night under a H2 
atmosphere at RT. The resulting mixture was filtered through Celite and the filtrate was 
evaporated under reduced pressure giving 0.27 g (2.1 mmol, 91%) of 66a as a white solid. 
mp = 98 
O
C. IR (cm
-1
): 3392(broad), 3177, 2877, 1704. = -20.4 (c = 0.33, MeOH). 
1
H-NMR (CD3OD, 400 MHz): 3.78 (m, 1H), 3.48 (m, 1H), 3.38 (m, 1H), 3.10 (d, 1H, J = 
12 Hz), 2.49 (m, 1H), 2.01 (m, 1H), 1.45 (s, 3H). 
13
C-NMR (CD3OD, 100 MHz): 176.0, 
53.0, 48.5, 45.0, 35.0, 21.0. HRMS [(C6H11NO2)2Na
+
]: calcd = 281.1472, found = 
281.1468. 
Synthesis of (R)-3-Methylpiperidine-3-Carboxylic Acid (66b) 
 A 0.3 g (1.3 mmol) portion of 65b was dissolved in 15 mL of MeOH and added 
to 0.06 g Pd/C (20% by weight).  The solution was allowed to stir overnight under a H2 
atmosphere at rt. The resulting mixture was filtered through Celite, and the filtrate was 
evaporated under reduced pressure giving 0.185 g (1.29 mmol, 93%) of 66b as a white 
solid. 
1
H NMR (CD3OD, 400 MHz): δ 3.53 (m, 1H), 3.28 (m, 1H), 2.97 (m, 1H), 2.83 (m, 
1H), 2.19 (m, 1H), 1.88 (m, 1H), 1.69 (m, 1H), 1.58 (m, 1H), 1.27 (s, 3H).  
13
C NMR 
(CDCl3, 100 MHz): δ 178.5, 50.10, 44.3, 41.4, 33.5, 23.5, 21.0. ESI-MS [C7H13NO2Na
+
] 
= 166.2, observed = 166.3. 
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Synthesis of  (2R, 3S)-Ethyl-3-Formyl-2-(4-Methoxyphenylamino)-4-Methylpentanoate 
(67a) 
 This compound was synthesized following literature reported procedure. 
23
 All 
characterizations complied with those reported in literature.
144
 HPLC (Diacel Chiral Pack 
OJ-H, hexane/i-PrOH = 99:1, flow rate = 1mL/min, λ = 254 nm); tanti (major) = 58.20 
min, tanti (minor) = 55.78 min, tsyn (major) = 51.31 min, tsyn (minor) = 41.28 min. 
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